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T Cell Responses In Pediatric-Onset Multiple Sclerosis: A Unique Window Into
Early Disease
Abstract
Multiple Sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), which leads to
accumulating neurological disability. Available therapies can ease symptoms and may decrease new
episodes of injury, but they broadly target the immune system and can lead to adverse effects. Although T
cells are implicated in MS, the particular subsets and their antigenic targets remain largely unknown.
Elucidating these could guide development of more selective and safer treatments. In this dissertation,
we focus on pediatric-onset MS, which offers us a window of opportunity into the earliest biological
events of this disease. We use a range of cell-based assays including cell culture, flow cytometry and
single-cell level proteogenomic analyses to assess the phenotype and functional profiles of circulating
immune cells within high quality cryopreserved peripheral blood mononuclear cells isolated from wellcharacterized children with MS and compare them to samples isolated from other CNS inflammatory
disease controls, as well as healthy children. The research presented in this dissertation provides novel
insights into early MS disease-implicated T cells and explores mechanisms by which both previously
implicated, as well as newly identified cell populations may contribute to disease pathogenesis. In
Chapter 2, we identify an imbalance between effector T cells and regulatory T cells as a distinguishing
characteristic in children with MS and implicate a particular pro-inflammatory memory T cell subset that
co-expresses the ‘CNS-homing’ CCR2 and CCR5 chemokine receptors, which is present at a higher
frequency in children with MS and exhibits exaggerated pro-inflammatory responses. In Chapter 3, we
evaluate spontaneous activation and antigen-specificities of T cells (including the implicated CD4 T cells)
to CNS (myelin) and Epstein-Barr Virus antigens, as well as determine how these abnormal T-cell
responses are impacted in patients undergoing treatment with an effective MS therapy. In Chapter 4, we
explore the single cell proteogenomic profile of T cells (with a focus on the implicated CCR2+CCR5+ CD4
T cells and memory T cells more generally) and discuss the potential implication of differential
expression profiles detected in cells of children with MS, as well as the more recently recognized
inflammatory demyelinating condition defined by presence of circulating anti-myelin oligodendrocyte
glycoprotein (MOG) antibodies (MOG-associated disease; MOGAD). Collectively, the data in this
dissertation broadens our understanding of T cell profiles and responses in these unique patient cohorts,
as well as provides insights into the potential interactions with other cell types and their targets involved
in early MS pathogenesis. We hope that this work will help develop better biological measures of disease
state and could ultimately lead to the development of potentially novel biomarkers and therapeutic
targets.
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ABSTRACT

T CELL RESPONSES IN PEDIATRIC-ONSET MULTIPLE SCLEROSIS:
A UNIQUE WINDOW INTO EARLY DISEASE
Ina Mexhitaj
Amit Bar-Or

Multiple Sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), which
leads to accumulating neurological disability. Available therapies can ease symptoms and may
decrease new episodes of injury, but they broadly target the immune system and can lead to
adverse effects. Although T cells are implicated in MS, the particular subsets and their antigenic
targets remain largely unknown. Elucidating these could guide development of more selective
and safer treatments. In this dissertation, we focus on pediatric-onset MS, which offers us a
window of opportunity into the earliest biological events of this disease. We use a range of cellbased assays including cell culture, flow cytometry and single-cell level proteogenomic analyses
to assess the phenotype and functional profiles of circulating immune cells within high quality
cryopreserved peripheral blood mononuclear cells isolated from well-characterized children with
MS and compare them to samples isolated from other CNS inflammatory disease controls, as
well as healthy children. The research presented in this dissertation provides novel insights into
early MS disease-implicated T cells and explores mechanisms by which both previously
implicated, as well as newly identified cell populations may contribute to disease pathogenesis. In
Chapter 2, we identify an imbalance between effector T cells and regulatory T cells as a
distinguishing characteristic in children with MS and implicate a particular pro-inflammatory
memory T cell subset that co-expresses the ‘CNS-homing’ CCR2 and CCR5 chemokine
receptors, which is present at a higher frequency in children with MS and exhibits exaggerated
pro-inflammatory responses. In Chapter 3, we evaluate spontaneous activation and antigenix

specificities of T cells (including the implicated CD4 T cells) to CNS (myelin) and Epstein-Barr
Virus antigens, as well as determine how these abnormal T-cell responses are impacted in
patients undergoing treatment with an effective MS therapy. In Chapter 4, we explore the single
cell proteogenomic profile of T cells (with a focus on the implicated CCR2+CCR5+ CD4 T cells and
memory T cells more generally) and discuss the potential implication of differential expression
profiles detected in cells of children with MS, as well as the more recently recognized
inflammatory

demyelinating

oligodendrocyte

glycoprotein

condition
(MOG)

defined

by
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presence

of

(MOG-associated

circulating
disease;

anti-myelin
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Collectively, the data in this dissertation broadens our understanding of T cell profiles and
responses in these unique patient cohorts, as well as provides insights into the potential
interactions with other cell types and their targets involved in early MS pathogenesis. We hope
that this work will help develop better biological measures of disease state and could ultimately
lead to the development of potentially novel biomarkers and therapeutic targets.
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CHAPTER 1: INTRODUCTION
Multiple Sclerosis overview
Multiple sclerosis (MS) is a multifaceted chronic autoimmune-mediated disorder in which a
disrupted balance in the immune system leads to a continuous attack of the myelin sheath in the
central nervous system (CNS; brain and spinal cord), resulting in demyelination, axonal loss, and
worsening disability over time (Compston and Coles 2002; Hauser and Oksenberg 2006; Garg
and Smith 2015; Dobson and Giovannoni 2019). MS initially manifests with acute focal
inflammatory demyelinated lesions predominantly in the CNS white matter and culminates with
chronic multifocal sclerotic plaques, axonal loss, and tissue degeneration (Lucchinetti, Bruck, and
Lassmann 2004; Lassmann and van Horssen 2011). This ultimately contributes to neurologic
impairments in children and young adults that affect motor, sensory, and cognitive capacities, as
well as quality of life (Compston and Coles 2002; Banwell et al. 2007). Despite considerable
efforts, no cure exists for MS and current treatments aim to arrest or slow down the progression
of the disease and alleviate symptoms but have adverse effects. Therefore, more targeted
therapies are necessary.
It has been speculated that an interaction of genetic and environmental factors contributes to
failure of central and peripheral mechanisms resulting in loss of tolerance to CNS myelin (self)
antigens (Hohlfeld et al. 2016a). All humans have autoreactive T cells against CNS myelin
antigens. Normally these autoreactive T cells bind to autoantigens with low-affinity. Activation in
these T cells is kept in check by several mechanisms of peripheral immune tolerance, which
prevent any attack on tissue or injury (Chaplin 2010). However, in a chronic autoimmune disease
such as MS, these mechanisms are disrupted and an imbalance in effector and regulatory
immune cell function is thought to trigger an abnormal peripheral-mediated immune response
(Rosenblum, Remedios, and Abbas 2015; Mexhitaj et al. 2019; Mansilla et al. 2021). Peripheral
myelin-autoreactive T cells may become abnormally activated in response to a stimulating
1

antigen such as myelin antigens or any other antigens similar in structure (Bielekova B. 2019).
These activated T cells migrate to the meninges, the protective membranes that are the first line
of defense of the CNS. Upon recognition of local CNS myelin antigens displayed by resident
antigen presenting cells (APCs) circulating in the cerebrospinal fluid (CSF), these T cells reactivate and initiate a complex immune response, through the release of chemokines and proinflammatory cytokines which then enables the recruitment of other peripheral cells (including B
cells, natural killer

cells and macrophages (Korn and Kallies 2017). Active secretion of

proinflammatory cytokines, proteolytic enzymes, and reactive oxygen species leads to activation
of resident immune cells, compromises CNS barriers, allows entrance of cells into the CNS and
contributes to an inflammatory state. Repeated re-activation of the myriad of CNS infiltrating
immune cells leads to constant attack on the myelin sheath and oligodendrocytes, causing
demyelination and eventually inflammatory injury in the CNS (Lassmann and van Horssen 2011;
Mallucci et al. 2015; Dobson and Giovannoni 2019). Myelin autoreactive T cells are often clonally
expanded and found to persist for a long time in patients with MS (Richert et al. 1983; Sospedra
and Martin 2005). Although T cell responses are strongly implicated in MS pathophysiology, the
actual T cell subsets and their antigenic targets involved in the initiation and propagation of CNS
injury in patients, remain to be elucidated (Hohlfeld et al. 2016a). Further studies on antigen
specificities in the peripheral and intrathecal compartment at an earlier stage in the disease are
needed.
Multiple environmental factors have been implicated in the development of MS, such as exposure
to infectious agents (eg, viruses), lower levels of vitamin D, and changes in latitude. Physiological
factors such as obesity, gut microbiota, sex hormones, and exposure to cigarette smoke have
also been shown to increase predisposition to developing MS (Olsson, Barcellos, and Alfredsson
2017). Based on migration studies, key environmental exposures that are associated with the
onset of MS occur before the age of 15 (Berg-Hansen and Celius 2015; Graves et al. 2017).
There is a genetic component to the development of MS, which increases with increased genetic
2

identity within a family (Harirchian et al. 2018). However, there is only a 30% concordance rate
even among female monozygotic twins (Ristori et al. 2006). The main susceptibility allele
implicated in MS has been the human leukocyte antigen (HLA) class II, HLA-DRB1*15:01, shown
to increase the risk of developing MS due to epigenetic changes, leading to increased expression
and antigen presentation that drives T cell activation (Waubant et al. 2019). However, only about
50% of MS patients have this allele. Genome-wide associated studies (GWAS) have implicated in
MS over 200 genes of non-HLA single-nucleotide polymorphisms (SNPs), majority associated
with the immune system (International Multiple Sclerosis Genetics et al. 2007; Dobson and
Giovannoni 2019; Goodin 2016). However, none of the identified SNPs are mutated or abnormal
genes per se, and none are unique to patients with MS. This suggests that even though there is a
genetic susceptibility in MS, genetic risk is conferred by small contributions from many individual
variants and that different individuals harbor different combinations of such variants. This
suggests that the cellular immunology of MS is both complex and likely heterogenous across
patients (Bielekova B. 2019; Celarain and Tomas-Roig 2020; Mansilla et al. 2021). Further
investigation into the nature and functional implications of this is warranted and likely required for
a more complete understanding of the mechanisms underlying MS pathogenesis and how one
might best target them in different individuals.
An abnormal immune response is the result of the interconnection of all components of the
immune system and the myriad of signals they orchestrate that leads to inappropriate activation
of immune cells and/or failure to regulate, thus allowing a prolonged survival of the diseaseimplicated immune cell subsets (Hohlfeld et al. 2016a). A combination of factors such as the
presence of dysfunctional tolerogenic antigen presenting cells, decreased frequencies and/or loss
of function of regulatory immune cells (T regulatory [Tregs], B regulatory [Bregs], natural killer
cells), increased frequencies and/or effector function of proinflammatory immune cells (T effector
[Teff], B effector [Beff]), and increased resistance of the latter to suppressive mechanisms of
regulatory cells lead to an imbalance between the effector and regulatory functions of the immune
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system in the peripheral and central nervous system (Li, Patterson, and Bar-Or 2018). Moreover,
increase in pro-inflammatory cytokines, as well as upregulation of chemokine receptors and
adhesion molecules on effector cells have been shown to facilitate activation and transmigration
of pathogenic autoreactive T and B cell subsets in the CNS where they trigger MS development
(Rosenblum, Remedios, and Abbas 2015). Studying the interaction between all the immune
components and the balance between these in the context of MS pathogenesis is instrumental.
MS animal model limitations
The aforementioned factors implicated in MS have been studied in the experimental autoimmune
encephalomyelitis (EAE) animal model of MS, which is induced in various species by active
immunization with myelin proteins, their peptide derivatives, or passive transfer of activated
myelin-specific CD4 T cells. EAE has proved to be a useful model for the human disease as it
shares some clinical, histological, immunological, and genetic features with MS (Baxter 2007;
Rangachari and Kuchroo 2013; Duffy, Lees, and Moalem-Taylor 2014). In genetically susceptible
animals, immunization induces brain inflammation accompanied by various signs of neurologic
disorders. As demonstrated in this model, myelin reactive CD4 T cells are able to mediate EAE,
and the use of this model has led to the development of three clinical therapeutics for MS
(glatiramer acetate, mitoxantrone, natalizumab) (Baxter 2007). However, several treatments
shown to be effective at limiting EAE (eg, altered peptide ligands, TACI-Ig, anti-TNFα) have been
ineffective in treating or even aggravated human MS (Bielekova et al. 2000; Holz et al. 2000;
Hartung and Kieseier 2010; Kemanetzoglou and Andreadou 2017). This suggests that the EAE
model is not an accurate predictor of the efficacy and safety of MS therapeutics (Steinman and
Zamvil 2006). Although the EAE model continues to provide important insights into MS, it does
not replicate MS in animals in terms of early/initiating events and longer-term progressive
pathology, making it a limited model that does not fully encapsulate the complexity of the human
disease. In the EAE model, several autoantigens have been established as being
encephalitogenic, (Gold, Linington, and Lassmann 2006; Ben-Nun et al. 2014), while in human
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MS the antigen(s) have yet to be identified (Hemmer, Kerschensteiner, and Korn 2015).
Elucidating the target antigens of MS would provide insights into the pathogenesis of MS and
pave the way to therapeutic biomarkers. To encompass the complexity of MS, the work in this
dissertation focuses on human samples collected from the peripheral compartment, where the
misguided autoimmune response is presumed to initiate.
MS therapies limitations
Heterogeneity in genetic, clinical, and pathologic features of patients with MS has led to the
development and current use of more than 20 approved MS therapies (Hauser and Cree 2020).
Current MS immunosuppressive and immunomodulatory therapies modulate peripheral immune
inflammatory responses and reduce focal lesion accumulation. Consequently, reducing the
frequency of relapse by 33%–66% (Steinman and Zamvil 2006), delaying disease progression,
and mitigating neurodegeneration in progressive forms of MS (Hauser et al. 2017; Hauser,
Belachew, and Kappos 2017). Although considerable progress has been made in MS therapies,
they non-specifically eliminate or inhibit broad immune cell populations and are limited in their use
due to concerns over adverse events (Bielekova B. 2019). To develop selective immune
treatments with better long-term safety profiles, more specific cellular disease mediators and their
antigen (Ag) targets must be identified. New efforts at ‘precision medicine’ platforms are being
pursued, such as assays that identify the predominant CNS-reactive T cell targets in an individual
and then direct therapy towards those cells selectively (eg, T cell vaccine strategies, Ag-specific
DNA vaccines) (Vandenbark and Abulafia-Lapid 2008; Stuve, Cravens, and Eagar 2008; Mansilla
et al. 2021). Since the target autoantigens may vary in different patients and are prone to change
during the disease course, selective immunotherapy requires a personalized approach. This
entails development of ‘antigen-specific’ therapies that selectively impact only the offending
immune cell responses and understand how those responses can be prevented and/or
redirected.

5

The search for putative antigenic targets and disease-relevant T cell subsets
Though T cell responses are strongly implicated in MS pathophysiology, the actual T cell subsets
and their antigenic targets involved in the initiation and propagation of CNS injury in patients,
remain to be elucidated. Antigens are first processed by APCs and then presented on the APCs’
major histocompatibility complexes (MHC) so that T cells can recognize the short processed
antigenic peptides through their T cell receptor (TCR). The complex antigen processing,
presentation, and recognition requirements have contributed to the challenges and the methods
used to identify T cell target antigens (Bielekova B. 2019).

Ag-specific assays have been used to determine the proliferation of autoreactive T cells to certain
putative antigenic targets to reproduce in vitro the most biologically accurate representation of MS
immunopathology (Hemmer et al. 1999; Bielekova et al. 2004b; Wuest et al. 2014; Cao et al.
2015; Hohlfeld et al. 2016b). However, detection of autoreactive T cells in the circulation is
challenging due to their rarity, heterogeneity, and the methods of evaluation and detection
(Hohlfeld et al. 2016a; Dan, Lindestam Arlehamn, et al. 2016). Depending on the antigen, the
precursor frequency of Ag-specific cells in circulation is very low (ranging from 104–106) (Reiss et
al. 2017). Over the past few years, several groups have overcome some of these limitations by
designing assays that capture Ag-reactive T cell responses based on upregulation of TCR
stimulation-induced surface markers, termed activation-induced markers (AIM) (Frentsch et al.
2005; Venken et al. 2008; Dan, Havenar-Daughton, et al. 2016; Reiss et al. 2017; Apostolidis et
al. 2021). Work in this dissertation includes the use of an adapted AIM assay to expand rare
autoreactive T cells and sensitively detect their surface markers downstream of TCR-engagement
as a sign of T cell activation in response to antigens of interest in MS.

Findings derived from the EAE model indicate that the target of the immune attack is the myelin
sheath, thus the prevailing theory in the MS field is that compact myelin antigens, such as myelin
basic protein (MBP) and the myelin oligodendrocyte glycoprotein (MOG), comprise major targets
of the aberrant immune response in MS (Steinman and Zamvil 2006; Hohlfeld et al. 2016a). Since
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T cells have broad specificities, they can recognize many different antigens, especially those that
are closely related in structure. Epidemiologic and experimental evidence (Cepok et al. 2005;
Levin et al. 2005; Ascherio and Munger 2007) implicate the ubiquitous double stranded DNA
human herpesvirus Epstein Barr-Virus (EBV) as a risk factor for MS (Ascherio et al. 2001;
Kurtzke 2013; Pakpoor et al. 2013; Goodin 2016). Moreover, there is some evidence of molecular
mimicry with myelin that has suggested EBV-reactive T cells may contribute to a misdirected T
cell response (Ascherio and Munger 2007; Dobson and Giovannoni 2019). This cross-reactivity or
molecular mimicry is one potential mechanism that may play an important role in the
pathogenesis of MS (Oldstone 2005). MS is heterogenous and unique in each patient, which
infers that immune cell responses can be directed against additional myelin or ubiquitous
intracellular autoantigens that have been released during tissue destruction leading to epitope
spreading following disease progression (Bhagavati 2021).

Putative antigenic targets
MBP constitutes about 35% of total myelin protein. Active immunization with MBP peptides and
passive transfer of MBP-autoreactive T cells efficiently induces EAE in susceptible animals
(Stoeckle and Tolosa 2010). MBP-autoreactive T cells have been isolated from patients with MS
and healthy individuals (Burns et al. 1983; Martin et al. 1990; Ota et al. 1990; Pette et al. 1990;
Hohlfeld et al. 2016a). The range and the relative immunogenicity of MBP epitopes is much more
diverse in humans than in mice, so the response of MBP-specific T cells is highly heterogenous in
both healthy individuals and patients with MS (de Rosbo and Ben-Nun 1998). Autoantibodies
that recognize MBP autoantigen may recruit inflammatory cells to the CNS that could theoretically
target CNS myelin components (Allegretta et al. 1990; Uccelli et al. 1998; Bielekova et al. 2004a).
MBP fragments are found within phagocytic microglia in MS lesions, further supporting an
involvement of this protein in MS pathology (Stoeckle and Tolosa 2010).

MOG is expressed late in myelogenesis and is exclusively present in CNS myelin. Although it
accounts for only <0.05% of total myelin protein, MOG is located in the outer part of the myelin
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sheath, thus making it directly accessible to immune cells and to antibody-mediated
demyelination. As with MBP, animal immunization with MOG antigen, MOG-derived peptides, or
passive transfer of MOG-reactive T cell cause severe disease mimicking many features of MS
(Linington et al. 1993; Hohlfeld et al. 2016b). Similar to MBP, reports on MOG-reactive T cells in
MS compared to controls are mixed with some but not all identifying increased frequencies of
MOG reactive T cells in patients (Sun et al. 1991; de Rosbo and Ben-Nun 1998). Improvements
in biological assays which more reliably measure conformationally relevant serum antibodies to
MOG, now categorize patients with such antibodies as having a distinct disease from MS,
recognized as MOG associated disease (MOGAD) (Ambrosius et al. 2020).

Although both

patients with MS and MOGAD can relapse, their clinical and imaging features are not identical
and treatments for one have not been necessarily beneficial in the other, suggesting that they are
distinct pathophysiologic entities (Fadda, Armangue, et al. 2021; Fadda, Banwell, et al. 2021).

EBV has been implicated as an environmental risk-factor for the development of MS (Ascherio
and Munger 2007, 2015, 2016; Bar-Or, Pender, et al. 2021). Although MS has not been shown to
develop in the absence of exposure to EBV, infection with this virus alone is not sufficient to
cause MS (Bar-Or, Pender, et al. 2021). The link between EBV infection and the development of
MS is supported by a strong correlation between the presence of high titers of anti-EBV
antibodies in the serum of patients with MS and their disease onset (Lunemann et al. 2010;
Mameli et al. 2012; Deeba et al. 2019), as well as by the observation of a higher rate of EBV
activation in patients with MS (Mechelli et al. 2011; Angelini et al. 2013) . Indeed, activation of
EBV has been shown to exhaust EBV-specific T cells which in the long-term reduces the ability of
these cells to limit EBV reactivation in MS (Cencioni et al. 2017; Pender et al. 2017). In addition,
molecular mimicry has been proposed as a plausible mechanism. T cells primed by exposure to
EBV proteins may cross-react to CNS antigens and play a role in the misdirected T cell response
against myelin proteins (Hohlfeld et al. 2016b). The immunodominant EBV protein linked to MS
has a homologous peptide sequence with the MBP autoantigen and this similarity between these
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antigen epitopes is believed to cause a T cell to respond not only to its cognate antigen (MBP),
but also to cross-react with similar antigens (Bray et al. 1992). The relationship between aberrant
T cell reactivities to CNS antigens and potentially environmental epitopes is of interest and
remains to be determined.

Alternative antigens
Aside from autoantigens of traditional CNS (myelin) and viral antigens, other antigenic targets
have been proposed, including oligodendrocyte antigens (eg, CNPase); neuronal, axonal, and
axoglial apparatus antigens (eg, neurofascin, neurofilament light chain, oligodendrocyte-myelin
glycoprotein, gliomedin); astrocytic antigen (eg, potassium channel KIR4.1); and other ubiquitous
autoantigens (eg, αβ-crystallin heat shock protein) (Dhaunchak et al. 2012; Hohlfeld et al. 2016b).
T cell epitope spread, which has previously been described as a phenomena in the EAE model
and in patients with MS, is thought to be driven by APCs exposed to an increasing repertoire of
CNS antigens resulting from CNS tissue injury (Goebels et al. 2000; Vanderlugt and Miller 2002).
The presence of intracellular antigens after the release of dying cells suggests that they may be
targets of a secondary immune response. Increase in the diversity of antigenic specificities from
the initial epitope-specific immune response can be to additional epitopes of either the same
(intramolecular) or different (intermolecular) antigens (Quintana et al. 2014).
In addition to increased T cell reactivity to putative environmental and CNS myelin and other selfantigens, it has been reported that adults with MS (as compared to controls) show a higher
spontaneous in vitro peripheral T cell proliferation in the absence of an exogenous antigen (Jelcic
et al. 2018). This T cell ‘auto-proliferation’ is reduced after B cell depletion with anti-CD20,
suggesting that B cell: T cell interactions play a central role in disease activity. The efficacy of B
cell depleting therapies in MS is not dependent on the reduction of autoantibodies, which
suggests a role for B cells as APCs in the activation of autoreactive T cells (Korn and Kallies
2017). Interactions between the different lymphoid and myeloid components of the immune
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system are proving to be much more complex, contributing to an evolving view on how they are
involved in the pathogenesis of MS (Li, Patterson, and Bar-Or 2018; van Langelaar et al. 2020).
Disease-relevant immune cells
CD4 T cells: There are several lines of evidence from EAE animal model studies as well as
genetic, ex vivo, in vitro, and clinical studies in humans that have supported the hypothesis that
myelin-antigen autoreactive CD4 T cells are the principal players in MS pathogenesis (Cao et al.
2015; Hohlfeld et al. 2016a). These include reports highlighting differences in the frequencies and
activation status of myelin reactive CD4 T cells in patients with MS as compared to controls.
Human GWAS indicating that HLA-DRB1*15:01 allele is associated with increased MS risk and is
involved in optimal binding and presentation of CNS-autoantigens to CD4 T cells. There is also
evidence from clinical trials in which the alteration of a disease-implicated peptide (MBP) has
been associated with increased MS disease activity (Hohlfeld et al. 2016a). Studies in EAE and in
adults with MS have suggested that cellular immune abnormalities include enhanced responses
of CNS-directed autoreactive Teff cells, particularly those with proinflammatory Th1 (IFNγ and
TNFα) and Th17 (IL-17 and GM-CSF) response profiles, as well as diminished or impaired
responses of Treg cells such as those secreting IL-10 (Fletcher et al. 2010; Rosenblum,
Remedios, and Abbas 2015). This persistent dysregulation/imbalance results in sustained
immune reactions in the long-term disease course of MS. The characterization of proinflammatory IFNy-producing Th1 cells and IL-17 producing Th17 cells in EAE has sparked a
search for similar cells in humans, however, the pathogenic T cells involved in CNS injury in MS
have not been identified because of confounding results (Hohlfeld et al. 2016a). Understanding of
the roles of CD4 T cells in MS will require deeper insights into their cell-intrinsic abnormalities;
receptors on their surface that integrate exogenous factors shaping the T cell functional
responses, (such as co-stimulatory and co-inhibitory receptors); as well as factors produced by
the T cells such as proteases, chemokines and pro- and anti-inflammatory cytokines which can
shape responses of other cells.
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CD8 T cells are also implicated in MS and can outnumber CD4 T cells in MS lesions (Saxena et
al. 2011). T cell repertoire and single-cell reports have shown that expanded CD8 T cells are
present and persist in MS parenchyma and CSF, suggesting that they may recognize CNS
resident and microbial antigens (Hohlfeld et al. 2016c). Based on these observations, CD8 T cells
seem to have an active role in MS pathogenesis but their function in MS is still not clearly
elucidated. Several studies have shown these cells as having cytotoxic effector, protective, and
regulatory functions (Hohlfeld et al. 2016c). In a model of EAE, myelin specific CD4 T cells recruit
CD8 cytotoxic T cells to kill the encephalitogenic effector cells and ameliorate EAE (Sun et al.
1988). Mice with depleted CD8 T cells seem to have a severe EAE trajectory (Koh et al. 1992).
CD8 T cells serving a regulatory function can identify autoantigens on CD4 Th1 and Th17 cells as
well as APCs (Sinha, Itani, and Karandikar 2014).

B cells: Many reports in human MS implicate B cells as playing a crucial role in MS
pathogenesis. B cells and oligoclonal immunoglobulins in the CSF of patients with MS are used
as diagnostic markers. B cells have shown to be functionally and phenotypically diverse. They
contribute to MS in an antibody-dependent and antibody-independent manner and have essential
functions, including effector and regulatory functions (Li, Patterson, and Bar-Or 2018; van
Langelaar et al. 2020). Moreover, B cells are effective APCs, especially when antigen
concentration is low, and they recognize the same antigen as T cells (van Langelaar et al. 2020).
These cognate interactions are important for both activation of Teff and Treg cells (Li, Patterson,
and Bar-Or 2018). These roles of B cells have been highlighted especially after the introduction of
anti-CD20 therapies, which work primarily by depleting B cells rather than reducing the production
of antibodies. anti-CD20 therapies have shown considerable efficacy in MS, by reducing relapse
rate and disease activity (Bar-Or, O'Brien, et al. 2021). This suggests a crucial role of B cells in
triggering new MS relapses. Such a role is independent of antibodies but instead depends on
other functions of B cells such as antigen presentation, T cell activation, and cytokine production.
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Myeloid cells: Although the lymphocytes of the adaptive immune system are considered the
main players in MS pathogenesis, the innate immune cells (dendritic cells, monocytes,
macrophages, microglia) also play an important role in disease initiation and progression (Ifergan
and Miller 2020). Depletion of circulating myeloid cells reduces or prevents EAE by stopping
lymphocyte influx into the CNS (Mishra and Yong 2016). Moreover, macrophages and microglia
constitute the predominant inflammatory cells in active and chronic MS lesions (Lucchinetti et al.
2000). These cells not only act as APCs to lymphocytes, but they can also produce
proinflammatory cytokines and chemokines that facilitate the differentiation of Th1 and Th17 cells
and their recruitment to the CNS (Codarri, Greter, and Becher 2013; Strachan-Whaley, Rivest,
and Yong 2014). In turn, these myeloid cells are induced to secrete proinflammatory cytokines
and produce radicals and proteases that promote BBB damage, thus facilitating the
transmigration of lymphocytes into the CNS. Within the CNS compartment, this continuous cycle
sustains lymphocyte proliferation and cytokine polarization leading to a sustained inflammatory
response, which culminates in tissue injury (Mossakowski et al. 2015). Myeloid cells are not the
main targets of therapeutic approaches in MS, however, they are still affected by these drugs and
ultimately contribute directly or indirectly to clinical efficacy. Those include: (i) alter expression of
co-stimulatory molecules needed for antigen presentation on myeloid cells, which prevent T cell
differentiation, downregulation of chemokines, proinflammatory cytokines, (ii) decrease
production of proteases, which reduces migratory capacity and prevents T cell re-activation and
(iii) induce polarization of these cells away from proinflammatory phenotype, increase in
production of regulatory functions, as well as prevent egress of these cells from lymph nodes
(Mishra and Yong 2016; Ifergan and Miller 2020).
Updated view of immune interactions in MS
Evidence from studies in the animal model of MS and in patients with MS have contributed to the
view that MS is primarily a T cell mediated disease attributed to an imbalance between Treg cells
and CNS-reactive Teff cells (Rosenblum, Remedios, and Abbas 2015). Recent evidence derived
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from the new generation of MS therapeutics, has expanded this view and considers all the major
players and their respective roles to be much more complex and involved in the pathogenesis of
MS. It has become apparent that T, B, and myeloid cells have both pro- and anti-inflammatory
functions, which in turn can upregulate or downregulate each other (Li, Patterson, and Bar-Or
2018; van Langelaar et al. 2020). The aberrant activation of B, T, and myeloid immune cells and
their bidirectional interactions in the periphery, lead them to across the CNS endothelial barriers,
reactivate effector cells and contribute to new MS attacks and eventually lead to CNS injury
(Figure 1.1). Although work in this dissertation will be focused primarily on T cell responses in
MS, we also consider how other immune cells interact with and contribute to T cells responses,
as well as how these T cell responses are affected by MS therapy.
Pediatric-onset MS relevance
To date studies have largely focused on adults with MS, in whom biological disease onset likely
started many years before clinical presentation. Thus, making it difficult to distinguish between
abnormalities that contribute to CNS injury from those that develop because of such injury, or as
an epiphenomenon of chronic dysregulation. In contrast, pediatric-onset MS offers a unique
opportunity to observe early mechanisms and potential disease initiating immune targets because
of the narrower range between biological and clinical disease onset. This could limit the effects of
irrelevant exposures or biological abnormalities that may emerge as a consequence (rather than
a cause) of disease. In this dissertation, we will focus our attention on pediatric-onset MS, though
rare, it offers a unique window into the earliest biological events and potential disease initiating
immune cells and targets (Banwell et al. 2007; Banwell et al. 2011; Bar-Or et al. 2016; Fisher et
al. 2020) (Figure 1.2).

Patients with pediatric-onset MS on average come to clinical attention at a time closer to their first
manifestation of the disease. They constitute 3%–5% of all MS patients below the age of 18 years
old. Treatment of pediatric-onset MS is currently based on strategies optimized for adult-onset
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MS, although clinical trials of disease-modifying therapies in children are underway (Banwell et al.
2007; Chitnis et al. 2012; Fadda, Armangue, et al. 2021). Active demyelinating lesions in
pediatric-onset MS occur with the perivascular infiltration of lymphocytes and macrophages
leading to axonal damage (Pfeifenbring et al. 2015). Children present with a relapsing-remitting
(RRMS) disease course that is characterized by attacks of new or increasing neurologic
symptoms followed by periods of partial or complete recovery (Waldman et al. 2016). Children
with confirmed MS have more frequent relapses than adults, especially in the first few years after
diagnosis, suggesting a higher proinflammatory state (Gorman et al. 2009; Fisher et al. 2020).
Although there is relatively low risk of early physical disability, a third of children with MS show
cognitive impairment (eg, attention, executive functions, memory, processing speed) (Banwell et
al. 2009; Ghassemi et al. 2014) . Moreover, children with MS show increased lesion burden,
volume loss in thalamic regions, early brain atrophy, and do not show age-expected brain growth
(Aubert-Broche et al. 2014; Fadda et al. 2019; Bartels et al. 2019) . This indicates that the
degenerative aspects of MS are present in these younger patients with a much more significant
inflammatory component. Therefore initiation of higher efficacy medications is necessary at the
time of diagnosis to target both abnormal immune responses, as well as the neurobiology of the
disease to decrease relapse rate and prevent disease progression (Fisher et al. 2020).

Pediatric-onset and adult-onset MS share the same genetic and environmental (eg, viral
infection) risk factors, supporting the hypothesis that these conditions constitute the same illness
manifesting at different ages (Disanto et al. 2011; Disanto and Ramagopalan 2013). HLADRB1*15:01 is a genetic risk factor for MS in children as are additional non-HLA SNPs, which
have been identified as a further predictor of MS risk in these children (Otallah and Banwell
2018). Pediatric-onset MS also has geographic risk factors, with an increased risk in those
residing further from the equator. Low vitamin D levels, obesity, and passive smoking also
increases the risk for pediatric-onset MS (Mikaeloff et al. 2007; Chitnis et al. 2016; Graves et al.
2020). A significant interaction between the immune system and the gut microbiome has been
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implicated in pediatric-onset MS pointing toward a more pro-inflammatory milieu, although it is not
clear whether this is a cause or a consequence of MS, treatments or dietary changes after
diagnosis (Tremlett and Waubant 2018). Infection with EBV has been associated with increased
risk for pediatric-onset MS (Banwell et al. 2011). Genetic and environmental factors might be
uniquely amenable to study in children with MS, as their nervous and immune system are actively
maturing (Bar-Or et al. 2016).

To date, relatively limited work has been done to characterize antigenic targets and immune
abnormalities in pediatric-onset MS. One study assessed T cell responses to CNS myelin
antigens in both pediatric-onset and adult-onset MS patients and found that in both groups T cells
responded to similar CNS myelin epitopes (Correale and Tenembaum 2006). In a subsequent
study, increased T cell proliferative responses to CNS myelin autoantigens were noted in
pediatric-onset MS, but these responses also existed in children with CNS injury, emphasizing
the inability to distinguish between immune responses that cause the injury from those that
develop as a consequence of injury (Banwell et al. 2008). In a small cohort of children with MS
increased Th17 responses of myelin-peptide stimulated peripheral blood mononuclear cells
(PBMC) were observed relative to healthy controls (Vargas-Lowy et al. 2013). Moreover,
abnormalities in Treg profile and their suppressive function have been shown in children with MS
as compared to adult MS and healthy controls (Balint et al. 2013). These studies (and most
studies in adults) have assessed either the Teff or Treg limbs of the immune system, but not both
at the same time, making it difficult to comment about the balance between them. Other pediatric
studies did not include an ‘other inflammatory CNS disease' control, which would help identify
abnormalities that are specific to MS. Taking advantage of the narrower gap between biological
and clinical disease onset in pediatric-onset MS and appropriate ‘other CNS inflammatory’
controls and age-matched healthy controls, this dissertation will explore early targets and cell
subsets involved in the regulation of CNS-directed immune responses in pediatric-onset MS.
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Pediatric onset-MS is rare so there are challenges to working with samples from children, which
require the application of stringent laboratory standards for collection and cryopreservation of
pediatric samples, as well as optimizing and miniaturizing any functional immunological assays in
adult samples first. For the past two decades, the unique Canadian Pediatric Demyelinating
Disease Study (CPDDS) has recruited children at 23 sites across Canada and at the Children’s
Hospital of Philadelphia (CHOP), at time of presentation with an initial episode of acquired
demyelinating syndrome (ADS). All ADS children are followed prospectively, with rigorous clinical
follow up, serial brain imaging, and biological sampling (Mexhitaj et al. 2019). An MS diagnosis is
subsequently ascertained based on evidence of further disease activity, while the rest of the
children remain monophasic (monoADS), and thus represent a control cohort of children with
‘other inflammatory CNS neurological disease’ (Banwell et al. 2011). Published work from this
dissertation (Chapter 2) has implicated the CD4 T effector cells that co-express the ‘CNS-homing’
CCR2 and CCR5 chemokine receptors, which circulates on average at a higher frequency and,
within PBMC, it responds to brief stimulation with enhanced expression of the pro-inflammatory
cytokines (IFNγ and IL-17) (Mexhitaj et al. 2019). The findings from several adult MS studies
implicate this subset as a relevant effector in MS including Sato et al., which observed the
subset’s selective enrichment in the CSF during relapse (Sato et al. 2012). Simpson et al
documented expression of both CCR2 and CCR5 on a large proportion of infiltrating lymphocytes
in chronic active MS lesions of post-mortem CNS tissue (Simpson et al. 2000). In keeping with
prior reports in adults with MS, we identified abnormalities in the function of pediatric MS Treg
cells, as well as decreased susceptibility to suppression of the disease-implicated proinflammatory T cells. The overall aim of the dissertation is to further characterize the response
profile and disease relevance of the CD4+CCR2+CCR5+ disease-implicated T cell subset (as well
as other T cells) in pediatric MS versus controls. Utilizing phenotypical, functional, and cell-based
assays, as well as single cell proteogenomic, we test the overarching hypothesis that in children
with MS this subset harbors disease-relevant molecular machinery and specificities to CNS
(myelin) and EBV antigens.
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Overview of dissertation
Within the one-of-a-kind pediatric demyelinating disease cohort, we have implicated the
CD4+CCR2+CCR5+ T cell subset as disease-relevant effectors in children developing MS. We are
uniquely poised to elucidate the cellular immunology of early MS thanks to the rigorous
prospective follow-up of children from their initial presentation (enabling reliable ascertainment of
their diagnosis and ability to go back to early disease samples) and the high quality PBMC
samples obtained from them using strict SOPs for all steps of isolation, processing, and storage.
The work presented in this dissertation has three main objectives. First, to assess for the first time
the phenotypic and functional response profiles of both Teff and Treg cells in the peripheral
compartment of children with MS and controls. Second, to assess whether T cells in children with
MS (particularly the CD4+CCR2+CCR5+ T cells implicated in the first part of the project) harbor
heightened spontaneous activation and/or antigen-specific T cell responses to CNS (myelin) and
EBV antigens. Also, to evaluate whether such abnormal T cell responses are impacted in patients
undergoing treatment with a highly effective MS therapy. Third, to assess single cell
proteogenomic profiles of CD4 T cells, including already disease-implicated T cells, as well as
potentially newly implicated populations in the circulation of children with MS and controls.
Studying this unique patient cohort provides novel insights into a specific CD4 T cells subset and
their potential interactions with other immune cell types involved in early MS pathogenesis.
Further work could lead to the development of more selective treatments (Figure 1.3).
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Figure 1.1: Overview of the underlying pathophysiological mechanisms implicated in
multiple sclerosis.
(1) In the peripheral compartment, unknown antigen (in MS) or CNS myelin antigen (in the MS
animal model, EAE) is presented in the MHC complex of antigen presenting cells (APC) to CD4 T
helper (Th) cells. (2) Following antigen recognition via the T cell receptor (TCR), different subsets
of Th cells are activated in the presence of various cytokines. The initially activated T cells start
producing IL-2 and several days later, also secrete additional cytokines, i.e., proinflammatory
cytokines secreted by Th1 and Th17 cells and anti-inflammatory cytokines secreted by regulatory
T cells (Treg). (3) Autoreactive CD4 T cells also cause APCs to activate CD8 T cells, which
clonally expand into different subsets, i.e., cytotoxic CD8 T cells, leading to direct damage of CNS
myelin and axons. (4) Moreover, the pro- and anti-inflammatory cytokines released by
autoreactive T cells along with activation of myeloid and B cells lead to bidirectional interactions
among these different cells. (5) B cell activation leads to plasma cell differentiation, which
produce anti-myelin antibodies. Antibody-independent roles of B cells, mediated in part through
distinct cytokines, can generate either effector B cells (Beff) or anti-inflammatory B cells (Breg),
which can activate or downregulate, respectively, proinflammatory responses of both T cells and
myeloid cells. (6) A disrupted balance between pro-inflammatory and anti-inflammatory T cells, B
cells and myeloid cells in the peripheral compartment leads to a CNS-directed autoimmune
response. (7) Secreted cytokines, chemokines, and proteases from these activated immune cells,
compromise and degrade the CNS barriers. Through adhesion molecules on the surface of
endothelial cells in the blood brain barrier (BBB), these immune cells enter the CNS. Once in the
CNS, T cells are reactivated upon interaction with myelin fragments presented by (8a)
autoreactive B cells (8b) resident APCs and (8c) microglia to incite the inflammatory cascade. (9)
Activated B cells produce autoreactive antibodies against CNS myelin-antigens contributing to
myelin damage. Resident macrophages increase local inflammatory response by releasing and
contributing to demyelination through myelin phagocytosis. While microglia lead to excessive
release of pro-inflammatory cytokines and chemokines, which further enhance infiltration of T
cells and macrophages. (10) This inflammatory cascade leads to damage of the myelin sheath
and eventually to axonal injury, which underlies the development of new MS attacks. Adapted
from (Khan and Smith 2014; Li, Patterson, and Bar-Or 2018; Celarain and Tomas-Roig 2020).
Adapted from “Multiple Sclerosis Pathogenesis”, by BioRender.com (2021). Retrieved from
https://app.biorender.com/biorender-templates
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Figure 1.2: Effect of genetic and environmental factors in developing MS in pediatric- and
adult-onset MS.
The interaction of genetic and environmental factors over time is thought to confer a risk of
developing MS, by contributing to an immune state in which peripheral effector immune cells
(particularly T cells) target the CNS. These inappropriately peripherally activated T cells are
thought to migrate to the brain and the spinal cord resulting in an abnormal CNS-directed antigenspecific immune response, which ultimately leads to inflammatory injury and new MS attacks. As
opposed to patients with adult-onset MS, in whom biological onset of disease starts many years
before clinical observation and immune cell assessment, patients with pediatric-onset MS are
diagnosed closer to their biological disease onset. This narrower range of environmental
exposures acting on genetic susceptibility provides a unique opportunity to investigate early
disease targets and mechanisms. Adapted from (Bar-Or et al. 2016).
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Figure 1.3: Overview of dissertation.
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Abstract
Elucidation of distinct T-cell subsets involved in multiple sclerosis (MS) immune-pathophysiology
continues to be of considerable interest since an ultimate goal is to more selectively target the
aberrant immune response operating in individual patients. While abnormalities of both effectorand regulatory-T cells have been reported in MS patients, prior studies have mostly assessed
average abnormalities in either limb of the immune response, rather than both at the same time
which limits the ability to evaluate the balance between effectors and regulators operating in the
same patient. Assessing both phenotypic and functional responses of effector and regulatory T
cells has also proven important. In studies of adults with MS, in whom biological disease onset
likely started many years before the immune assessments, an added challenge for any reported
abnormality is whether the abnormality indeed contributes to the disease (and hence of interest to
target therapeutically) or merely develops consequent to inflammatory injury (in which case
efforts to develop targeted therapies are unlikely to be beneficial). Pediatric-onset MS, though
rare, offers a unique window into early disease mechanisms. Here, we carried out a
comprehensive integrated study, simultaneously assessing phenotype and functional responses
of both effector and regulatory T cells in the same children with MS, monophasic inflammatory
CNS disorders, and healthy controls, recruited as part of the multi-center prospective Canadian
Pediatric Demyelinating Disease Study (CPDDS). Stringent standard operating procedures were
developed and uniformly applied to procure, process, and subsequently analyze peripheral blood
cells using rigorously applied multiparametric flow cytometry panels and miniaturized functional
assays validated for use with cryopreserved cells. We found abnormally increased frequencies
and exaggerated pro-inflammatory responses of CD4+CCR2+CCR5+ effector T cells (Teff) in
pediatric-onset MS, compared to both control groups. CD4+CD25hiCD127lowFOXP3+ regulatory T
cells (Tregs) of children with MS exhibited deficient suppressive capacity, including diminished
capacity to suppress disease-implicated Teff. In turn, the implicated Teff of MS patients were
relatively resistant to suppression by normal Tregs. An abnormal Teff/Treg ratio at the individual
child level best distinguished children with MS from controls. We implicate abnormalities in both
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frequencies and functional responses of distinct pro-inflammatory CD4 T cell subset, as well as
Treg function, in pediatric-onset MS, and suggest that mechanisms contributing to early MS
development differ across individuals, reflecting an excess abnormality in either Teff or Treg limbs
of the T cell response, or a combination of lesser abnormalities in both limbs.
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Abbreviations
CPDDS=Canadian Pediatric Demyelinating Disease Study
EAE=Experimental Autoimmune Encephalomyelitis
ETP=Experimental Therapeutics Program
IFNγ=Interferon Gamma
KLRB1=Killer cell Lectin-like Receptor subfamily B member
MCP=Monocyte Chemoattractant Protein
MIP=Macrophage Inflammatory Protein
monoADS=monophasic Acquired Demyelinating Syndromes
PBMC=Peripheral Blood Mononuclear Cells
RANTES=Regulated upon Activation Normal T cell Expressed and Secreted
SOP=Standard Operating Procedure
TCR=T-cell Receptor
Teff=T effector cells
TNF=Tumor Necrosis Factor
Treg=T regulatory cells
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Introduction
Elucidation of immune cell subsets and their responses that contribute to multiple sclerosis (MS)
immune-pathophysiology continues to be of major interest. Cellular immune responses relevant
to MS inflammatory disease activity almost certainly reflect interactions between different immune
cell types (such as T cells, B cells and myeloid cells) and their pro-inflammatory and antiinflammatory subsets (Li, Rezk, Healy, et al. 2015). Among these, effector and regulatory T cells
continue to be regarded as important participants in mediating CNS injury in MS. While
abnormalities in both effector (CD4+ and CD8+) T cells (Teff) and regulatory T cells (Treg) have
been implicated in MS (Viglietta et al. 2004; Mahad et al. 2006; Venken et al. 2008; Annibali et al.
2011; Sato et al. 2012; Abrahamsson et al. 2013; Balint et al. 2013; Darlington et al. 2013;
Vargas-Lowy et al. 2013), these findings have not always been replicated and it has been difficult
to conclusively define disease-relevant immune cell subsets (Kleinewietfeld and Hafler 2013;
Carbajal et al. 2015; Grant et al. 2015). In part, such difficulties reflect inherent limitations of
conducting these studies in adults, in whom biological disease onset likely started many years
before biological sampling. This has made it challenging to distinguish abnormalities that reflect
pathogenic roles of implicated immune cells from abnormalities that develop secondary to
ongoing injury or chronic immune dysregulation in persons with long-standing disease. In
contrast, a potentially narrower window between biological- and clinical-disease onset in pediatric
MS offers an opportunity to elucidate early and putatively disease-relevant immune cell subsets
and their abnormal response profiles.
Prior studies in adult- and pediatric-onset MS have generally focused on either effector or
regulatory T cell measures, but not both. This includes two studies comparing pediatric MS to
healthy pediatric controls, one reporting average abnormalities in Teff cells (Vargas-Lowy et al.
2013) and the other implicating the Treg (Balint et al. 2013) limb of the immune response in
children with MS. An integrated examination of both Teff and Treg subsets in the same cohort
would address key unanswered questions, including whether individual patients preferentially
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harbor abnormalities in effector or regulatory limbs of their immune response (or whether both
abnormalities tend to co-exist within the same individual patients), and to what extent failure to
contain effector responses relates to functional defects in the regulatory capacity of the Treg limb,
versus resistance of the Teff limb to be regulated [as suggested in adults (Schneider et al. 2013)].
The importance of assessing not only phenotypes but also functional response capacities of
disease-implicated cells has been emphasized in recent work in adult MS (Cao et al. 2015). We
previously showed that, even in pediatric-onset disease, distinguishing abnormal immune
responses that contribute to injury from those that emerge as part of the immune response to
injury is not straightforward (Banwell et al. 2008). Comparing immune profiles of children with MS
soon after their sentinel clinical attack not only with healthy control children, but also with children
who experienced a monophasic inflammatory demyelinating episode of the central nervous
system (CNS) (ie, non-MS CNS inflammatory disease), permits evaluation of early immune
abnormalities of MS and features that are more likely to be specific to MS rather than non-specific
features of immune response to inflammatory CNS injury.
While studies in pediatric MS are attractive as noted above, such efforts have been constrained
both by the small volumes of blood available and by the rarity of the disorder which often requires
multi-site recruitment (with inherent challenges of ensuring consistency in sample processing and
assay implementation). Here, we developed standardized methodologies for high quality multicenter sample procurement and handling, assay miniaturization and centralized implementation,
and applied these to prospectively followed children recruited at time of incident acute acquired
demyelinating syndromes (ADS). This enabled us to prospectively define for the first time
phenotypic and functional abnormalities in both Teff and Treg subsets that distinguish children
confirmed to have MS from children with non-MS monophasic inflammatory CNS disorders
(referred to as monoADS), and healthy controls (HC).
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Materials and methods
Study participants
We studied children recruited at time of presentation with incident acute acquired demyelinating
syndromes (ADS) and followed prospectively as part of the Canadian Pediatric Demyelinating
Disease Study (CPDDS) to ascertain those with a diagnosis of MS versus those remaining with
monophasic disease (monoADS). Inclusion/exclusion criteria and clinical characteristics of the
overall CPDDS have been previously described (Banwell et al. 2011) The Supplementary
Methods detail (Appendix 2.1) the criteria used to select representative participants for the
current study and Table 2.1 identifies demographics of children with ADS ascertained as having
MS, children with ADS remaining monophasic (monoADS), and healthy controls (HC), including
age at time of incident ADS presentation, age at time of blood sampling, and total follow-up
duration from ADS onset. All protocols and informed consent/assent were approved by the
institutional ethics-review boards.
Standard operating procedures (SOPs) for CPDDS biological sample procurement, processing,
and analysis
Since reliable study of functional immune response profiles in children with a relatively rare
condition is predicated on the ability to interrogate high-quality viable cell samples using limited
volumes of blood obtained in the context of multi-center recruitment, our Experimental
Therapeutics Program (ETP) developed and implemented standard operating procedures (SOPs)
for all steps of venous blood sample procurement, handling, shipping, central lab processing
(Ficoll-density

gradient

centrifugation

to

peripheral

blood

mononuclear

cells;

PBMC),

cryopreservation (liquid nitrogen vapor phase), storage and subsequent thawing of PBMC.
Recruiting sites were all trained and regularly monitored, and the SOPs were consistently
implemented throughout the CPDDS, with the identical approach also used for samples obtained
from the HC children. The multi-parametric flow cytometry panels and functional assays
(described below), together able to characterize both the phenotype and function of immune-cell
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subsets of interest, were also standardized, miniaturized, and validated for use with
cryopreserved cells obtained using the study SOPs.
Identifying and functionally-phenotyping T cell subsets of interest
Comprehensive literature review (Appendices 2.1 and 2.3.1) was carried out to identify effector
(CD4+ and CD8+) T cell subsets putatively implicated in MS as well as other human autoimmune
diseases. Multi-parametric flow-cytometry panels (Appendices 2.3.2 and 2.3.3) designed to
characterize the T cell subsets within PBMC were developed and validated for use with
cryopreserved samples (Appendix 2.1). PBMC were rapidly thawed and rested for 2 hours. In
each experiment, phenotypic and functional analyses of PBMC were analyzed in batch using all
samples passing pre-defined quality control (Appendix 2.1) from a balanced number of children
with MS, monoADS and HC. Rested cells were either left unstimulated or activated for 4 hours
with PMA/ionomycin and Golgi stop, then stained for T cell subset surface markers, and for
intracellular cytokines, using appropriate isotype-controls (Appendix 2.3.3). Samples were
acquired on LSR-Fortessa (BD Biosciences), and analysed using FlowJo (version 10.7, Tree
Star, Ashland, OR, USA). Appendix 2.2.1 depicts the basic strategy for CD4+ and CD8+ T cell
subset gating. HLA-DRB1 genotyping was carried out using allele specific PCR amplification as
previously described (Disanto et al. 2011).

Cross-over Treg suppression and Teff resistance assays
Regulatory T cell (Treg)-suppression assays were first developed using freshly isolated adult
PBMC (Nyirenda et al. 2015), then miniaturized, adapted, and validated for use with pediatric
cryopreserved PBMC, and applied in a standardized way to balanced batches of samples from
children with MS, monoADS and HC (Appendix 2.1). Briefly, thawed PBMC were sorted into
CD4+CD25hiCD127low regulatory T cells (Tregs); CD4+CD25-CD127+ (conventional responder T
cells); and CD4+CCR2+CCR5+ effector T cells (Teff), with confirmed subset purities >95%
(Appendix 2.2.4. A, B). Treg suppression assays were performed in a ‘cross-over’ design to
compare the ability of Tregs sorted from the different cohorts to suppress the same responder
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cells (conventional or Teff), as well to assess the ability of responder cells sorted from the
different cohorts to resist suppression by the same Tregs. CD4+CD25hiCD127low Tregs were
titrated into co-culture with fixed numbers of responder T cells (1.2 x 103 stimulated with platebound anti-CD3 and anti-CD28, achieving Treg/Tresp ratios of 0:1, 1:8, 1:4 and 1:2 in 96-well Ubottom plates). After 5 days at 37°C, 16-hour tritiated-thymidine incorporation was measured and
cell proliferation was expressed as counts per minute (cpm). Percent suppressive capacity of
Tregs was determined as: (1 - cpm of Treg:Tresp co-culture/cpm of Tresp alone) x 100.
Statistical analysis
Between-group comparisons of average frequencies of surface-molecule expressing immune cell
subsets and cytokine-expressing or FOXP3-expressing immune cell subsets were analyzed by
using two-tailed non-parametric Mann-Whitney U test for independent groups and p-values are
based on Mono and MS z-scores derived from the HC group (using mean and SD). For Treg
suppression assays, the mean ± SEM counts per minute (cpm) of triplicate cultures was
calculated for each co-culture condition, and data were analyzed using two-tailed paired
comparisons with the Wilcoxon signed rank test for paired samples (monoADS and MS). All
statistical analyses were performed using SPSS software (IBM SPSS Statistics for Windows,
Version 24.0. Armonk, NY: IBM Corp). p values < 0.05 were considered statistically significant.

30

Results
Study participants
Based on the planned selection criteria (see Methods and Appendix 2.1), a total of 71 children
were studied (Table 1), including 23 with confirmed MS (F:M = 14:7; age at ADS: 12.8 ± 2.4
years; age at sampling: 14.1±2.3 years), 26 with monophasic disease (F:M = 15:11; age at ADS:
9.6 ± 3.2 years; age at sampling: 12.3±2.9 years) for whom biological samples were available for
comparison, and 22 healthy control (HC) children without a personal or family history of MS or
autoimmune disease (F:M = 11:11; age at sampling: 14.4 ± 2.1 years).
Abnormal frequencies and proinflammatory responses of CD4+CCR2+CCR5+ T cells in pediatric
MS
Overall frequencies of CD3+ T cell or of CD4+ and CD8+ T cell subsets (Appendix 2.2.2. A, D),
were no different between children with MS, monoADS, or HCs, nor were there differences in the
frequencies of activation-induced IFNγ or IL-17 expressing T cells within the total CD4 or CD8 T
cell subsets across cohorts (Appendix 2.2.2. B, C, E, F). However, children with MS selectively
harboured increased frequencies of CCR2+CCR5+ CD4+ T cells (Figure 2.1. A, B) averaging
6.5% of circulating CD4+ T cells, compared to both HC (3.5%) and children with monoADS (also
3.5%). These cells in the children with MS also exhibited abnormally increased activation-induced
Th1 and Th17 pro-inflammatory cytokine responses (7.95% and 8.9%, respectively), compared to
both HC children (4.5% and 3.2%) and children with monoADS (5.4% and 5.1%) (Figure 2.1. CE).
Similar overall frequencies but reduced FOXP3 expression and suppressive capacity of Tregs in
children with MS
While overall frequencies of CD4+CD25hiCD127low T cells (an estimate of regulatory T cells;
Tregs) did not differ across groups (average frequencies for MS: 3.5%; HC: 4.1%; monoADS:
3.4%) (Figure 2.2. A, B), their average expression of FOXP3 (Figure 2.2. C) was slightly lower in
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children with MS compared to both monoADS and HC children. Subset analysis indicated that the
frequency of memory (CD45RO+FOXP3+) Tregs was increased, frequencies of naïve (CD45ROFOXP3+) Treg and RTE (CD31+CD45RO-FOXP3+) Treg subsets were decreased in children with
MS compared to both control cohorts (Appendix 2.2.3. A, B). CD4+CD25hiCD127loFoxP3+ Treg
cells expressing CD39 showed a trend toward increase in children with MS as compared to
controls (Appendix 2.2.3. C). Since FOXP3 expression has been correlated with Treg
suppressive capacity, we compared the relative capacities of CD4+CD25hiCD127low Treg sorted
from the different groups (Appendix 2.2.4 for gating strategy) to suppress proliferation of
conventional responder (CD4+CD25-CD127+) T cells, sorted from HC subjects (HC-Tresp). While
Tregs of monoADS and HC children exhibited similar capacities to suppress proliferation of the
same normal Tresp, Tregs of MS children exhibited deficient suppressive capacity (Figure 2.2.
D).
Pediatric MS Tregs exhibit reduced capacity to suppress disease-implicated Teff cells, and their
Teff cells are resistant to suppression
We next assessed the capacity of Tregs from children with MS to suppress the very effector cells
implicated as abnormal in these children. We focused on the CD4+CCR2+CCR5+ Teff cell subset
(whose activation is more readily induced in short-term cultures). Compared to Tregs of both
monoADS and HC children, Tregs of MS children exhibited deficient capacity to suppress the
CD4+CCR2+CCR5+ Teff cells (Figure 2.2. E).

Our cross-over design enabled us to further

examine the relative susceptibility of responder cells to Treg suppression. Both conventional
(CD4+CD25-CD127+)

responder

T

cells,

as

well

as

the

disease-implicated

effector

(CD4+CCR2+CCR5+) T cells, isolated from children with MS were relatively resistant to regulation
compared to the responder T cell subsets of healthy children (Figure 2.2. F).
Pediatric MS CD4+CD161+ T cells are enriched in CCR2+CCR5+ T cells, and an abnormal Teff to
Treg balance distinguishes children with MS from controls
Since resistance to Treg suppression has been reported in CD4+ Th17 cells from patients with
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rheumatoid arthritis that co-express CD161+ (Basdeo et al. 2015)(Basdeo, 2015), we wished to
assess co-expression of CCR2, CCR5 and CD161 on CD4+ T cells. We first found that children
with MS harbor abnormally increased frequencies of circulating CD4 T cells expressing CD161
(average 10.1%) compared to both HC (6.3%) and monoADS controls (6.1%) (Figure 2.3. A, B).

Compared to the frequencies of CCR2+CCR5+ T cells within total CD4+ T cells (Figure 2.1. A, B;
Figure 2.4. C, D), CCR2+CCR5+ T cells were enriched within the CD4+CD161+ cell population,
and this enrichment was substantially exaggerated in the children with MS (Figure 2.3. C, D).
Further supporting a pathogenic role of this particular Teff subset in MS, was the observation that
the balance between these CD4+CD161+CCR2+CCR5+ T cells and the Tregs (assessed using the
simple ratio between the Teff/Treg frequencies in individual children), was highly abnormal in the
MS children, better distinguishing them from both healthy and monoADS children (Figure 2.3. E)
than any single abnormality noted above.
Serial assessment of Teff to Treg balance in children with MS and monoADS controls
We considered whether the Teff/Treg abnormalities noted in individual children reflected episodic
abnormalities (potentially related to disease activity) or a characteristic of the individual that is
relatively stable over time. To address it, we serially studied the Teff and Treg frequencies as well
as Teff/Treg ratios in 10 children (6 with MS and 4 with monoADS) at 3 time points (separated
over at least 2 years).

To avoid the potential confounding effects of immune therapies we

focused on children for whom we had collected serial untreated samples (on no disease
modifying therapy and at least 60 days following steroid treatment, for all time points). We first
considered

the

trajectories

of

the

CD4+CD161+CCR2+CCR5+

Teff

frequencies

and

CD4+CD25hiCD127lo Treg frequencies in all children captured at the three timepoints (TP1, TP2
and TP3; Figure 2.4. A, B). While fluctuations were observed, overall, there appeared to be
particular individuals with consistently lower frequencies, and other individuals with overall higher
frequencies of both Teff and Tregs, over time. We then calculated the Teff/Treg ratios, shown
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separately for the 4 children with monoADS (Figure 2.4. C) and the 6 children with MS (Figure
2.4. D). The Teff/Treg ratios of the children with monoADS tended to be low, and relatively stable
over time. In contrast, there appeared to be greater variability across the children with MS;
several of the children exhibited greater magnitude fluctuations though, overall, particular
individuals again tended to have lower ratios and others, higher ratios over time.
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Discussion
While abnormalities of both effector- and regulatory-T cells have been reported in MS patients,
prior studies have typically assessed either limb of the immune response. We hypothesized that
mixed contributions of abnormalities in effectors and regulators may exist across individuals with
MS. Testing this would require both limbs of the immune response to be assessed at the same
time. To better understand how such an imbalance between disease-implicated effectors and
regulators may manifest in patients with MS, we chose to focus on pediatric-onset MS since
these individuals, on the average, would be expected to be closer to biological-disease onset,
and any imbalances between effectors and regulators may more likely reflect their actual
involvement in the disease process rather than manifestation as epi-phenomena or
consequences of chronic disease and immune response to injury. We also considered that past
difficulties duplicating individual study findings (such as consistent disease-implication of
particular immune cell subsets) may in part reflect methodological differences between studies,
including the limited number of studies that assess both phenotype and function of subsets of
interest and the lack of inclusion of controls with other (non-MS) inflammatory CNS disease.

We report abnormal frequencies and pro-inflammatory functions of a distinct subset of CD4 T
cells in children with MS compared to both healthy and other CNS inflammatory disease
(monoADS) controls. In findings that further support prior reports in adults with MS, we identify
abnormalities in the function of pediatric MS regulatory T cells, as well as decreased susceptibility
to suppression of their disease-implicated pro-inflammatory T cells. Based on our integrated
analysis of both effector and regulatory T cell populations, we suggest that MS can manifest
when the balance between the effector and regulatory limbs of the immune response in individual
children is disrupted, whether the abnormality is predominantly due to exaggerated proinflammatory responses of their distinct effectors, insufficient regulation by their regulatory cells,
or lesser combinations of both.
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Recruitment of children following the sentinel clinical presentation of their disease, enabled us to
evaluate immunological features of pediatric MS without the confound of immunomodulatory
therapy exposure. We note that selection of samples from patients who remained untreated over
the first years of disease could bias our sample to individuals who opted not to be treated,
including those with milder disease. However, such a bias would be expected to diminish rather
than enhance differences between disease-relevant immune cell subsets assessed in children
with MS compared to the controls. To overcome operational challenges inherent to the study of
rare patient populations, and to minimize the impact of pre-analytical variables that can severely
hamper sample quality and interpretation of results in such studies, we developed and validated
rigorous methodologies for all phases of sample processing and analysis. Consistent
implementation of these protocols which we validated for use with the small-volume samples,
multi-site procurement, and cryopreserved specimens, enabled us to comprehensively
characterize distinct immune cell subsets, both phenotypically and functionally, as well as
evaluate how distinct Teff and Treg subsets perform within a given patient and across patients
and controls.
T cells expressing CCR2 (which binds several chemokines including CCL2 (MCP-1)) or CCR5
(which binds CCL3 (MIP-1a) and CCL5 (RANTES) amongst others) have individually been
implicated in autoimmune diseases including colitis and MS (Appendix 2.3.1). In MS, earlier
immunohistologic studies identified both CCR2 and CCR5 expressing cells in perivascular lesions
of MS brain with colocalization of their ligands around the vessels (Balashov 1999; Simpson
2000). Our findings in pediatric-onset MS support a pro-inflammatory role for the subset of CD4+
T cells that co-express both CCR2 and CCR5, a chemokine receptor profile particularly suited for
cell homing to the CNS (Kivisakk et al. 2002 ; dos Santos et al. 2005 ; Mahad et al. 2006 ; Sato et
al. 2012; Balashov et al. 1999; Fife et al. 2000; Simpson et al. 2000). CD4+CCR2+CCR5+ T cells
have been consistently implicated as pro-inflammatory, including prior findings from adult patients
with MS, in whom CD4+CCR2+CCR5+ T cell frequencies were found increased in the CSF, as
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well as in the blood at time of relapse (Sato et al. 2012). Functionally, circulating CCR5+ T cells
isolated from PBMC of MS patients were previously shown to secrete high levels of IFNγ
(Balashov et al. 1999) and the interaction of CCR2 with its ligand MCP-1 has been shown to play
an important role in effector CD4 T cells migration across the blood brain barrier (Mahad et al.
2006). By assessing functional responses of both effector and regulatory T cells in our pediatric
population, we provide support for a pro-inflammatory role of CD4+CCR2+CCR5+ T cells in
pediatric-onset MS, not only with the demonstration that they tend to circulate at higher
frequencies and exhibit abnormally increased IL-17 and IFNγ responses but also with the novel
observation that this T cell subset is relatively resistant to regulation in the children with MS.
Future studies with technologies such as single cell RNASeq or CITE-seq using 10X genomics
are warranted to assess whether the Teff subset implicated here in the periphery of children with
MS are also implicated in the CNS of these children.
Both reduced functional capacity of Tregs and resistance of effector cells to suppression by Tregs
have been proposed to play a role in the incomplete control of pro-inflammatory effector cells in
MS (Goodman et al. 2011; Wehrens et al. 2011; Schneider et al. 2013; Trinschek et al. 2013;
Nyirenda et al. 2015). The cross-over design of our functional assays extends prior work (Balint et
al. 2013) by demonstrating that defective Treg function in children with MS is not a general
feature of pediatric CNS inflammatory demyelinating conditions. It further demonstrates that,
among the overall responder T cell population, resistance to suppression is a feature of the very
CD4+ CCR2+CCR5+ effector T cell subset we implicate here as abnormally pro-inflammatory in
the children with MS. The molecular mechanisms underlying Teff resistance to suppression are
not fully elucidated and may include decreased expression by the Teff of receptors that bind
inhibitory Treg cytokines (such as IL-10 or TGFβ) or limiting Treg function through downregulation
of Foxp3 within the Treg or local secretion of cytokines including IL-6, IL-17 or TNFα by other
cells (Grant et al. 2015). It would indeed seem unlikely that T cells contribute to autoimmune
disease in isolation. In this regard, the remarkable success of selective B cell depletion using anti37

CD20 therapies in MS patients (Hauser et al. 2017) together with the elucidation of non-antibody
dependent functions of B cells (including their ability to shape pro-inflammatory T cell responses
through secretion of TNFα, IL-6 and GM-CSF (Bar-Or et al. 2010; Barr et al. 2012; Li, Rezk,
Miyazaki, et al. 2015) and reviewed in (Li, Rezk, Healy, et al. 2015) implicate important B cell:T
cell interactions in the human disease. Of interest in future studies will be to examine such
interactions as well as both antibody-dependent and antibody-independent functions of B cells
and their relation to disease activity in patients with pediatric- and adult-onset MS.
While functions of CD161 (KLRB1; killer cell lectin-like receptor subfamily B member) are not fully
elucidated, its expression has been associated with resistance to suppression by Treg in patients
with rheumatoid arthritis (Basdeo et al. 2015). Of note, we found that CCR2+CCR5+ T cells are
enriched within CD4+ T cells expressing CD161, and to a much greater extent in children with MS
compared to controls. Moreover, children with MS exhibited a highly abnormal ratio between their
circulating CD4+CD161+CCR2+CCR5+ Teff cells and Tregs. Together our results point to the
CD4+CD161+CCR2+CCR5+ subset of T cells as the most abnormally implicated subset of Teff in
children with MS, exhibiting increased frequencies, exaggerated pro-inflammatory responses and
potential resistance to Treg suppression (that may be due to both active molecular mechanisms
of resistance, as well as numerical abundance relative to Tregs).
In a small subset of pediatric patients, we explored the behavior of the balance between the Teff
and Treg (assessed as the Teff/Treg ratios in individual children) over time, using serial samples
collected over at least a 2-year period. Specifically, we wished to assess whether the Teff/Treg
abnormalities we noted in individual children with MS reflected episodic abnormalities (that could
potentially reflect the state of disease activity) or a characteristic of the particular individual that is
relatively stable over time. These samples were selected from children who were off disease
modifying treatment (DMT), to avoid potential confounds of immune therapy. This could introduce
a bias towards children with relatively little disease activity over time, although many of these
samples were obtained at a time that most children with MS remained untreated with DMTs
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unless they had particularly active disease. Because we also avoided recent steroid use, these
samples were not collected around the time of acute clinical relapses (though this would not
preclude subclinical disease activity), hence our assessment is not ideally suited for defining
whether MS patients experience major fluctuations in their Teff/Treg ratios in relation to acute
disease activity. Rather, our findings are in keeping with the view that, overall, greater variability
exists across individuals, while the ratio within an individual tends to be a relatively stable
characteristic of that individual, over time. This finding is consistent with results from Kivisäkk and
colleagues who previously reported that expression of CCR2 and CCR5 by CD4+ T cells is stable
over time in the same person, though varies across individuals (Kivisakk et al. 2003).
The samples we selected to compare children with MS and monoADS were well balanced with
respect to HLA-DRB1 genotype (with approximately 65% homozygous-negative, 25%
heterozygous and less than 10% homozygous-positive in both cohorts). HLA may be particularly
relevant in the context of antigen-specific MHC-restricted responses, while our study compared
overall T cell subset frequencies and responses to polyclonal activation. The balanced HLADRB1 genotype between the patients with MS and monoADS in our cohort suggests that this
genotype is not the driving force for the abnormal Teff/Treg balance seen in children with MS.
One could speculate that HLA influences MS disease susceptibility through mechanisms that are
different/complementary to those that modulate the state of disease in patients with established
disease. This also raises the interesting possibility that the differences in T cell subset responses
that we report here between MS and monoADS cohorts may be shaped by other
genetic/environmental/epigenetic features. Future studies with larger numbers of pediatric MS
patients and controls could examine the relationship between the GWAS-implicated genetic
variants as well as other suspected disease modulators (eg, vitamin D levels, EBV status,
adiposity and smoking exposure) on the Teff and Treg measures in these individuals, and
potentially relate these to clinical and MRI measures of disease activity.
Collectively, our findings indicate that the ultimate capacity to regulate disease-relevant effector T
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cell responses in children with MS may reflect a combination of deficient suppressive capacity by
the regulatory compartment, as well as relative resistance to suppression by particular pathogenic
effector subsets. Future studies will establish whether measurement of the particular Teff/Treg
ratio (rather than each measure in isolation) will better serve to distinguish MS patients from
controls and, if validated, emerge as a useful measure of disease state and response to particular
therapies. An abnormal balance between CD4+ pro-inflammatory Teff cells co-expressing CD161,
CCR2 and CCR5 may not only be a distinguishing feature of individuals with early MS but may
also emerge as a useful measure of disease state and possibly response to therapy, warranting
future study.
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Tables
Table 2.1: Participant Demographics and Immune Assays Performed
Age at

Timing of

Follow-up

ADS

blood

blood draw

available

presenting

sampling

after ADS

after ADS

Immune

Diagnosis

Sex

phenotype

(years)

(years)

(years)

Assays

MS-01

F

Polyfocal

9.8

2.1

9.0

FIP

MS-02

M

Monofocal

17.6

1.9

9.4

FIP

MS-03

F

Monofocal

16.2

0.5

7.4

FIP

MS-04

F

Polyfocal

14.9

0.3

10.3

FIP

MS-05

F

Monofocal

14.3

0.05

11.1

FIP

MS-06

F

Monofocal

14.6

4.4

13.0

FIP

MS-07

M

Monofocal

16

0.6

11.2

FIP

MS-08

F

Polyfocal

14

2.3

11.6

FIP, SIP

MS-09

M

Monofocal

15.9

0.5

10.0

FIP

MS-01

F

Monofocal

17.3

7.1

13.3

FIP

MS-11

M

Monofocal

16

2.1

12.1

FIP

MS-12

F

Monofocal

14.5

0.9

9.1

FIP

MS-13

F

Monofocal

12.5

0.4

7.2

FIP

MS-14

M

Monofocal

15.6

0.2

6.7

FIP

MS-15

F

Monofocal

11.6

0.4

7.2

FIP, Reg,
ER, SIP

MS-16

F

Monofocal

14.2

0.2
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7.7

FIP, Reg,

ER, SIP
MS-17

F

Monofocal

11.9

1.1

7.8

Reg, ER

MS-18

F

Polyfocal

13.9

3.0

12.6

Reg, ER

MS-19

M

Monofocal

10.2

0.4

7.9

Reg, ER

MS-20

F

Monofocal

15.5

0.2

7.3

Reg, ER

MS-21

M

Monofocal

12.7

0.03

7.2

Reg, ER, SIP

MS-22

F

Polyfocal

9

3

10

SIP

MS-23

F

Monofocal

8.6

0.1

5

SIP

16F

13.8

1.38

9.3

7M

(± 4.9)

(± 1.7)

(± 2.3)

Age at

Timing of

Follow-up

ADS

blood

blood draw

available

presenting

sampling

after ADS

after ADS

Immune

Sex

phenotype

(years)

(years)

(years)

Assays

Mono-01

M

Polyfocal

11.4

1.1

10.2

FIP

Mono-02

F

ADEM

5.6

2.0

9.4

FIP

Mono-03

F

Monofocal

12

1.0

7.2

FIP

Mono-04

M

Monofocal

13.4

8.2

13.9

FIP, SIP

Mono-05

F

Monofocal

15.2

0.6

6.9

FIP

Mono-06

F

ADEM

15.8

4.1

13.9

FIP

Mono-07

F

Monofocal

14.6

5.2

13.1

FIP, SIP

Mono-08

M

Monofocal

15.8

3.9

11.0

FIP, SIP

Diagnosis
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Mono-09

M

Monofocal

12.3

0.02

10.2

FIP

Mono-10

M

Polyfocal

14.9

1.9

12.3

FIP, SIP

Mono-11

F

Monofocal

11.3

0.1

10.6

FIP

Mono-12

M

ADEM

17.6

7.4

12.6

FIP

Mono-13

F

ADEM

15.6

2.2

7.5

FIP

Mono-14

M

Polyfocal

12.8

0.8

5.9

FIP

Mono-15

M

Monofocal

14.7

1.9

7.9

FIP

Mono-16

M

Monofocal

16.3

2.1

7.8

FIP

Mono-17

F

Monofocal

12.3

1.9

11.2

FIP

Mono-18

F

Monofocal

10.5

5.1

11.1

FIP

Mono-19

M

ADEM

11.1

3.9

10.2

FIP

Mono-20

F

ADEM

8.4

4.1

13.7

FIP, Reg, ER

Mono-21

F

Monofocal

10.3

4.1

10.3

FIP, Reg, ER

Mono-22

F

Monofocal

13.3

3.0

11.2

Reg, ER

Mono-23

F

Monofocal

9.9

0.3

9.3

Reg, ER

Mono-24

M

Monofocal

11.8

3.9

10.5

Reg, ER

Mono-25

F

Monofocal

9.7

4.0

12.0

Reg, ER

Mono-26

F

Polyfocal

8.5

0.7

7.7

Reg, ER

15F

12.3

2.83

10.3

11M

(± 2.9)

(± 2.16)

(± 2.3)
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Age at
blood
sampling

Immune

Sex

(years)

Assays

HC-01

M

10.3

FIP

HC-02

F

16

FIP

HC-03

M

14.9

FIP

HC-04

F

15.1

FIP

HC-05

F

15.6

FIP

HC-06

M

15.6

FIP

HC-07

M

16.6

FIP

HC-08

F

16

FIP

HC-09

F

16.4

FIP

HC-10

F

14

FIP

HC-11

M

14.7

FIP

HC-12

F

16.5

FIP

HC-13

F

11.5

FIP

HC-14

F

14.6

FIP

HC-15

F

14.5

FIP

HC-16

M

14.5

FIP

HC-17

M

11.1

FIP, Reg,

Diagnosis

ER
HC-18

F

16.2

FIP, Reg,
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ER
HC-19

M

14

FIP,

Reg,

ER
HC-20

M

10.2

Reg, ER

HC-21

M

14.0

Reg, ER

HC-22

M

16.9

Reg, ER

11F

14.4

11M

(± 2.1)

Abbreviations:

ADEM=acute

disseminated

encephalomyelitis;

ADS=incident

acquired

demyelinating syndrome; ER=effector-resistance assay; F=female; FIP=functional immune
phenotyping; HC=healthy control; M=male; Mono=monophasic (mono)ADS; MS=multiple
sclerosis; R=regulatory assay.
None of the children had ever received immune modulatory treatments and the majority (92%)
had not received any steroids within 30 days of blood procurement.
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Figures
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Figure

2.1:

Increased

frequencies

and

pro-inflammatory

cytokine

responses

of

CD4+CCR2+CCR5+ T cells in children with MS.
Peripheral Blood Mononuclear Cells (PBMC) were stained with appropriate antibodies and
isotype controls and initially gated on singlet, live, total CD4 +CD3+ T cells (Supplementary Figure
2). (A) Dot-plots depicting approach to gating on CD4+CCR2+CCR5+ T cells in representative
healthy control (HC), monoADS (Mono), or multiple sclerosis (MS) children. (B) Percentages of
circulating CD4+CCR2+CCR5+ T cells in HC (n=17), Mono (n=18), and MS (n=15). Two-tailed
non-parametric Mann-Whitney U test for independent groups of Mono and MS z-scores using the
mean and SD of the HC; U=71, p=0.021. (C) Following short-term activation with PMA/Ionomycin
and Golgi stop, PBMC were stained for both surface markers and intracellular cytokines. Dot
plots are shown for HC, Mono, or MS children depicting IFNγ and IL-17 expression by activated
CD4+CCR2+CCR5+ T cells. (D, E) Percentages of IFNγ and IL-17 expressing CD4+CCR2+CCR5+
T cells in HC (n=13), Mono (n=13), and MS (n=14). Mann-Whitney U=19, p=0.034 for IFNγ and
U=44, p=0.023 for IL-17.
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Figure 2.2: Reduced FoxP3 expression and suppressive capacity of circulating
CD4+CD25hiCD127low regulatory T cells (Tregs), and relative resistance to suppression
by disease-implicated effector T cells (Teff), in children with MS.
Peripheral Blood Mononuclear Cells (PBMC) were stained with appropriate antibodies and
isotype controls and initially gated on singlet, live, total CD4+CD3+ T cells (Appendix 2.2.1). (A)
Dot-plots gating within CD4+CD3+ T cells on CD25hiCD127low T cells as an estimate of circulating
regulatory T cells (Tregs) in representative healthy control (HC), monoADS (Mono), or multiple
sclerosis (MS) children. (B) Similar Treg frequencies observed across groups HC (n=18), Mono
(n=21), and MS (n=15). Two-tailed non-parametric Mann-Whitney U test for independent groups
of Mono and MS z-scores using the mean and SD of the HC group; U=144, p=0.665. (C)
decreased FOXP3 expression by CD25hiCD127low Tregs of children with MS compared to
controls; U=26, p=0.041. (D) Tregs of children with MS have reduced capacity to suppress
CD4+CD25-CD127+ responder (Tresp) cells. Treg suppression assays were performed using
FACS-sorted CD4+CD25-CD127+ Tresp cells and CD4+CD25hiCD127low Tregs (Appendix 2.2.4.
for gating strategy). To compare Treg functional capacity across pediatric cohorts, constant
numbers of Tresp cells (1.2x103 cells) from HC donors were cultured alone or with
CD4+CD25hiCD127low Tregs isolated from children with MS, Mono, or HC, at Treg/Tresp ratios of
0:1, 1:8, 1:4, and 1:2 (n=7 children per group). Cells were cultured in triplicates in 96-well Ubottom plates in the presence of plate-bound anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) and
incubated for 5 days at 37oC then pulsed [3H]thymidine for an additional 16 h of culture
(Appendix 2.1. Supplementary Methods). Proliferation (counts per minute [cpm]) of Tresp cells
is shown in the absence or presence of Tregs, at the indicated ratios. Non-parametric Wilcoxon
signed rank test was used; Z1:8=-2.108, p=0.03; Z1:4=-1.725, p=0.08; Z1:2=-2.492, p=0.01. (E)
Tregs of children with MS have reduced capacity to suppress the disease implicated
CD4+CCR2+CCR5+ Teff cells. Constant numbers of FACS-sorted CD4+CCR2+CCR5+ diseaseimplicated

Teff

cells

CD4+CD25hiCD127low

from

HC

donors

were

cultured

alone

or

co-cultured

with

Tregs from children with MS, Mono, or HCs, using the same ratios and

assessment of proliferation as described above. Non-parametric Wilcoxon signed rank test; Z1:8=1.214, p=0.22; Z1:4=-2.492, p=0.01; Z1:2=-2.747, p=0.006. (F) Tresp and Teff cells of children with
MS are relatively resistant to suppression by normal Treg cells. Constant numbers of FACSsorted CD4+CD25-CD127+ Tresp or CD4+CCR2+CCR5+ Teff T cells (1.2x103 cells) from children
with MS or HCs, were cultured alone or co-cultured with HC CD4+CD25hiCD127low Tregs at 0:1,
1:8, 1:4 and 1:2 Treg/Teff ratios. ‘Percent suppression’ of proliferation was determined as 1-(cpm
incorporated in the co-culture/cpm of Tresp cells alone) x 100%. (n=7). Non-parametric Wilcoxon
signed rank test; Z Tresp=-2.625, p=0.009 and Z Teff=-3.077, p=0.002.
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Figure 2.3: CCR2+CCR5+ Teff cells are enriched within CD4+CD161+ T cells, particularly in
children with MS, who exhibit an abnormal balance between disease-implicated
CD4+CD161+CCR2+CCR5+ Teff and Treg cells.
Peripheral Blood Mononuclear Cells (PBMC) were stained with appropriate antibodies and
isotype controls and initially gated on singlet, live, total CD4 +CD3+ T cells (Appendix 2.2.1). (A)
Flow cytometry dot-plots depicting approach to gating on CD4+CD161+ T cells in representative
healthy control (HC), monoADS (Mono) or multiple sclerosis (MS) children. (B) Percentages of
circulating CD4+CD161+ T cells in HC (n=10), Mono (n=13), and MS (n=12). Two-tailed nonparametric Mann-Whitney U test for independent groups of Mono and MS z-scores using the
mean and SD of the HC group; U=10, p < 0.001. (C) Flow cytometry dot plots depicting coexpression of CCR2 and CCR5 within CD4+CD161+ T cells in representative HC, Mono, or MS.
(D) Percentages of circulating CCR2+CCR5+ T cells among total CD4+ T cells and among
CD4+CD161+ T cells in HC (n=7), Mono (n=10), and MS (n=8); Mann-Whitney U=13, p=0.016. (E)
The ratio between the frequency of CCR2+CCR5+ T cells (within CD4+CD161+ T cells) and the
frequency of Tregs in individual children with MS (n=8) compared to either Mono (n=9) or HC
(n=8); Mann-Whitney U=10, p<0.001.
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Figure 2.4: The Teff/Treg ratio tends to be a relatively stable characteristic of individuals
subjects.
Thirty peripheral blood mononuclear cells (PBMC) samples were serially at 3 time points (TP1,
TP2, TP3) separated over at least 2 years from 6 children with multiple sclerosis (MS) and 4
children with monoADS (Mono) who were not exposed to disease modifying therapy or steroids.
Frequencies of effector T cells (Teff, CD161+CCR2+CCR5+ CD4+T cells) and regulatory T cells
(Tregs, CD25hiCD127low CD4+ T cells), and Teff/Treg ratios were determined by flow cytometry as
detailed above, with all serial samples from the same individual assessed side by side in the
same experiment. (A) Serial measurements of the CD161+CCR2+CCR5+ CD4+ Teff cell
frequencies in both MS and Mono. (B) Serial measurements of CD4+CD25hiCD127lo Treg
frequencies in both MS and Mono. (C) Serial Teff/Treg ratios in the Mono group. (D) Serial
Teff/Treg ratios in MS group. Teff/Treg ratios of the children with monoADS tended to be low and
relatively stable over time. In children with MS, greater variability in Teff/Treg ratios was observed
across individuals, though individual children generally maintained their ratio over time.
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Abstract
Abnormal pro-inflammatory T cell responses are reported in children with MS, though the
antigenic specificities of such T cells are largely unknown and difficult to assess. The objective
was to develop a new Activation-Induced Marker (AIM) assay able to quantify antigen-specific T
cell responses to putative disease-relevant target antigens in children with MS. Cryopreserved
PBMC collected using strict standard protocols from children with MS, matched with healthy
controls and other CNS inflammatory diseases controls were thawed and studied in parallel.
PBMC

were

either

left

with

no-antigen

(‘unstimulated’),

stimulated

polyclonally

with

Staphylococcal enterotoxin B (SEB) as positive control, or with previously defined immunedominant peptide-pools of disease-implicated myelin and viral antigens. Cells were maintained
with IL-2-containing media for 7 days, then re-stimulated with respective antigen before flow
cytometry-based assessment of the stimulation-induced expression of surface activation markers.
The magnitude of T cell activation was measured as the frequency of CD25+CD154+ T cells
within total CD4 T cells and within the previously disease-implicated double chemokine receptor
expressing CD4+CCR2+CCR5+ T cell subset. Polyclonal activation with SEB revealed no obvious
differences in general T cell activation in children with MS compared to children with other CNS
inflammatory diseases. We did observe variable degrees of abnormally increased activation of
CNS-antigen specific and EBV-antigen specific T cells in the children with MS as compared to
controls. However, T cells of children with MS consistently exhibited abnormal T cell activation in
absence of exogenous antigen (ie, ‘unstimulated’ condition), which we refer to as abnormal ‘autoactivation’, likely recapitulating the abnormal T cell ‘auto-proliferation’ recently reported in adults
with MS. The abnormally enhanced antigen-specific T cell responses to both EBV and CNS
myelin antigens appear superimposed on the abnormal T cell auto-activation in the children with
MS. The consistent presence and higher magnitude of autoactivation in the face of the more
variable presence of abnormal CNS- and EBV-directed reactivities suggest that auto-activation in
our AIM assay more sensitively captures a hallmark abnormality of MS T cell responses. We
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further report that T cell auto-activation seen in adult MS was abrogated following initiation of antiCD20 therapy, suggesting that abnormal auto-activation seen in pediatric MS may also reflect
aberrant T cell: B cell interactions that can be reversed by effective B-cell targeting therapy.
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Abbreviations
AIM=Activation-Induced Marker
CAL=Candida albicans
CNS=Central Nervous System
EBV=Epstein-Barr Virus
MBP=Myelin Basic Protein
MOG=Myelin Oligodendrocyte Glycoprotein
SEB=Staphylococcal enterotoxin B
TCR=T cell Receptor
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Introduction
MS is a chronic inflammatory disease of the CNS presumed to attack CNS myelin auto-antigens
by autoreactive T cells, which results in demyelination and axonal loss leading to disability over
time. Despite continued efforts to pursue antigen (Ag)-specific therapies in MS there have been
multiple challenges, among them the continued lack of clarity about disease-relevant antigenic
target(s) and the T cell subsets involved. Elucidating these could guide development of more
selective and safer treatments.
In terms of antigens, the focus of the MS field on myelin Ags has been driven in large part by the
commonly used EAE animal model, as well as through ex vivo and in vitro studies with human
cells (Cao et al. 2015; Hohlfeld et al. 2016b). Actively immunizing mice with CNS myelin antigens
(ie, including crude extracts, as well as purified proteins and some of their peptides), or passively
transferring enchephalitogenic T cells induces an autoreactive inflammatory cell infiltration in the
CNS (Rangachari and Kuchroo 2013). EAE studies have contributed to a better understanding of
autoreactive T cell activation and CNS inflammation by recapitulating some of the immune
components and aspects of MS in susceptible animals. However, these findings do not provide a
complete explanation of antigenic targeting in patients with MS (Baxter 2007; Stoeckle and
Tolosa 2010). Prior studies have largely been done in adults with MS, where autoreactive T cells
against myelin Ags have been found to clonally expand and persist for extended periods
(Sospedra and Martin 2005). However, the biological disease onset in adult MS likely starts many
years before clinical presentation. There remains a concern that abnormal T cell responses
doumented in adults with MS may reflect responses to chronic injury and dysregulation rather
than disease mediating responses. Thus, we focus here on pediatric-onset MS which, though
rare, offers us a unique window into early biological events and putative disease targets.
Abnormal T cell reactivities against myelin antigens have been documented also in children with
MS (Banwell et al. 2008; Correale and Tenembaum 2006), raising the possibility that myelin
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epitopes are among the early disease targets (Correale and Tenembaum 2006). Among the most
prominent and best-described myelin protein components targetted by the autoreactive T cells
are myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG), both
components of the myelin sheath (Bielekova et al. 2004a; Sospedra and Martin 2005; Stoeckle
and Tolosa 2010). Molecular mimicry and cross-reactivity between components of environmental
pathogens (eg, viruses) and CNS myelin antigens have been proposed as mechanisms
underlying the triggering of MS relapses. Epidemiologically, Epstein-Barr Virus (EBV) is the most
strongly implicated infectious environmental risk-factor for MS development, in both adult and
pediatric MS studies (Ascherio and Munger 2007; Banwell et al. 2011). Children with MS shed
EBV (but not other viruses) in saliva more frequently than EBV-infected healthy controls,
suggesting failure of EBV control and/or more frequent EBV reactivation in children with MS (Yea
et al. 2013). Molecular mimicry is supported with the documentation of a degree of peptide
sequence homology between the immunodominant EBV nuclear antigen 1 (EBNA-1) and the
putative autoantigen, MBP, such that T cells responding to viral antigens may cross-react with
and result in injury to the CNS (Bray et al. 1992).

In addition to increased T cell reactivity to putative environmental and CNS myelin antigens, it has
been reported that adults with MS (as compared to controls) show a higher spontaneous in vitro
peripheral T cell proliferation in the absence of an exogenous antigen (Jelcic et al. 2018). This T
cell ‘auto-proliferation’ was diminished after B cell depletion with anti-CD20, suggesting that B
cell: T cell interactions may play a central role in aberrant T cell responses and inflammatory MS
disease activity. The observation that the efficacy of B cell depleting therapies in MS is not
dependent on reduction of autoantibodies, is consistent with a role for B cells as antigen
presenting cells (APCs) in the activation of autoreactive T cells (Korn and Kallies 2017). The
relationship between abnormal T cell auto-proliferation and aberrant T cell reactivities to CNS
(and potentially environmental epitopes) is of interest and remains to be determined.
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In our previous work in children with MS, we found increased frequencies and increased
propensity of proinflammatory (Th1 and Th17) responses of CD4 effector T cells that co-express
the ‘CNS-homing’ CCR2 and CCR5 chemokine receptors (Mexhitaj et al. 2019). Our access to
additional high quality samples from well characterized children with MS and controls places us in
the unique position of being able to further assess whether T cells of children with MS, including
those co-expressing CCR2 and CCR5 chemokine receptors, harbor heightened spontaneous
responses and/or heightened antigen-specific T-cell responses to CNS (myelin) and EBV
antigens, as well as evaluate whether such abnormal T-cell responses are impacted in patients
undergoing treatment with an effective MS therapy.

To identify disease-relevant Ag-reactive T cells to self and foreign antigens, several groups have
improved in recent years on prior approaches and designed assays that detect these T cells by
measuring upregulation of T-cell receptor (TCR) stimulation-induced surface markers, termed
activation-induced marker (AIM) assays that do not necessarily require the cells to proliferate
(Dan, Lindestam Arlehamn, et al. 2016; Yang et al. 2017; Reiss et al. 2017; Bowyer et al. 2018;
Grifoni et al. 2020). These assays can detect both foreign and auto-Ag-reactive cells without
being limited by pre-determination of the cytokine(s) to be analyzed (Bowyer et al. 2018), which
allows for less biased detection of TCR-dependent activated T cells. Upregulation of T cell
activation markers is made possible through in vitro stimulation of these T cells in the presence of
peptide pools from Ags of interest (Vandenbark and Abulafia-Lapid 2008; Stuve, Cravens, and
Eagar 2008). This approach allows for epitope mapping, which is commonly performed using a
functional readout following stimulation with overlapping peptide pools that span the candidate
protein, presumably encompassing all possible T cell epitopes (Anthony and Lehmann 2003;
Hoffmeister et al. 2003). An epitope with a sequence spanning two sequential peptides would be
missed if it is not encompassed by the overlapping sequence. We use overlapping combinatorial
peptide pools consisting of 15-mer peptides covering the complete sequence of the selected
target proteins, with an 11–amino acid overlap. This provides binding capacity to both MHC class
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I and class II, thus avoiding the need for separate CD8 and CD4 peptide panels, respectively
(Kiecker et al. 2004).

After developing, adapting, and miniaturizing an AIM assay for use with pediatric samples, we
observed that aside from T-cell reactivities to CNS and EBV peptide pools, children with MS
appear to exhibit increased T-cell activation even in the absence of adding exogenous antigen
(ie, ‘unstimulated’ condition), which we coin ‘auto-activation’. This auto-activation could be
consistent with prior priming/sensitization of the T cells, and/or cell-intrinsic increased reactivity in
children with MS, potentially reflecting the same abnormal phenomenon termed ‘autoproliferation’ that was reported in adults with MS by Jelcic et al (Jelcic et al. 2018). In follow up
experiments, we used samples from adult MS patients obtained before and following treatment
initiation with anti-CD20 therapy (ocrelizumab) to determine first whether T cell auto-activation
can be documented in these adult patients and then, as ‘proof of principle’, whether autoactivation can be diminished with this effective therapy as previously shown for auto-proliferation.
Overall, we report that T cell responses of children with MS, including those co-expressing CCR2
and CCR5 chemokine receptors, exhibit abnormally increased auto-activation in the absence of
exogenous antigen. We speculate that this auto-activation contributes to the heightened
responses that we also document to CNS (myelin) and EBV antigens in children with MS CNS.
These abnormalities may reflect aberrant T cell: B cell interactions as they are reversed by
effective B-cell targeting MS therapy.
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Materials and methods
Study participants
Table 3.1 identifies the demographics of children with acquired demyelinating syndrome (ADS)
and subsequently ascertained in prospective follow-up as having multiple sclerosis (MS) or
remaining monophasic (monoADS), as well as healthy controls (HC), including their age at blood
sampling. Inclusion/exclusion criteria as well as selection of representative participants for the
current study were performed as stated previously (Banwell et al. 2011; Mexhitaj et al. 2019). All
protocols and informed consent/assent were approved by institutional ethics review boards.
Table 3.3 identifies the demographics of adults with multiple sclerosis prior and after treatment
with anti-CD20 therapy (ocrelizumab), including their expanded disability status scale (EDSS),
disease duration before treatment with ocrelizumab, the three different timepoints (baseline,
depletion, and partial reconstitution) and days after the infusion when the blood was sampled. All
protocols and informed consents were approved by institutional ethics review boards.
Antigen preparation
Commercially available lyophilized peptide pools (Miltenyi Biotec) consisting of 15-mer
sequences with 11 amino acids overlap covering Myelin Basic Protein Isoform 5 (MBP, Cat# 130097-287), Myelin Oligodendrocyte Glycoprotein (MOG, Cat# 130-096-770) and Candida albicans
mp65 protein (CAL, Cat# 130-096-776) were used to stimulate the cells. A consensus pool of
Epstein-Barr Virus (EBV, Cat# 130-099-764) consisting of 43 peptides of 8-20 amino acids in
length (32 peptides are MHC I and 11 peptides are MHC II) was also used. Sequences of these
peptides were derived from 13 different lytic and latent EBV proteins. Average purity of peptides
was >70% (HPLC) and they were stored as lyophilized product in -20°C before reconstitution.
Company instructions were followed, and peptide pools were reconstituted in 200uL of sterile
distilled water with a concentration of stock solution of 30 nmol (~50 ug/peptide/mL) and aliquots
were stored in -80°C until day of experiment. 20uL of peptivator stock solution was added per mL
with a final concentration in cell suspension of 0.6nmol (~1 ug/of each peptide/mL). Additionally,
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bacterial polyclonal stimulant Staphylococcal enterotoxin B (SEB) (EMD Millipore, Cat# 324798)
was reconstituted in sterile distilled water, aliquoted and stored in individual vials at -20°C and
used at a final concentration of 1ug/mL. (Refer to Table 3.2 for a detailed summary of candidate
antigens and their concentrations adapted from (Wuest et al. 2014).
Activation Induced Markers (AIM) assay
Cryopreserved PBMC from children with MS (n=11), CNS inflammatory diseases controls (n=10)
and healthy controls (n=10) were thawed in warm 10 mL serum-free X-VIVO15 media (Lonza
Bioscience). Cells were washed, centrifuged and after discarding the supernatant, cells were
incubated in a humidifed incubator 37°C, 5% CO2 in X-VIVO15 media containing DNase (Roche)
at a final concentration of 0.1mg/mL to avoid formation of cell clumps. After two additional
washes, cells were resuspended at a concentration of 1 x 106 cells in X-VIVO15 and counted with
a hemocytometer. After cells were rested for 2 hours in the incubator, cells were washed a final
time and resuspended at a concetration of 1 x 106 cells in X-VIVO15 medium containing 10%
heat-inactivated human serum (Sigma-Aldrich), 2mM L-Glutamine, 100 U/mL Penicillin, and 100
mg/mL Streptomycin (Combined T cell Media [CTM]). CD40 blocking antibody (Miltenyi)
(0.5mg/mL final concentration) was added to cultures for 15 minutes before antigen stimulation.
For each condition, 5 duplicate wells containing 2x105 cells in 200mL were plated in 96-well
round-bottom plates and cells were subsequently stimulated for 24 hours with different antigens
(see material section below). Matched unstimulated samples were plated for each donor. After 24
hours of stimulation, plates were spun down and supernatants were discarded. Cells were
washed once with fresh and warm X-VIVO15 and then resuspended with fresh CTM media
containing IL-2 (Peprotech) (at a 50U/mL final concentration). Half of the CTM media was
replenished on Day 4 of culture with fresh IL-2 containing CTM. 24 hours before re-stimulation,
plates were spun down and resuspended in fresh media without IL-2. On Day 7, plates were spun
down, supernatant descarded and cells from each antigen condition were combined and restimulated with respective antigen for 6 hours before surface staining with antibodies. After re62

stimulation, cells were washed three times with cold 1X PBS (Thermo-Fischer) to remove any
remaining serum and stain with LIVE/DEAD™ Fixable Aqua dead cell stain (Thermo-Fisher, Cat#
L34966) protected from light for 30 minutes at 4°C to exclude dead cells. Cells were washed
once and stained initially with a cocktail of antibodies targeting chemokine receptors CD192
(CCR2; clone K036C2) and CD195 (CCR5; clone J418F1) for 10 minutes at 37°C and then with
the rest of the antibody cocktail of surface markers directed against CD3 (clone UCHT1), CD4
(clone SK3), CD8 (clone SK1), CD161 (clone HP-3G10), CD127 (HIL-7R-M21), CD154 (CD40L;
clone 24-31), CD69 (clone MOPC-21), CD25 (clone 2A3), CD38 (clone HB7) and CD279 (PD-1;
clone EH12.1)) for 20 minutes at room temperature. To set gates for defining negative and
positive cells for multicolor staining, samples were stained using FMOs. Cells were then washed
and resuspended in 270 uL of 1% paraformaldehyde in FACS buffer (1X PBS + 1% Fetal Bovine
Serum [Thermo-Fischer]). 30 uL of 123count eBeads (Thermo-Fisher, Cat#01-1234-42) were
added to the cell suspensions where measured quantities of cell:bead mixtures are used to
determine absolute cell counts for data acquisition in the flow cytometer. AIM assay design and
approach are graphically summarised in (Figure 3.1) adapted from (Cao et al. 2015; Reiss et al.
2017).
Flow cytometry
Samples were acquired on a 5 laser BD LSR Fortessa flow cytometer (BD Biosciences).
SPHERO rainbow beads (Spherotech, Cat#RFP-30-5A) were used to track and adjust PMTs over
time. ArC™ Amine Reactive and Ultra Comp eBeads™ Plus compensation beads (ThermoFisher, Cat#A-10346 and 01-2222-42, respectively) were used for each batch experiment for flow
cytometry color compensation. Data from the AIM expression assays were generated using the
software package FlowJo (LLC). Representative flow cytometry plots show the general gating
strategy after 7-day culture as well as percentages of AIM+ T cells were defined primarily by dual
expression of CD25 and CD154, among other marker combinations (Appendix 3.1 for general
gating strategy after 7-day culture). To capture Ag-specific responses without contribution of
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background, ‘Stimulation Index (SI)’ was calculated as (Counts of Ag stimulated condition - Count
of ‘No Ag’ condition)/Count of ‘No Ag’ condition, with a threshold arbitrarily set at >2, where
counts were calculated using counting beads added at the same concentration in all wells to
normalize across antigen conditions and groups.
Statistical analysis
Data were analysed using a mixed-effect model (1-way ANOVA) followed by Tukey’s multiple
comparison test (adjusted p value, *p < 0.05, **p<0.001, ***p<0.0001) in GraphPad Prism 9.
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Results
Higher auto-activation and frequency of activated cells for CNS myelin and EBV antigens within
CD4 T cell responses in the pediatric MS patients
Initially, we assessed total CD4 T cell responses to CNS (myelin) and EBV antigens
simultaneously in children with MS, age-matched healthy controls, and other CNS inflammatory
disease controls (monoADS) by using an assay that is based on TCR-triggered upregulation of
surface activation induced markers (AIM). Co-expression of CD154 (a co-stimulatory molecule
and marker for Ag-reactive cells (Frentsch et al. 2005) and CD25 (an activation marker that is
upregulated upon TCR stimulation and sustained after expression of IL-2 in an autocrine and
paracrine manner (Dan, Lindestam Arlehamn, et al. 2016)) appeared to be higher in the absence
of exogenous antigen of CD4 T cells in children with MS, as compared to the healthy control
group (p=0.05), which we termed as ‘auto-activation’ (Figure 3.2. A, B). This phenomenon is
consistent with the abnormal T cell ‘auto-proliferation’ recently reported in adults with MS (Jelcic
et al. 2018). Aside from this higher auto-activation in children with MS, we observed significantly
increased frequencies of activated T cells to MBP, as compared to monoADS (p=0.01) and
healthy controls (p=0.03) (Figure 3.2. C). Frequencies of activated T cells to MOG were also
significantly increased in children with MS as compared to monoADS (p=0.006) and healthy
controls (p=0.005) (Figure 3.2. D). Additionally, we observed a significant increase in the
frequencies of activated T cells in the presence of EBV antigens in EBV-seropositive pediatric MS
group, as compared to healthy controls (p=0.008) (Figure 3.2. E). There was no statistically
significant change in the frequency of activated T cells to C. albicans between groups (Figure
3.2. F). To capture Ag-specific responses without contribution of background auto-activation, we
assessed Ag-activated responses using a ‘‘Stimulation Index (SI)” calculated as (Counts of Ag
stimulated condition - Count of ‘No Ag’ condition)/Count of ‘No Ag’ condition, with a threshold
arbitrarily set at >2. We observed ‘within group’ variability in terms of T-cell reactivities to CNS
myelin and EBV antigens in children with MS, but at the group level, none of these antigens
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induced SIs above the background (as defined by the No Antigen condition) (Figure 3.2. G).
Taken together, although there seem to be enhanced peripheral CD4 T cell responses to EBV
and CNS myelin antigens in children with MS, this reactivity appears to be largely attributed to,
and superimposed on, responses of previously primed or sensitized auto-activated T cells.
Disease-implicated CD4+CCR2+CCR5+ T cell subset responses in the absence of exogenous
antigen or in the presence of CNS (myelin) or EBV antigens in pediatric MS patients
Previously we showed that the frequency of the double-chemokine receptor expressing
CD4+CCR2+CCR5+ T cell subset was significantly increased on average in the circulation of
children with MS and exhibited abnormally increased proinflammatory cytokine responses as
compared to controls.

To further characterize this disease-implicated subset, we assessed

whether it would show any heightened auto-activation in the absence of exogenous antigen
and/or harbor any reactivities to the CNS myelin and EBV antigens implicated in MS. Ex vivo
(prior to culture) the frequencies of CCR2+CCR5+ T cells within circulating CD4 T cells were
higher in children with MS (on average ~ 6.5%) as compared to healthy controls (3.5%) and
children with monoADS (3.5%) (Refer back to Figure 2.1. A, B). In culture, in the absence of
exogenous antigen, the frequency of this subset gated within CD4 T cells increased for all three
groups (to an average of 15%, 10% and 8%, respectively), exhibiting a significant increase in
children with MS as compared to CNS inflammatory disease controls (p=0.05) (Figure 3.3. A &
B). This double chemokine expressor subset did not show any additional increase in frequency in
the presence of CNS myelin, EBV or C. albicans antigens (Figure 3.3. C-F). However, when
assessing the activated CD25+CD154+ T cells within CD4+CCR2+CCR5+ T cells in the pediatric
MS group, we observed increased auto-activation (Figure 3.3. G, H) which was on average three
times (~7.5%) that of the total CD4 T cell auto-activation (~2.5%) (Figure 3.2. B). This suggests
an enrichment of auto-activation in the CCR2+CCR5+ T cell subset and a higher propensity for
this subset to be activated in children with MS as compared to controls. Although there appears
to be an increase in activated cells in this CD4 T cell subset in the presence of all antigens
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(Figure 3.3 I-L), we report significant increases in frequencies of CD25+CD154+ T cells reactive
to MOG in pediatric MS patients as compared to children with CNS inflammatory diseases
controls (p=0.02) (Figure 3.3. J) and healthy controls (p=0.008), and to EBV antigens in pediatric
MS as compared to healthy controls (p=0.01) (Figure 3.3. K). This suggests that the
CCR2+CCR5+ disease-implicated T cell subset exhibits more than average auto-activation, as
well as CNS myelin and EBV reactivities compared to other subsets found within CD4 T cells of
the patients.
No auto-activation and increased proliferation of activated cells in response to EBV antigens in
CD8 T cells of pediatric MS patients
Our combinatorial overlapping peptide pools allow for stimulation of both CD4 and CD8 T cells,
we did not observe, however, an induction of the CD25+CD154+ expression on CD8 T cells in the
absence of exogenous antigen. Auto-activation levels within CD8 T cells were lower and
indistinguishable across the three pediatric groups, in contrast to the higher auto-activation we
observed within CD4 T cells of the children with MS (Figure 3.4. A, B). MBP, MOG and EBV
reactivities of CD8 T cells were measurable, though appeared indistinguishable across groups
(Figure 3.4. C-E). CD8 T cell responses to C. albicans were generally low, reflecting the fact that
C. albicans is primarily an antigen that elicits Th rather than Tc responses (Figure 3.4. F). Due to
a higher absolute count of CD8 T cells in the presence of EBV and a lower auto-activation within
CD8T cells, there was a significant SI for EBV (p=0.03) in children with MS as compared to
children with CNS inflammatory diseases controls (Figure 3.4. G) further attesting to the merits of
an assay where we observe coordinated behavior of CD4 and CD8 T cell specific responses to
EBV (Wuest et al. 2014).
B-cell directed therapy impacts the abnormal auto-activation and antigen reactivities of T cell
responses in adult MS patients
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The success of anti-CD20 B cell-depleting antibodies in reducing MS relapse rate and limiting the
development of new inflammatory CNS lesions (Bar-Or et al. 2020) has also contributed to a
deeper understanding of B cell biology and B cell contributions to MS, highlighting the roles of T :
B cell interactions. Jelcic et al. recently reported that after anti-CD20 therapy in adults with MS,
the abnormal auto-proliferation seen in patients before anti-CD20 treatment was diminished,
suggesting a role for B cells in mediating this auto-proliferation, presumably through direct T: B
cell interaction. In their system, T cell ‘auto-proliferation’ was found to be dependent on
recognizing self-antigens expressed on memory B cells (Jelcic et al. 2018). We wished to obtain
‘proof-of-principle’ that auto-activation would also diminish with anti-CD20 therapy. Since antiCD20 therapies have not yet been approved for use in pediatric MS (Phase II trial underway), we
used our identical AIM assay, to assess the impact of anti-CD20 treatment in adult MS patients
on auto-activation, in addition to determining if self and foreign antigen responses also decreased
after the treatment with ocrelizumab. Briefly, PBMC from adult MS (n=6) before treatment with
ocrelizumab (baseline) and post treatment (3 and 6 months) were thawed, washed, and
stimulated with antigens (MOG, EBV, and C. albicans) using the same protocol as above (Table
3.3 and Figure 3.1). Frequencies of activated CD25+CD154+ T cells relative to total CD4 T and
CD8 T cells were detected. CD4 T cell responses decreased after anti-CD20 therapy in adult with
MS, including auto-activation where the frequencies of CD25+CD154+ T cells appeared to be
decrease at 3 months as compared to baseline (p=0.07) and were significantly decreased at 6
months as compared to baseline (p=0.04) (Figure 3.5. A, B). While CD4 T cell responses to EBV
antigens were not significantly changed after treatment, we observed statistically significant
decreases of MOG reactivities at both 3 and 6 months as compared to baseline (p=0.03 and
p=0.003, respectively) (Figure 3.5. C, D). We also observed statistically significant decreases of
C. albicans reactivities at both 3 as compared to baseline (p=0.02) (Figure 3.5. E), corroborating
previous findings from our group showing that in vitro depletion of B cells in PBMC samples from
adults with MS results in decreased CD4 T cell responses to C. albicans (Li et al. 2017). We
further assessed CD8 T cell responses in the absence of antigen and auto-activation was also
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significantly reduced in terms of frequency of CD25+CD154+ T cells at 6 months post-treatment
as compared to baseline (p=0.02) (Figure 3.5. F, G). It became apparent again that the
frequency of CD25+CD154+T cells within CD8 T cell compartment was on average much lower
than the frequency of these activated cells within the CD4 T cell compartment, suggesting this
phenomenon of auto-activation may be primarily relevant to CD4 T cells. CD8 T-cell reactivities to
MOG, EBV and C. albicans appeared to be reduced post anti-CD20 treatment as compared to
baseline, but these changes were not statistically significant (Figure 3.5. H-J). We observed
lower auto-activation within CD8 T cells at baseline (relative to CD4 T cells Figure 3.5. A, B),
suggesting a higher fold change for MOG and EBV reactivities when normalized by the removal
of background auto-activation, which is consistent with our observations in children with MS.
Finally, we observed on average a higher auto-activation at baseline within CD4 T cell responses
in the absence of exogenous antigen (~5%) for adult-onset MS patients (Figure 3.5. B) as
compared to that same condition (~2.5%) in pediatric-onset MS patients (Figure 3.2. B). Even
though the pediatric and adult experiments were not performed side by side, the assay
conditions, readouts and analysis were the same. This suggests that there is an in vivo peripheral
auto-activation which may be amplified in vitro. However, this amplification could be explained by
the accumulation of primed and perhaps perpetually activated T cells in MS over the time course
of the disease.
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Discussion
While abnormal T cell reactivities have been detected against myelin antigens in children with
MS, prior studies have assessed these responses either in the absence of age- and sexmatched controls with other (non-MS) inflammatory CNS disease (Correale and Tenembaum
2006) or have not assessed reactivities to disease-implicated myelin and viral antigens
simultaneously in the same individuals (Banwell et al. 2008). In this study, we had the unique
opportunity to investigate for the first time T cell reactivities to CNS (myelin) and EBV antigens
simultaneously in children with MS, age-matched healthy controls, and other CNS inflammatory
disease controls by identifying Ag-reactive T cells using an assay based on TCR-triggered
upregulation of surface activation induced markers (AIM). Alongside detection of CNS myelinand EBV-specific T cell reactivities, the sensitivity of this adapted AIM assay consistently
captured for the first time abnormally increased peripheral CD4 T cell (but not CD8 T cell) autoactivation in the absence of exogenous antigen in children with MS as compared to controls. This
auto-activation appears after in vitro expansion, which is an observation parallel to that described
as ‘auto-proliferation’ (Jelcic et al. 2018) and the ‘spontaneous activation’ (Wuest et al. 2014)
captured in adult-onset MS studies. This suggests that the observed auto-activation may be
specific to the peripheral CD4 T cell compartment in MS and occurs regardless of age of the
affected individuals, albeit it is much lower in pediatric-onset MS, suggesting that it may augment
with disease duration and as such have implications in the MS autoimmune response.
Jelcic et al. cultured cells in serum-free media for 7 days and captured abnormal ‘autoproliferation’ of CD4 T cells (but not CD8 T cells) in adults with MS, assessed as the frequency of
CFSElow self-reactive cells, in the absence of exogenous antigen. The auto-proliferation was
reduced after B cell depletion with anti-CD20 therapy, suggesting a potential role of B cells in
triggering and/or maintaining T cell auto-proliferation via direct cell-cell interaction (Jelcic et al.
2018). In the same study, patients with MS were treated with natalizumab (which blocks
peripheral lymphocyte migration to the brain and increases circulating B cells), exhibited
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enhanced auto-proliferation off circulating cells. This was in line with their observation of higher
frequency of activated effector memory auto-proliferating cells in adults with MS during remission
as compared to those during relapse (when pathogenic cells most likely migrate to the brain).
Another adult MS study offers a similar observation of increased levels of ‘spontaneous
activation’ measured as the frequency of double positive IFNγ+ TNFα+ intracellular cytokine
expressing peripheral CD4 T cell in the absence of exogenous antigen, where autologous
dendritic cells (DCs) and peripheral/intrathecal T cells were co-cultured in serum-free media for 7
days (Wuest et al. 2014). CSF T cells from MS patients did not proliferate ‘spontaneously’,
suggesting that this phenomenon may be intrinsic to peripheral immune responses.
Interestingly, these findings in adult-onset MS studies are in line with much earlier observations
highlighted in patients with MS with autologous mixed lymphocyte responses (AMLR), which
manifest in vitro as when T cells are co-cultured with autologous non-T cells in the absence of
exogenous antigen (Cai and Hafler 2007). The AMLR has been found to be decreased in patients
with MS during relapse and is correlated with increase in peripheral Teff/Treg ratio in the
periphery as compared to patients with ‘inactive’ MS and healthy controls (Hafler, Buchsbaum,
and Weiner 1985). Possible reasons for this low proliferative response during relapse include a
deficiency in antigen presenting cells (APCs; B and DC cells), decreased presence and/or
function of suppressive mechanisms (such as Tregs) and/or recruitment of peripheral activated T
cells to the CNS. We have already implicated an abnormal Teff/Treg balance which distinguishes
children with MS from controls (Mexhitaj et al. 2019). Taken together, these findings suggest that
what may be leading to the higher magnitude of auto-activation of peripheral T cells in pediatricand adult-onset MS patient is highly dependent on the presence of peripheral APCs (including B
cells), increases in Teff/Treg ratios in the periphery, and the ability of circulating CD4 T cells to be
abnormally primed in vivo and sensitized to respond to self-antigens.
In the adult-onset MS studies, the cell cultures referred to above did not contain any stimulating
agents (such as PHA or IL-2). Regardless, an abnormal auto-activation of CD4 T cells in the
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absence of exogenous antigen was still observed. In our approach, IL-2 was used to stimulate
and expand rare peripheral antigen-activated T cells, since their precursor frequency is very low.
IL-2R (CD25) is an activation marker upregulated upon TCR stimulation and sustained after
expression of IL-2 in an autocrine or paracrine manner (Ross and Cantrell 2018). The addition of
IL-2 in vitro leads to hyper physiological increase in CD25 expression, which would not otherwise
happen in vivo. Moreover, the absence of negative feedback mechanisms to prevent high CD25
upregulation in vivo may play a role (Dan, Lindestam Arlehamn, et al. 2016). At the end of culture,
we observed an upregulation of CD25 both by CD4 and CD8 T cells, which was otherwise
expressed in very low amounts ex vivo (observed in pilot experiments). CD25 upregulation in the
persistent presence of IL-2 could have led to bystander activation (independent of specific TCR
stimulation) through either soluble factors or co-stimulatory molecules binding to receptors other
than the TCR (Bangs, McMichael, and Xu 2006). If the observed auto-activation was IL-2
dependent, we would have seen a similar magnitude of auto-activation by the induction of double
positive CD25+CD154+ CD8 T cells in the absence of exogenous antigen in children with MS, but
that was not the case. The auto-activation levels within CD8 T cells in the absence of exogenous
antigen were much lower and indistinguishable across groups. This suggests that even though
IL-2 in culture may have contributed to the expansion of rare self-reactive T cells within peripheral
CD4 T cells, these cells were not generated as a result of bystander activation. Bystander
activation could also result from upregulation of markers caused by cell culture contaminants,
factors secreted by bystander cells and cell-to cell contact leading to false positives. In an
extensive study using similar readouts as our AIM assay, Reiss et al. showed that bystander
activation either through Lipopolysaccharide (LPS), soluble factors or cell-to-cell contact has a
very limited effect on the detection of Ag-reactive T cells, which provides an additional degree of
confidence in the validity of this assay (Reiss et al. 2017).
It should be noted that levels of IL-2 signaling can change the phenotype and define the effector
and memory fates of CD4 T cells. In data observed in pilot experiments, immunophenotyping of
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the auto-activated CD4 T cells in our pediatric cohort, showed an effector memory phenotype.
These CD25+CD154+ T cells also showed upregulation of activation markers (CD69 and CD38)
and exhaustion marker of PD1 as compared to single positive CD25 + and double negative CD25CD154- populations. Additionally, within these auto-activated cells we observed high expression
of HLA-DR, consistent with a highly activated phenotype (data not shown).
Few studies have addressed antigenic specificity of T cells in pediatric-onset MS (Correale and
Tenembaum 2006; Banwell et al. 2008). Tenenbaum et al. were the first to describe epitope
mapping of CNS antigens in pediatric-onset MS patients, raising the possibility that myelin
epitopes are among the early disease targets (Correale and Tenembaum 2006). They isolated
PBMC from pediatric- and adult-onset MS patients, generated T cell lines to CNS myelin antigens
and measured T cell proliferative responses to overlapping peptides of CNS myelin antigens. This
study revealed similarities in T cell responses to different MBP and MOG epitopes in both
pediatric- and adult-onset MS, and T cells from both groups recognized structurally similar CNS
autoantigens. We previously conducted a study using a broader range of antigens, including
target self-tissue antigens (myelin, pancreatic, glial) and selected dietary antigens and compared
T cell reactivities to such antigens in children with early MS, established MS and pediatric control
cohorts (including children with T1D and CNS injury, and healthy controls) (Banwell et al. 2008).
This work demonstrated that abnormal T cell activation is an early feature of the human
inflammatory demyelinating disease spectrum. Moreover, this study suggested that increased
auto-reactive T cell responses are dependent on age or disease duration since higher autoreactivities were observed in adult samples when using similar assay readouts.
Adding to these findings, we observed enhanced antigen-reactive CD4 T cell responses to both
foreign (EBV) and CNS myelin antigens which were superimposed on the abnormal T cell autoactivation in the children with MS. However, once this auto-activation background was subtracted
from the antigen-reactive T cell responses, at the group level we did not appreciate any
statistically significant differences in T cell reactivities toward CNS and EBV antigens above the
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designated threshold, except in a few individual children with MS. It is reasonable to suggest that
due to the propensity for auto-activation, when cells from MS patients become activated to self
and/or foreign antigens, their responses may be more vigorous that those seen in other CNS
inflammatory controls and healthy controls. The consistent presence and higher magnitude of
auto-activation in face of the more variable presence of abnormal CNS- and EBV-directed
reactivities suggest that auto-activation in our AIM assay more sensitively captures a hallmark
abnormality of T cell responses, potentially reflecting a broader range of MS relevant antigens
priming these cells in vivo, that differ across individual children.
We can speculate that during early disease, implicated T cell subsets could be initially found in
the periphery where they could be primed, activated, and expanded in response to self or foreign
antigens and then later decrease in the circulation as the cells traffic to the target organ (ie, in the
CNS). In the context of MS, the migration of activated leukocytes to the CNS is facilitated in part
by the interaction of surface-expressed chemokine receptors and their recruiting chemokines,
leading to an accumulation of these infiltrating leukocytes in active MS lesions. Chemokine
receptors such as CCR2 and CCR5 have been ascribed a pathogenic role since they have been
found to be highly expressed by infiltrating T cells within and around MS lesions (Fantuzzi et al.
2019; Mahad et al. 2006). CD4 T cells that co-express CCR2 and CCR5 are enriched in the CSF
of adult MS patients during relapse (Sato et al. 2012). In our previous work, we demonstrated that
the double-chemokine expressing subset of CCR2+CCR5+ within CD4+ T cells tends to circulate
at a higher frequency in pediatric-onset MS and has a proinflammatory role, as it exhibited
abnormally increased IFNy and IL-17 responses after short stimulation with PMA/Ionomycin. This
is in line with work done by Zhang et al. indicating that this subset, as compared to other memory
subsets and naïve cells from healthy adults, showed an increased rapid effector capability by
expressing relatively high levels of mRNA of cytokines IFNy and IL-17 rapidly after stimulation
with PMA/Ionomycin. Intracellular cytokine staining showed that this double-positive chemokine
receptor expressing T cell subset produced IFNy and IL-17. Their detailed study showed that this
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CCR2+CCR5+CD4+T cell subset is highly differentiated ex vivo, displays an increased effector
memory phenotype (with loss of CCR7) and, as such, is more amenable to TCR-mediated
activation. In addition, it can undergo rapid reactivation upon encountering antigens and have
more proliferation cycles as compared to the double-negative subset (Zhang et al. 2010). Sato et
al. corroborated the phenotype and functional profile of this subset in adults with MS, showing
that this circulating T cell subset contains both central and effector memory cells (higher
TEM/TCM ratio), secretes IFNy and IL-17 and, when activated, it produces proteases that give it
the ability to disrupt the blood brain barrier and invade the CNS much more efficiently as
compared to other memory subsets, implicating this subset in the pathogenesis of MS (Sato et al.
2012).
In pilot experiments we confirmed the dual central and effector memory phenotype of
CCR2+CCR5+ CD4 T cell subset (higher TEM/TCM ratio), and in this study we further show that
this subset exhibits a high degree of activation across the pediatric groups (in the absence of
exogenous antigen). Albeit, with a lot of variability in children with MS (similar in trend to our ex
vivo published data). This suggests that this highly differentiated effector memory CD4 T cell
subset may have an intrinsic propensity to become primed, especially in children with MS. It is
noteworthy that these cells might not be the same cells found ex vivo or activated in the same
context that they got activated in vivo.
Zhang et al. showed that this subset displayed an increased responsiveness to survival
cytokines, such as IL-7 and IL-15, which may increase differentiation among CD4 T cells (Zhang
et al. 2010). In analyzing receptors for these cytokines, they found progressive increases in
expression of IL-2Rβ (CD122) and IL-2Rγ (CD132) in CCR2+CCR5+. This suggests that these
cells would be quite responsive to the survival cytokine IL-2 (supplemented in our media) which
would lead to an increased expression of IL-2Ra (CD25). When gating on this CCR2+CCR5+
CD4+T cell subset, we observed an upregulation of the CD25 marker and along with it an
upregulation of CD154. Their co-expression was significantly increased in children with MS as
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compared to controls. The CCR2+CCR5+ CD4 T cells in children with MS showed a higher autoactivation (as measured by the upregulation of both CD25 and CD154) and seemed to have
significantly heightened reactivity to MBP, MOG and EBV antigens as compared to controls.
Indeed, Sato et al. showed that circulating CCR2+CCR5+ T cells of adult MS patients produced
larger quantities of IFNy in response to myelin antigen (MBP) as compared to controls (Sato et al.
2012). The CCR2+CCR5+ T cell subset exhibits more than the average auto-activation, MOG and
EBV reactivity as compared to total CD4 T cells, which suggests that this subset could be one of
the most highly activated subsets as compared to other subsets within total CD4 T cell population
It is possible that auto-reactive T cells that express both CCR2 and CCR5 have survived and
persist following repeated reactivation over time and they are more prone to respond quickly to
self and/or foreign antigen in pediatric-onset MS. Targeting this population may be a novel
therapeutic approach early-onset MS.
While anti-CD20 therapy has not yet been approved for use in pediatric MS (Phase II trial
underway) (Fadda, Armangue, et al. 2021), it was important to determine (as a ‘proof-ofprinciple’) whether it was possible to demonstrate treatment associated reductions in autoactivation using our AIM assay, in addition to determining if self and foreign antigen responses
also decrease after treatment with ocrelizumab. While CNS reactive CD4 T cells have been
implicated in MS for many years (Hohlfeld et al. 2016a), B cells are now also thought to be very
relevant to new disease activity. The advent and success of the anti-CD20 B cell depleting
therapies in clinical trials (Hauser et al. 2017; Hauser et al. 2020) has made it clear that MS
disease activity is driven at least in part if not largely by interactions between disease-relevant T
and B cells. B cells can act as antigen presenting cells and present myelin antigens through their
MHCII to TCR of CD4 T cells and potentially both induce and maintain T cell responses (Harp et
al. 2010; Michel et al. 2015; Baker et al. 2017). CNS B cells in MS have also been attributed an
antigen-driven response since these cells show high levels of clonal expansion and somatic
hypermutation in their immunoglobulin variable regions (Lovato et al. 2011). Recently, Jelcic et al.
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showed that peripheral CD4 T cells from adults with MS were able to proliferate in the absence of
any exogenous antigen and this auto-proliferation was dependent on B cells (Jelcic et al. 2018).
Depletion of B cells after anti-CD20 therapy in those same adult MS patients resulted in reduced
T cell auto-proliferation, consistent with B cells playing an important role in triggering and
sustaining abnormal T cell auto-proliferation.
In our study, we observed higher auto-activation (on average) by CD4 T cells of adult patients as
compared to CD4 T cells of pediatric-onset MS patients, as well as a reduction in CD4 T cell
activation following B cell depleting therapy. One of the main reasons for studying pediatric-onset
MS is to capture early disease targets and mechanisms that may be less confounded by, or at the
very least less susceptible to, consequences of chronic inflammation. From our data, we can
speculate that compared to controls, circulating CD4 T cells of pediatric-MS patients are primed
(and potentially repeatedly activated) in vivo, potentially making them more prone to react to self
and/or foreign antigens. As these individuals age, their cells have a lower threshold for activation
which contributes to disease activity. If we were to assess auto-activation in serial experiments at
different timepoints in these children with MS, we might expect this auto-activation to increase
over time.
We observed reduced CD4 and CD8 T cell responses to MOG in adults with MS three months
after treatment with ocrelizumab. Although we attribute the reduction of MOG-specific T cell
responses primarily to the absence of B cells in culture, we cannot exclude the possibility that a
small subset of activated pro-inflammatory T cells which also express CD20, are also depleted
after treatment with ocrelizumab as well. In fact, recent data from Sabatino et al. showed that
CD8 expressing CD20+ T cells are found to be increased in circulation in MS patients and that
anti-CD20 therapy depletes activated myelin-specific CD8 T cells in MS, with MOG being one of
those antigens (Sabatino et al. 2019). It is possible that depletion of both CD20+ B cells and
CD20+ T cells from adult MS patients treated with ocrelizumab could have led to the reduced
MOG T cell reactivities observed in our study.
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We also observed decrease of EBV-reactive T cell responses after treatment with ocrelizumab.
EBV has high tropism for B cells and once these cells are infected, the virus persists and
promotes the long-term survival and accumulation of EBV-infected autoreactive B cells.
Moreover, EBV activation has been shown to drive proinflammatory B cell cytokine responses
(TNFα, IL-6 and GM-CSF) and interfere with the downregulatory function of IL-10 (D'Addario et
al. 2001; Li, Rezk, Healy, et al. 2015). These changes in B cell biology in the presence of EBV
infection have been shown to contribute to an aberrant immune response in MS which mediates
peripheral inflammation and can underlie disease relapses (Ascherio and Munger 2015;
Fernandez-Menendez et al. 2016).
In summary, the loss of central and peripheral tolerance to CNS myelin antigens likely heightens
peripheral T cell reactivity to self antigens and can mediate in vivo priming or sensitization of
peripheral T cells, so they respond to these self antigens repeatedly. It is not yet known whether
these CNS auto-reactive T cells initiate the disease, or if they just have an increased immune
reactivity due to previous CNS injury. The sensitivity of our adapted AIM assay captured autoactivation, which provides a glimpse of the peripheral abnormality of CD4 T cell responses,
overlaid by the more variable presence of CNS myelin and EBV-reactivities in children with MS.
These abnormal T-cell responses are impacted in patients undergoing treatment with an effective
B cell targeting therapy. Further investigation of the proteogenomic, functional responses to selfantigens of these auto-activated cells is warranted in individuals with MS across the age-span. To
determine how disease progression affects auto-activation it is useful to assess serial timepoints
in pediatric- and adult-onset MS, both during relapse and remission. Finally, further studies need
to address how auto-activation is related to auto-proliferation and whether they reflect the same
effector T cells subsets which are activated and/or proliferate in the absence and presence of
self-antigens.
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Tables
Table 3.1: Pediatric Participant Demographics
ADS

Live cells (% of

presenting

Age at blood

Aqua Live/Dead

Sex

phenotype

sampling (years)

stain negative)

MS-01

M

Monofocal

12.4

89

MS-02

F

Polyfocal

14.2

96

MS-03

F

Polyfocal

15.0

89

MS-04

M

Monofocal

16.0

90

MS-05

F

Polyfocal

14.9

93

MS-06

M

Monofocal

14.8

92

MS-07

F

Monofocal

13.7

87

MS-08

F

Monofocal

14.3

86

MS-09

F

Monofocal

12.0

89

MS-10

M

Monofocal

12.9

90

MS-11

F

Monofocal

15.8

93

14 (+/-1.3)

90 (+/-3)

Diagnosis

7F:4M
Mono-01

M

Monofocal

13.0

92

Mono-02

F

Monofocal

8.8

93

Mono-03

F

ADEM

10.2

76

Mono-04

M

Monofocal

16.1

93

Mono-05

M

Monofocal

12.9

91

Mono-06

F

Monofocal

12.5

89

Mono-07

M

Monofocal

16.8

82

Mono-08

F

Monofocal

14.3

85

Mono-09

M

ADEM

12.3

89

Mono-10

F

Monofocal

9.9

87

12.7 (+/-2.6)

88 (+/-5)

5F:5M
HC-01

F

N/Ap

16.0

94

HC-02

F

N/Ap

15.8

95

HC-03

F

N/Ap

15.7

93

79

HC-04

M

N/Ap

8.9

89

HC-05

F

N/Ap

15.9

90

HC-06

F

N/Ap

15.8

93

HC-07

F

N/Ap

13.5

90

HC-08

M

N/Ap

13.9

91

HC-09

F

N/Ap

15.5

91

HC-10

F

N/Ap

16.0

89

14.7 (+/-2.2)

91 (+/-2)

8F:2M
Abbreviations:
demyelinating

ADEM=acute
syndrome;

disseminated

F=female;

encephalomyelitis;

HC=healthy

control;

(mono)ADS; MS=multiple sclerosis; N/Ap=not applicable.
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ADS=incident

M=male;

acquired

Mono=monophasic

Table 3.2: Summary of candidate antigens used for AIM assay

Abbreviation

Vendor &
Catalog #

Final
Concentration

No Antigen

No Ag

-

-

Myelin
Basic
Protein

MBP

Miltenyi, Cat#
130-097-287

1g/peptide/ml

Myelin
Oligodendrocyte
Glycoprotein

MOG

Miltenyi, Cat#
130-096-770

0.5g/peptide/ml

Epstein-Barr Virus

EBV

Miltenyi, Cat#
130-099-764

1g/peptide/ml

Candida albicans

CAL

Miltenyi, Cat#
130-096-776

0.5g/peptide/ml
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Antigen
Conditions

Product Format
Background
‘unstimulated’
condition to set the gates
170 amino acids ~ 43 peptides
15-mer with 11 amino acid overlap
peptide pool spans the length of
the MBP protein
247 amino acids ~ 62 peptides
15-mer with 11 amino acid overlap
peptide pool spans the length of
the MOG protein
Consensus pool contains 43
peptides of 8-20 amino acid in
length (32 peptides are MHC I and
11 peptides are MHC II)
Sequences of these peptides were
derived from 13 different lytic and
latent EBV proteins
379 amino acids ~ 95 peptides
15-mer with 11 amino acid overlap
peptide pool covers the sequence
of C. albicans mannoprotein
(MP65)

Relevance
to Multiple Sclerosis
Negative (vehicle) control; background
T cell activation
Myelin
autoantigen;
traditionally
presumed involved as a target in
pathogenesis of MS
Myelin
autoantigen;
traditionally
presumed involved as a target in
pathogenesis of MS
Foreign antigen;
linked to MS

epidemiologically

Fungal positive control; considered a
major T cell antigen used in antigenspecific assays in MS studies; serves
to identify populations of human T cells
that elicit Th1 and Th17 responses

Staphylococcal
Enterotoxin B

SEB

EMD
Millipore,
Cat# 324798

1g/ml

A
heat
stable
bacterial
superantigen
prepared
from Staphylococcus
aureus,
strain
S6
by
dye
ligand
chromatography

Bacterial
positive
control
elicits
activated T cell responses by
specifically crosslinking MHCII with
TCR leading to CD154 expression in
Th cells

Table 3.3: Adult Participant Demographics
Disease
duration at

ID
MS-01

MS-02
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MS-03

MS-04

MS-05

MS-06

Live cells (% of

EDSS score

baseline

Time point

Sex

Age

Diagnosis

at baseline

(years)

(months)

F

40

RRMS

2.5

7

0

0

666

91.7

3

110

560

95.8

6

177

489

87.6

0

0

662

96.3

3

110

565

97.5

6

182

516

91.8

0

0

631

93.4

3

110

503

93.9

6

172

459

89.1

0

0

621

97.4

3

110

518

91.9

6

214

407

96.8

0

0

621

87.2

3

50

530

86.0

6

202

419

75.0

0

0

606

94.4

3

100

526

91.8

6

185

421

76.0

M

M

M

F

F

3F:3M

40

42

24

44

66

RRMS

RRMS

RRMS

RRMS

PPMS

2

2

2

1

3.5

0

18

1

2

5

Days after

Days after

the infusion cryopreservation

Live/Dead
negative)

43

2.16

540

90.7

(+/- 13.5)

(+/-0.81)

(+/-82.5)

(+/-0.065)

Abbreviations: EDSS=expanded disability state score; PPMS=primary progressive MS; RRMS=relapsing-remitting MS

Figures
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Figure 3.1: Activation Induced Marker (AIM) assay approach.
Briefly, cryopreserved peripheral blood mononuclear cells (PBMC) from age- and sex-matched
cohort of children with multiple sclerosis (MS), CNS inflammatory diseases controls, and healthy
controls were thawed in warm media, treated with DNAse and rested for 2 hours in the incubator.
CD40 blocking antibody was added to cultures for 15 minutes before antigen stimulation. For
each condition, 5 duplicate wells containing 2x105 cells in 200mL media were plated in 96-well
round-bottom plates and cells were stimulated for 24 hours with different antigens. Matched
unstimulated samples were plated for each donor. After 24 hours of stimulation, cells were
resuspended in fresh media containing IL-2. Half of the media was replenished on Day 4 of
culture. Twenty-four hours before re-stimulation, plates were resuspended in fresh media without
IL-2. On Day 7, cells from each antigen condition were combined and re-stimulated with
respective antigen for 6 hours before surface staining with antibodies. After re-stimulation, cells
were washed and stained with LIVE/DEAD™ Fixable Aqua dead cell stain for 30 minutes
protected from light, sequentially stained with a cocktail of antibodies targeting chemokine
receptors CD192 (CCR2) and CD195 (CCR5) for 10 minutes at 37°C and then stained with the
rest of the antibody cocktail of surface markers directed against CD3, CD4, CD8, CD161, CD127,
CD154 (CD40L), CD69, CD25, CD38 and CD279 (PD-1) for 20 minutes at room temperature
protected from light. Cells were washed and acquired in the flow cytometer. Approach adapted
(Cao et al. 2015; Reiss et al. 2017).
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Figure 3.2: Higher auto-activation and frequency of activated cells for CNS myelin and EBV
antigens within CD4 T cell responses in the pediatric MS patients.
Peripheral blood mononuclear cells (PBMC) were stained with appropriate antibodies initially
gated on singlet, live, total CD3, CD8 and CD4 T cells (Appendix 3.1 for general gating strategy
after culture). Within CD4 T cell population, we assessed co-expression of CD25 and CD154 to
account for activated cells. (A) Flow cytometry representative plots for each group in the absence
or presence of different antigens (Ags) gated on CD25+CD154+ T cells. (B-F) Group summary
graphs of the percentages of CD25+CD154+ gated on CD4+ T cells of pediatric HC (n=10), Mono
(n=10), and MS (n=11) for the no Ag condition, MOG, EBV and C. albicans (CAL) and MBP (n=9)
Mono (n=9) and MS (n=8). (G) Group summary graph presented ‘Stimulation Index (SI)’ was
calculated as (Counts of Ag stimulated condition-Count of ‘No Ag’ condition)/Count of ‘No Ag’
condition, with a threshold arbitrarily set at >2. Statistical analysis was performed by a mixedeffect model (1-way ANOVA) followed by Tukey’s multiple comparison test (adjusted p value,
*p<0.05, **p<0.001, ***p<0.0001).
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Figure 3.3: Disease-implicated CD4+CCR2+CCR5+ T cell subset responses in the absence
of exogenous antigen or in presence of CNS or EBV antigens in pediatric MS patients.
(A) Peripheral blood mononuclear cells (PBMC) were stained with appropriate antibodies initially
gated on singlet, live, total CD3, CD8 and CD4 T cells. Flow cytometry representative plot of
CCR2+CCR5+ T cell subset within CD4 T cells in a pediatric MS patient sample in the absence of
exogenous antigen. (B-F) Group summary graphs of the percentages of CCR2+CCR5+ gated on
total CD4 T cells of pediatric HC (n=10) Mono (n=10) and MS (n=11) for no antigen condition,
MOG, EBV and C. albicans (CAL) and MBP (n=9) Mono (n=9) and MS (n=8). (G) Flow cytometry
representative plot of CD25+CD154+T cells gated within CCR2+CCR5+CD4+ T cells in a pediatric
MS patient sample in the absence of exogenous antigen. (H-L) Group summary graphs of the
percentages of CD25+CD154+ within CD4+CCR2+CCR5+ T cell subset in the absence of
exogenous antigen and presence of CNS myelin, EBV and C. albicans antigens. Statistical
analysis was performed by a mixed-effect model (1-way ANOVA) followed by Tukey’s multiple
comparison test (adjusted p value, *p<0.05, **p<0.001, ***p<0.0001).
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Figure 3.4: No auto-activation and increased proliferation of activated cells in response to
EBV antigens in CD8 T cells of pediatric MS patients.
Peripheral blood mononuclear cells (PBMC) were stained with appropriate antibodies initially
gated on singlet, live, total CD3, CD8 and CD4 T cells. Within CD8 T cell population, we
assessed co-expression of CD25 and CD154 to account for activated cells. (A) Flow cytometry
representative plots for each group in the absence or presence of different antigens gated on
CD25+CD154+ T cells. (B-F) Group summary graph of the percentages of CD25+CD154+ gated
on CD8 T cells of pediatric HC (n=10) Mono (n=10) and MS (n=11) for no antigen condition,
MOG, EBV and C. albicans (CAL) and MBP (n=9) Mono (n=9) and MS (n=8). (G) Group
summary graph presented ‘Stimulation Index (SI)’ was calculated as (Counts of Ag stimulated
condition-Count of ‘No Ag’ condition)/Count of ‘No Ag’ condition, with a threshold arbitrarily set at
>2. Statistical analysis was performed by a mixed-effect model (1-way ANOVA) followed by
Tukey’s multiple comparison test (adjusted p value, *p<0.05, **p<0.001, ***p<0.0001)
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Figure 3.5: In vitro CD4 T and CD8 T cell responses pre and post anti-CD20 therapy in
adult MS patients in the absence of exogenous antigen or in the presence of MOG, EBV
and C. albicans antigens.
Peripheral blood mononuclear cells (PBMC) were stained with appropriate antibodies initially
gated on singlet, live, total CD3 CD8 and CD4 T cells.

Within CD4 T cell population, we

assessed co-expression of CD25 and CD154 to account for activated cells. (A) Flow cytometry
representative plots for each timepoint (baseline, 3 months, 6 months) in the absence or
presence of different antigens gated on CD4+CD25+CD154+ T cells. (B) Group summary graphs
of the percentages of CD25+CD154+ gated on CD4 T cells for no antigen condition, (C) MOG, (D)
EBV and (E) C. albicans pre- and post-treatment with ocrelizumab baseline (n=6), 3 months
(n=5), and 6 months (n=5). (F) Flow cytometry representative plots for each timepoint (baseline, 3
months, 6 months) in the absence or presence of different antigens gated on CD8+CD25+CD154+
T cells. (G) Group summary graphs of the percentages of CD25+CD154+ gated on CD8 T cells for
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no antigen condition, (H) MOG, (I) EBV and (J) C. albicans pre- and post-treatment with
ocrelizumab baseline (n=6), 3 months (n=5), and 6 months (n=5). Statistical analysis was
performed by a mixed-effect model (1-way ANOVA) followed by Tukey’s multiple comparisons
test (adjusted p value, *p < 0.05, **p<0.001, ***p<0.0001)
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Abstract
Previously, our work in children with MS implicated the CD4+CCR2+CCR5+ T cell subset, which
has increased frequencies and pro-inflammatory cytokine responses, as well as a decreased
propensity to be suppressed by regulatory T cells. To further characterize this subset, we follow
up with a more detailed gene-expression level analysis using an innovative single cell RNA
sequencing platform, which integrates oligo-conjugated surface marker antibodies into existing
single-cell sequencing workflow for simultaneous characterization of protein and RNA ((Cellular
Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq)). We take advantage of this
novel CITE-seq platform to investigate differences in quantitative transcriptomics and protein
expression levels of disease-implicated T cells, as well as explore gene expression profiles that
may be differentially regulated between the memory CD4 T cell populations in the peripheral
blood of cryopreserved samples of children with MS, newly defined MOG-associated disorder
(MOGAD), non-MS/non-MOGAD and healthy controls. Based on simultaneous RNA transcript
and protein expression levels, we reconstruct the pediatric peripheral immune cell composition by
identifying major lymphoid and myeloid cells. We identify several novel aspects of the
CCR2+CCR5+ T cell profiles in children with MS. The clearest distinctions between cohorts are
observed as clusters of differentially expressed genes within memory CD4 T cells of pediatriconset MS and MOGAD. The majority of differentially expressed genes in the pediatric MS
memory CD4 T cells relate to altered T1/Th17/Treg responses, cell trafficking and adhesion,
metabolism, and senescence. While those differentially expressed in children with MOGAD
appeared particularly related to Th1 anti-viral and Th2 responses. While all our findings warrant
confirmation in larger cohorts, our study constitutes the first ever comprehensive proteogenomic
analysis in pediatric MS, as well as MOGAD and provides helpful comparisons to children with
other inflammatory diseases as well as healthy controls. This single cell analysis allows for more
detailed investigation of potentially relevant molecular machinery of implicated in immune cell
subsets in these children. While we recognize that individual genes or groups of differentially
expressed genes may not be able to readily differentiate MS from other disorders, this is a step
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forward toward identifying pathogenic mechanisms and potentially novel biomarkers and
therapeutic targets.
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Abbreviations
ADT=Antibody Derived Tag
CITE-seq=Cellular Indexing of Transcriptomes and Epitopes by Sequencing
DE=Differentially Expressed
HTO=Hash Tag Oligonucleotide
MOGAD=Myelin Oligodendrocyte Glycoprotein Antibody Disorders
UMAP=Uniform Manifold Approximation and Projection
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Introduction
Prior studies in adults have implicated multiple cellular abnormalities in the peripheral blood of
MS patients (Voskuhl et al. 1993; Lassmann and Ransohoff 2004; Kebir et al. 2007; Tzartos et al.
2008; Kebir et al. 2009; Hohlfeld et al. 2016a), but distinguishing which mediate disease from
others that may develop as a consequence of longstanding dysregulation is not straightforward.
In our previous work studying children developing MS (who are thought to be closer to their
biological disease onset), we reported increased frequencies and enhanced pro-inflammatory
(Th1 and Th17) cytokine responses of CD4+CCR2+CCR5+ T cells in children with MS compared
to controls (Mexhitaj et al. 2019). These T cells appear ‘activated’ or ‘primed’ in children with MS,
which may reflect cell-intrinsic factors such as a lower threshold of activation, a prior activation
history, a decreased propensity to be suppressed by Treg and/or an ability to limit Treg function.
In this study, we aimed to further characterize this subset (among other immune cells) by
proteogenomic assessment at the single-cell level in the peripheral blood compartment of
pediatric-onset MS as compared to other CNS inflammatory demyelinating disorders and healthy
controls.
In children, when one considers all-comers presenting with an incident episode of inflammatory
CNS demyelination, referred to acquired demyelinating syndromes (ADS), approximately 20% will
eventually be diagnosed with MS based on careful prospective follow-up (Banwell et al. 2011;
Fadda, Armangue, et al. 2021). Advances in neuroimaging have led to refinement of the MS
diagnostic criteria and improvements in biological assays now help to reliably measure ‘spectrum’
defining antibodies such as anti-AQP4 antibodies for the diagnosis of neuromyelitis optica
spectrum disorders (NMOSD) and antibodies to myelin-oligodendrocyte glycoprotein (MOG) that
now is defined MOG associated disease (MOGAD) (Otallah and Banwell 2018; Fadda,
Armangue, et al. 2021). Approximately 30% of children who present with ADS have MOGAD
(Fadda, Armangue, et al. 2021). Although both patients with MS and MOGAD can relapse, their
underlying immunopathological and clinical features are not identical and treatments for one are
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not necessarily beneficial in the other – contributing to the view that these warrant consideration
as distinct pathophysiologic entities (Ambrosius et al. 2020). Both patients with MS and MOGAD
have T and B cells infiltrates in brain lesions, but in MS, CD8 T cells and B cell are more
abundant in the infiltrates, while in MOGAD CD4 T cell infiltration predominates (Machado-Santos
et al. 2018; Hochmeister et al. 2020; Hoftberger et al. 2020). In MS, convergence of findings
implicate Th17 and Th1/Th17 responses in disease pathophysiology. While MOGAD is more
recently described and much less well studied, a recent report indicated that after stimulation with
human recombinant MOG, Th2 and Th17 responses were upregulated in PBMC of patients with
MOGAD as compared to MS (Horellou et al. 2021). CSF and serum chemokine/cytokine profiles
associated with MOGAD also appear to be distinct, as compared to MS (Hofer et al. 2019).

Further elucidation of distinct disease mechanisms may lead to improved and more targeted
therapies for these conditions, and these mechanisms may be informed by careful comparisons
of phenotypic and functional response profiles of peripheral blood cells from children with MS and
other CNS inflammatory demyelinating diseases. In this study, we set out to (i) follow up on our
recent implication of CD4+CCR2+CCR5+ T cells in children with MS, by testing whether these cells
harbor additional features consistent with a presumed role of propagating pro-inflammatory
responses and injury in the CNS; (ii) explore more broadly the memory T cell subset of children
with MS versus controls; (iii) identify distinguishing features of CD4 T cells in children with
MOGAD, providing a ‘first-look’ into the peripheral cellular immunology of this condition. We hope
our findings which are largely exploratory, will nonetheless point to possible mechanisms that
distinguish these conditions and may lead to the identification of potentially useful diagnostic
biomarkers or markers of disease state, as well as potentially novel targets for therapy. With the
use of an innovative single cell technology, we made an initial attempt to analyze cellular
transcriptomics and proteomics comprehensively and simultaneously in the peripheral immune
compartment of children with MS and other CNS inflammatory demyelinating disorders.
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Technologies like high-parametric flow cytometry and CyTOF have allowed for characterization of
the phenotype and function of immune cell populations, but they are limited in their targeted
approach by panels of restricted number of proteins that are defined a priori (Neu et al. 2017).
This makes it harder to identify in a more unbiased way potential markers that may define novel
functionally distinct cells. The more recently developed technology of Cellular Indexing of
Transcriptomes and Epitopes by Sequencing (CITE-Seq) integrates oligo-conjugated surface
marker antibodies into existing single-cell sequencing workflow for simultaneous characterization
of protein and transcriptome measurements in single cells (Stoeckius et al. 2017; Mair et al. 2020;
Zhou et al. 2020; Buus et al. 2021). While single cell RNA-sequencing (scRNAseq) has been
useful for studying in detail transcriptomic profiles of cell populations, transcriptomic analysis
alone is at times not able to differentiate between immune cells which may appear molecularly
similar but are nonetheless functionally distinct (Liu and Trapnell 2016; Nguyen et al. 2018; Chen
et al. 2020; Hao et al. 2021). Assessing the expression of cell-surface proteins and
transcriptomics can contribute to more robust analysis of both known and novel cell subsets.
To identify and validate major immune cell populations among peripheral leukocytes and
subsequently their transcriptome, we pursued a proteogenomic approach combining 10X singlecell RNA sequencing (scRNASeq) with a wide selection of antibodies that allow labelling of
known cell-subset defining markers at the protein level (their identification is based on antibodyderived tag (ADT) expression patterns that can be combined with expression of canonical marker
genes).

We then confirmed the surface marker expression of CD4 T cell subsets and their

differentiation states (naïve vs. memory) based of known cell surface markers, while also
performing unbiased transcriptional profiling of the T cells, comparing findings across four
pediatric cohorts, including children with MS, MOGAD, ADS that is neither MS nor MOGAD, and
healthy controls.
We observed that the disease-implicated CD4+CCR2+CCR5+ T cell subset in pediatric MS
exhibited differentially expressed genes associated primarily with chemotaxis and cell survival,
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with implications for Th1/Th17 and Treg differentiation. Among the overall CD4 T cell memory
population, differentially expressed genes in pediatric MS include genes that relate to modulation
of T cell responses (a shift toward Th1 and Th17 responses, rather than Tregs), trafficking and
extravasation activities, and metabolic changes towards autophagy as well premature
senescence. Upregulated genes in MOGAD suggested skewing toward Th2 responses as well as
anti-viral responses. Overall, these findings are consistent with pediatric-onset MS and MOGAD
representing pathophysiologically distinct entities manifesting in different functional response
profiles of their memory CD4 T cells, as well as T cells more generally. Our initial analysis did not
pursue CD8 T cells and B cells, as well as myeloid cells – all of which are likely relevant in these
conditions.
While all our findings warrant confirmation in larger cohorts, our study constitutes the first ever
comprehensive proteogenomic analysis in pediatric MS, as well as MOGAD and provides helpful
comparisons to children with other inflammatory diseases as well as healthy controls. The
multimodal single cell analysis allows for more detailed investigation of potentially relevant
molecular machinery of implicated immune cell subsets in these children. We recognize that MS
is a multifaceted disease, so individual genes or groups of differentially expressed genes may not
be able to readily differentiate it from other disorders, or immediately inform on the heterogeneity
that exists within the same condition, but this is a step forward toward identifying pathogenic
mechanisms and potentially novel biomarkers and therapeutic targets.
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Materials and methods
Study participants
All participants were followed as part of the ongoing prospective Canadian/CHOP Pediatric
Demyelinating Disease Network (CPDDN) study of children presenting with any form of acquired
demyelinating syndrome (ADS). Inclusion/exclusion criteria of the overall CPDDN population
have been previously reported (Banwell et al. 2011). Table 4.1 describes demographics of the
participants selected for the current immune profiling study, including children ascertained in
prospective follow-up as having multiple sclerosis (MS); those seropositive for MOG antibodies
with either monophasic or relapsing courses (MOGAD or MOG+), and those with ADS that
remained monophasic and seronegative for MOG antibodies (MOG- monoADS) throughout
follow-up, as well as healthy controls (HC). These selected participants were generally
representative of their corresponding CPDDN cohorts, and we refer to them here as MS, MOG+,
MOG- and HC, respectively. Their ADS presenting phenotype, age at blood sampling and follow
up available after are included. All protocols and informed consent/assent were approved by the
recruiting institutional ethics review boards.
Sample preparation, sorting, and staining for CITE-seq
Cryopreserved PBMC from cohorts of children with MS (n=6), MOG+ (total n=6; including 3
monophasic MOG+ and 3 relapsing MOG+), non-MS MOG- (n=6), and HC (n=6) who were
balanced for sex and age at blood draw, were thawed in warm 10 mL serum-free X-VIVO15
media (Lonza Bioscience). Cells were washed, centrifuged and after discarding the supernatant,
cells were incubated in a humidifed incubator 37°C, 5% CO2 in X-VIVO15 media containing
DNase (Roche) at a final concentration of 0.1mg/mL to avoid formation of cell clumps. After two
additional washes, cells were resuspended at a concentration of 1 x 106 cells in X-VIVO15 and
counted with a hemocytometer. After cells were rested for 2 hours in the incubator, cells were
washed a final time and resuspended at a concetration of 1x106 cells in X-VIVO15 medium.
These experiments were performed in three batches, where 8 samples (2 samples/group) were
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processed per batch. Use of hashtags facilitated pooling of samples before library preparation
and sequencing and later enabled identification of cells from original samples by demultiplexing.
Dilutions for the hashtags (BioLegend, TotalSeq-B0251-B0258) and oligo-conjugated antibodies
(55) (all from BioLegend, please refer to Table 4.2) were prepared while cells were rested.
Optimal antibody dilutions for the 55 oligo-conjugated antibodies were mixed before staining the
cells (Buus et al. 2021).
After cells were rested for 2 hours, they were washed once with cold 1X PBS (Thermo-Fischer) to
remove any remaining serum and stained with LIVE/DEAD™ Fixable Aqua dead cell stain
(Thermo-Fisher, Cat# L34966) protected from light for 30 minutes at 4°C to exclude dead cells.
Cells were washed once and cell suspesions were filtered with a cell strainer (40 micron
FlowmiTM Cell strainer, Millipore Sigma) to remove any large clumps. Cells were resuspended in 5
mL FACS buffer (1X PBS + 1% Fetal Bovine Serum [Thermo-Fischer]) at cell consentration 10-20
x 106 cells/mL (in 500-800 uL) and 2 x 106 cells were sorted from each sample on FACSAria (BD
Biosciences). Purity check for each sample was <95% post-sort analysis. 2 x 105 sorted
cells/sample were transferred into 1.5 mL Eppendorf tubes (~200 uL) and microcentrifuged at
5000rpm for 5 minutes at 4°C. Cells were resuspended in 45 uL of labeling buffer (PBS + 1%
Bovine Serum Albumin) and 5 uL of Human TrueStain FcX (BioLegend; Cat#422301) was added
to be incubated for 10 minutes at 4°C to block any non-specific antibody binding. 4 uL of
individual sample diluted hashtag (HTO#1-8) was added to each sample and 46 uL of the mixture
of diluted oligo-conjugated antibody was added to the cell suspension for a total staining volume
of 100 uL. Antibody concentrations were 1 ug per test, as recommended by manufacturer
(Biolegend, USA) for flow cytometry applications. Cells were then incubated for 30 minutes at 4°C
protected from light. Once cells were stained, they were washed three times with 1.4mL of
labeling buffer and centrifuged at 400 rcf for 5 minutes at 4°C. Cells were resuspended in
resuspension buffer (PBS and 0.04% Bovine Serum Albumin) and were pooled from the 8
samples (in each batch) in equal ratios to obtain a 1000 cells/uL concentration. Cells were
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counted one last time before library preparation with 10X Genomics platform (Please refer to
Appendix 4.1: CITE-Seq Workflow Part 1).
Library preparation, feature barcoding, and RNA-sequencing
Library preparation and sequencing was performed at the Center for Applied Genomics (CAG) at
the Children’s Hospital of Philadelphia (CHOP) according to manufacturer’s instructions (10X
Genomics, USA). 10X Genomics Chromium single cell (3’ gene expression) was used for Gel
Bead-In-EMulsions (GEM)-single cell generation, RNA library preparation and sequencing. With 6
donors per condition (4 different conditions), a total of 24 samples were split into 3 reactions (one
reaction/batch with 8 samples each). Each reaction containing a total of 80,000 cells was split into
4 lanes (replicates) accounting for a total of 12 reactions for all three batches. Up to a total of
20,000 cells were used per lane for loading, with a recovery rate of 50%. At the end of each
reaction, 5000 cells/sample were recovered and used for sequencing. To expose the mRNA,
individual cells were lysed within individual droplets while the cellular mRNA and the antibodyderived oligos both hybridized with the microbeads that contain oligo-dT. These were later
indexed by a shared cellular barcode during reverse transcription. Reverse transcription reaction
occurred and produced cDNAs containing the reverse complement of the mRNAs and their
specific barcode sequence. The amplified cDNAs and antibody derived tags (ADTs) were
separated by size and converted into Illumina-sequencing libraries independently. Simultaneously
but separately from the gene expression library, a feature barcoding library preparation was also
generated to account for all cell surface proteins (Antibody-Derived Tags (ADT)). cDNA was
amplified for 10 cycles and products were then sized separated with beads into <300 base pairs
containing the ADT and >300 base pairs containing cDNA derived from cellular mRNA (Stoeckius
et al. 2017). ADT was amplified for 10 additional cycles using specific primers which were used to
be clustered on Illumina flowcells. Since the two library types were generated separately, their
relative proportions were adjusted in a pooled single lane and the required sequencing depth was
obtained for each library. Then ADT and cDNA libraries were merged and sequenced. Depth of
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sequencing was 40,000 reads/cell (for a total of 4.8 billion reads) for the 3’ gene expression and
5000 reads/cell (for a total of 600 million reads) for feature bar-coding. Based on the expected
output range a Nova Seq S4 (200 cycles) flow cell was used for sequencing all samples at once
(Illumina) (Please refer to Appendix 4.1: CITE-Seq Workflow Part 2).
Computational methods
Single-cell data processing and filtering: Sequencing data were processed using Cell Ranger
6.0.2 and reads were aligned to the provided Cell Ranger 6.0.2 human reference sequence and
feature barcode sequences (including ADT oligonucleotide sequences and HTO oligonucleotide
sequences). Samples were de-multiplexed and labelled as singlets, multiplets, or non-tagged
cells using the HTODemux function in Seurat (Stoeckius et al. 2017). Non-tagged cells were
filtered out following this analysis. Next, to predict doublets/multiplets, a k-nearest-neighbors
(kNN) graph was built using the PCA-reduced dimension space based on single cell HTO
expression values; singlet cells with more than 20% of neighbors corresponding to HTODemux
doublets/multiplets were labelled as likely-doublets. Likely-doublets and HTODemux doublets
were then filtered out from the analysis. To exclude dead cells, the SeuratWrappers
implementation of miQC (Hippen et al. 2021) was utilized with a backup percentile of 0.99. Cells
labelled as live cells by miQC were then kept for downstream analysis.
RNA and ADT normalization and clustering: ADT values were transformed using the
centralized log-ratio (CLR) transformation across cells, limited to cells from each individual donor.
Single cell RNA levels were library scaled and “log-plus-one” transformed. The top 2000 most
variable genes were determined from the merged RNA dataset utilizing the FindVariableFeatures
function in Seurat (‘vst’ method) and scaled and centered. CLR-transformed ADT values were
also scaled and centered across each individual donor. PCA was then performed on the scaled
and centered gene expression values and the scaled and centered ADT values, separately. RNAPCA transformation was then followed by Harmony (Korsunsky et al. 2019) integration of this
PCA space across each donor. ADT-PCA transformation was not integrated across donors as an
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ADT-PCA UMAP projection showed consistent overlap/distribution of cells across donors (data
not shown). The Weighted-Nearest-Neighbors (WNN) algorithm (Hao et al. 2021) was then
utilized to create a WNN graph across the RNA-PCA-Harmony embeddings and the ADT-PCA
embeddings. The WNN graph was then utilized for UMAP projection and Louvain clustering.
Differential abundance and differential expression testing: Following Louvain clustering,
clusters were assigned to either CD4 T, CD8 T, CD8 T MAIT, B, Antibody-secreting cell (ASC),
NK CD56dim, NK CD56bright, CD14 Mono, CD16 Mono, pDC, DC, or Platelet identities based on
expression of marker genes and ADT expression patterns. For the current analysis, we chose to
focus on CD4 T cells since abnormalities in the CD4 T cell compartment have been previously
implicated in both pediatric-onset and adult-onset MS. Sub-clusters were then identified within the
CD4 T cluster, and differential abundance testing was performed utilizing a t-test for
compositional abundances within the CD4 T cell compartment. CD4 T clusters were also labelled
as naïve-like or memory-like based on ADT expression patterns. A pseudobulk approach (Squair
et al. 2021) was then utilized with the merged naïve-like and merged memory-like CD4 T clusters
(per donor) in order to perform differential gene expression analysis utilizing DESeq2’s likelihoodratio-test (LRT) framework (Love, Huber, and Anders 2014). Within the LRT, the full model is ~
10xbatch + condition and the reduced model is ~10xbatch where 10xbatch denotes the day the
10X experiment was performed for that sample and condition is either HC (healthy control), MS
(patients with MS), MOG positive, or MOG negative. Genes with an adjusted p-value lower than
0.05 were then labelled as differentially expressed and clustered in rlog-gene-expression-scaled
space (Love, Huber, and Anders 2014) to determine expression patterns across all 4 conditions.
CCR2hi/CCR5hi and CCR2lo/CCR5lo populations were determined by partitioning the CD4 T cell
ADT CCR2 and CCR5 expression distributions into 4 quartiles (within each 10X batch) and
labelling either the highest quartile as “hi” or lowest quartile as “lo”. Differential expression
analyses were then performed using the pseudobulk method outlined above with DESeq2,
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limiting the pseudobulk comparison to CCR2hi/CCR5hi cells within the memory-like CD4
compartment.
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Results
Identification of major immune cell populations in pediatric cohorts by CITE-seq
A total of 24 pediatric samples, obtained from six donors in each of the four different pediatric
cohorts (HC, MOG-, MOG+ and MS) were studied in three batched experiments. We recovered a
total of ~120,000 live PBMC from all participants and used these to generate the sequencing
data, evenly distributed across the 24 different donors (~5000 cells/donor).
We first aimed to examine the cell subset composition of circulating leukocytes and assess how
well antibody-defined subsets corresponded to sequencing matches for known immune cell
types. Based on a simultaneous analysis of the selected antibody defined molecules using ADT,
and single cell RNA transcripts, we generated a Uniform Manifold Approximation and Projection
(UMAP) dimensionality reduction plot and Louvain clustering of the merged 120,000 single cells
from all 24 children and identified 12 major immune cell populations (Figure 4.1. A).
The identity of major adaptive and innate immune cell populations was established based on
known ADT expression and classical marker genes (Figure 4.1. B). Classical marker genes were
used to help identify CD4 and CD8 T cell subsets, CD8 MAIT cells (CD3, CD8, CD161, TCR
Vα7.2, KLRB1), B cells (CD19, CD20, HLA-DRB1, MS4A1, IGHD), antibody secreting cells
(CD19, MZB1, TNFRSF13B, HLA-DRB1), dim and bright natural killer cells (CD56, CD161,
KLRB1), classical CD14 and non-classical CD16 monocytes (CD33, ITGAX, HLA-DRB1),
dendritic cells (CD33, CD11c, CD123, HLA-DRB1, ITGAX), plasmacytoid dendritic cells (CD11c,
CD123, HLA-DRB1, MZB1) and platelets (PPBP) (Figure 4.1. C, D). As expected, CITE-seq
successfully reconstituted the circulating leukocyte lineages with good overall correspondence
between the known protein and transcript markers of cell types.
Splitting the UMAP plots by pediatric diagnosis did not reveal gross differences in major cell types
across the four conditions (Figure 4.2. A). Differential abundance testing of major cell populations
also did not reveal statistically significant differences across the four diagnostic groups (Figure
107

4.2. B) which of course may in part reflect the limited power. We note a slight increase, although
not statistically significant, in the frequency of CD56NKdim cells and CD16-expressing monocytes
at the group level in children with MS as compared to controls (Figure 4.2. B).
For the current analysis, we decided to target the CD4 T cell population given the prior implication
of CD4 T-cell abnormalities in the pathogenesis of both adult- and pediatric-onset MS. We
identified 10 distinct sub-clusters of CD4 T cells (Figure 4.3. A) based on ADT expression
markers, including naïve and memory markers, co-stimulatory and co-inhibitory markers, as well
as adhesion and chemokine receptor markers, among others (Figure 4.3. B). Cluster 9
represented less than 1% of all cells assessed in the clustering and had rather low level of
expression of CD4, so it was excluded from downstream analysis. CD4 T cell clusters were
identified as naïve-like or memory-like based on ADT expression patterns. We could identify six
naïve-like clusters (0, 2, 3, 4, 5 and 7) and three memory-like clusters (1, 6 and 8) (Figure 4.3.
B). Naïve-like clusters expressed higher levels of CD27 and ICOS and clusters 3 and 4 also
expressed higher levels of chemokine receptor CXCR3; with cluster 4 showing higher expression
of other chemokine receptors including CXCR5 and CCR6; cluster 7 upregulated CD25 and
CXCR5 consistent with a T follicular helper cell-like phenotype. Memory-like CD4 T cell clusters
showed, as expected, higher expression of co-stimulatory, as well as chemokine receptors and
adhesion molecules. Cluster 1 exhibited lower levels of expression of chemokine receptor CCR4
but higher expression of other markers including chemokine receptors (CCR2, CCR5, CCR6,
CXCR3), CD161 and adhesion molecules (CD29 and CD49d). RNA transcripts and ADT
expression levels of low CD45RO and high CD45RA, CCR7 and CD62L were further used to
confirm naïve-like vs. memory-like CD4 T cell clusters (Figure 4.3. C), which for current purposes
we will refer to as ‘naïve’ and ‘memory’ T cells, moving forward. Differential abundance of these
respective CD4 T cell populations across the different pediatric groups, showed a slight decrease
of CD4 naïve T cells and a slight increase of CD4 memory T cells in the children with MS as
compared to the controls (Figure 4.3. D), recapitulating prior reports (Schafflick et al. 2020).
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Differentially expressed genes of CD4+CCR2+CCR5+ T cells of pediatric MS
First, we were interested in studying the double-chemokine receptor (CCR2 and CCR5)
expressing T cell subset, whose frequency we previously found to be abnormally increased in
pediatric-onset MS as compared to controls (Mexhitaj et al. 2019). It was reassuring that, despite
the small numbers off participants per group, standard flow cytometry in samples from the same
individuals used for the CITE-seq (Figure 4.4. A), recapitulated the abnormal increase in
CCR2+CCR5+ T cell frequencies within CD4 T cells in pediatric-onset MS patients as compared
to those with other CNS demyelinating diseases and healthy controls, corroborating the findings
of our previous larger dataset (Figure 2.1. B). We also found that ADT expression levels from the
CITE-seq expressed high levels of both CCR2 and CCR5, which appear to co-localize to the
memory CD4 T cell cluster #1 (Figure 4.4. B, Figure 4.3. A, B).
We then compared the CCR2+CCR5+ T cell gene expression profiles of the pediatric MS, MOG+
MOG- and HC participants (Figure 4.4. C). We identified two main categories of differentially
upregulated genes in the CCR2+CCR5+ T cells of pediatric MS compared to MOGAD children
(Figure 4.4. C, Table 4.3).

Upregulated genes in pediatric MS were associated with two

categories, including: (i) chemotaxis and (ii) cell survival. The first category included: a Ca+2 ion
sensor and chemoattractant able to induce CCL2 expression in activated T cells (S100A11)
(Zhang et al. 2021); a platelet-activating factor and chemoattractant which regulates expression
of CCR5 on T cells, as well as induce Th17 differentiation (PAFAH1B1) (Drolet et al. 2011;
Kelesidis et al. 2015); and a chemoattractant for CCR6-expressing cells, including Th17 cells
(CCL20) (Maddur et al. 2012; Jafarzadeh et al. 2014) . In the second category we observed
upregulation of autophagy and cell survival genes (SQSTM1 and GLN3, respectively) (Figure
4.4. C, Table 4.3), shown to be upregulated in genome-wide gene expression analysis of the
blood of untreated MS patients (Riveros et al. 2010; Hassanpour et al. 2020).
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Differentially expressed genes among overall memory CD4 T cells of pediatric MS
Since our findings (Figure 4.3. D) suggest increased frequencies of memory CD4 T cells in
children with MS that would not be fully explained by the (relatively small) increases in the
CCR2+CCR5+ T cell subset frequencies, we considered that additional abnormalities may exist in
the memory CD4 T cell population of pediatric MS patients that would be of interest to explore at
the gene expression level across the cohorts (Figure 4.5). We found that upregulated genes
within the memory CD4 T cells of pediatric-onset MS patients could be classified into four
categories: including: (i) immune cell response (ii) cell trafficking and extravasation activity (iii)
metabolism, autophagy, and senescence and (iv) tumor suppressors (Figure 4.5. B, Table 4.4).
The first category includes genes that encode for a myelin component considered one of the
putative MS target autoantigens and a potential activator of T cells (MBP) (Pitchekian-Halabi et
al. 1996; Hohlfeld et al. 2016a); a transcription factor that is involved in Th1 and Th17
differentiation (STAT4) (Rodriguez et al. 2006; Martinez et al. 2008; Nageeb et al. 2018); a
positive regulator of Th17 and inhibitor of Foxp3+ regulatory T cells (PRMT1) (Bedford and Clarke
2009); a TNF receptor associated factor which regulates pathways leading to production of
cytokines and interferons, as well as induces signal transduction of CD40 (TRAF3) (Grammer et
al. 1998; Hacker, Tseng, and Karin 2011); and several other genes which, among other functions,
determine T cell development, activation state, differentiation and proliferation (ZHX2, KDSR,
AMPD2, TMEM8A) (Liu, Ma, and Ji 2015; Tuomela et al. 2012; Ehlers et al. 2021; Lee et al.
2016).
The second category includes genes that encode for chemokine receptor and marker for Th17
cells (CCR6) (Cao et al. 2015; Restorick et al. 2017); a protein that increases Ca+2 ion binding
activity to promote cell-cell adhesion, activation and migration (HEG1); a GTPase which promotes
cell trafficking and migration (ARHGAP31); a long non-coding RNA which promotes matrix
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metalloproteinase (MMP) activity known to increase leukocyte extravasation (LINC01128) (Yao
and Chen 2020); and a component of the VCAM-1/CD106 signaling which promotes blood-brain
barrier penetration and immune cell transmigration (JAM3) (Kummer and Ebnet 2018).
The third category includes genes that encode for a protein involved in vesicle-mediated transport
(AP1S3) and endosomal recycling process in the Golgi apparatus promoting autophagy
(RAB11FIP1 and FAM241A)(Mahil et al. 2016; Muller et al. 2017); regulator of RNA polymerase
playing a critical role in telomere maintenance and cellular senescence (NOLC1) (Yuan, Li, and
Tong 2017) and genotoxic stress (DYRK3) (Mediani et al. 2021). Within this category there are
also two genes (KDSR and AMPD2) whose products are involved in sphingosine metabolism and
reduction of adenosine in immune cell response, respectively, both attributing to an increased
state of inflammation (Maceyka and Spiegel 2014; Pasquini et al. 2021; Ehlers et al. 2021).
The fourth category includes genes that encode for: tumor suppressors (RASSF2); (RBMS1); a
(VSIG1), where the latter two genes are found to be upregulated in regulatory T cells (Donninger
et al. 2010; Pfoertner et al. 2006; Zhao et al. 2014).
Differentially expressed genes in CD4 T cells of children with MOGAD
Our study provides a unique opportunity to explore abnormalities in children with MOGAD, a
relatively recently recognized inflammatory demyelinating syndrome that was previously
considered an atypical form of MS, but now understood to be distinct. Disease mechanisms,
including the cellular immunology of MOGAD, are poorly understood. Assessing the gene
expression profiles of the memory CD4 T cells of children with monophasic or relapsing MOGAD
compared to the other pediatric cohorts identified upregulated genes that could be classified into
two main categories, which include (i) Th1 anti-viral and (ii) Th2 responses (Figure 4.5. C, Table
4.5).

The first category includes genes that encode for a broad antiviral host factor to viruses (TRIM22)
(Lian and Sun 2017); a Ca+2 ion binding protein which transfers glycosyl groups leading to protein
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glycosylation and is involved in host-anti-viral immunity (GALNT3) (Wang et al. 2018); and an
interferon induced GTPase which impacts inflammasome responses, inhibits influenza A virus
replication and promotes survival of EBV-infected T cells during chronic EBV infection
(GBP5)(Tripal et al. 2007; Ito et al. 2008; Feng et al. 2017).

The second category includes genes that encode for a transmembrane transporter protein and a
specific eosinophil cell surface marker, whose down-regulation is involved in eliciting an antigenspecific Th2 response (MFSD10) (Ushijima et al. 2008; Motoi et al. 2012; Nishimura et al. 2014);
an actin-binding protein important in cell trafficking, interacts with the first committed enzyme in
leukotriene biosynthesis in leukocytes, which have a pathogenic role in inflammatory Th2mediated diseases (COTL1) (Haeggstrom 2018); and a signal transducer which overlaps both
categories by displaying anti-viral activity against different infections, as well as help skew toward
Th2 differentiation (IFITM1) (Yanez, Ross, and Crompton 2020).
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Discussion
This dataset to our knowledge constitutes the very first single cell proteogenomic study of
peripheral blood immune cells of pediatric-onset MS. The inclusion of age- and sex-balanced
controls, particularly children with other CNS inflammatory demyelinating disorders in addition to
healthy controls, is a strength that enables focus on features specific to MS and not CNSinflammatory demyelination more generally. Based on simultaneous RNA transcript and ADT
expression levels, we can reconstruct the pediatric peripheral immune cell composition by
identifying major lymphoid and myeloid cells. I chose to focus this initial analysis on CD4 T cells
and their sub-clusters. Differential expression analysis of memory CD4 T cells, with a particular
focus on CD4+CCR2+CCR5+ T cells, which we previously implicated in children with MS,
identifies distinct patterns of gene expression between these cells of children with pediatric-onset
MS compared to other CNS demyelinating disorders. The majority of differentially expressed
genes in the pediatric MS memory CD4 T cells relate to altered Th1/Th17/Treg responses, signal
transduction, cell trafficking and adhesion, metabolism, and senescence. These include some of
the main categories implicated in previous gene expression studies of T cells in adult-onset MS
patients as well as novel ones implicated here for the first time (Lindberg et al. 2008). While
differentially expressed in children with MOGAD appeared particularly related to Th1 anti-viral
and Th2 responses. Some of the strengths of this dataset include well characterized patients with
high quality samples and robust application of an innovative technique. At the same time, the
number of samples per group is small and includes multiple comparisons, so caution should be
taken in interpreting any given result and a larger independent cohort would need to be studied to
validate findings.
In addition to raising intriguing hypotheses about distinct disease mechanisms involved in
pediatric MS and MOGAD, further work following up on the differential gene expression patterns
implicated here at the individual, as well as at the group level may prove useful in the differential
diagnosis of these children early in their presentation, may help account for the heterogeneity of
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MS manifestations, and potentially help considerations of optimal treatment selection among the
approved disease modifying therapies for individual patients. Although yet to be explored in its
totality, this foundational dataset indicates that discovering altered genes in pediatric-onset MS
patients could serve as a steppingstone to identify distinct patters of gene expression and
potentially relevant gene products that could be applicable for more targeted treatment
approaches.
While any given finding bears validation, the following considers some of the potentially
interesting observations that emerge from this analysis. I consider first the CD4+CCR2+CCR5+ T
cells of pediatric MS patients as a focus follow-up to prior work. I, then, more broadly consider the
memory CD4 T cell population in children with MS, and finally take advantage of the different
groups included in this study to explore for the first time the relatively recently recognized
syndrome of MOGAD. For each of these, I describe key molecular features and prior implication
in the field, and for many also potential for future work including therapeutic targeting.
1. Differentially expressed genes of CD4+CCR2+CCR5+ T cells of pediatric MS
The CCR2+CCR5+ CD4 T cell subset that we previously implicated as abnormally increased in
frequency in children with MS, is defined based on ‘CNS-homing’ receptors, and we expected it
may express higher levels of other CNS trafficking molecules (eg, CCR6 and CXCR3) and cell
adhesion molecules [e.g., VLA-4 (CD49d/CD29), which are all identified in cluster #1 (Figure 4.3.
A, B, Figure 4.4. B). Since this subset in children with MS has been shown to be resistant to
Treg suppression, we also considered these cells may express decreased levels of transcripts
associated with molecules that receive signals from regulatory cells and/or potentially increased
levels of molecules that inhibit Treg capacity to suppress. We found that differentially expressed
genes in this cell subset in pediatric children with MS are associated primarily with (i) chemotaxis
and (ii) cell survival, but also have implications for Th1/Th17 and Treg differentiation.
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Several genes involved in chemotaxis and trafficking were differentially expressed in the
CD4+CCR2+CCR5+ T cells of pediatric MS patients, suggesting these cells may play roles in
recruiting other cells to inflammatory sites. S100A11 (S100 calcium binding protein A11) codes
for a Ca+2 ion sensor, which mediates signal transduction and can act as a chemoattractant agent
in inflammatory disease. S100A11 is one of the genes found to be upregulated in the whole blood
of untreated adult MS patients and down-regulated in interferon-treated patients after 1-2 years of
follow up (Nickles et al. 2013). When the cytokines TNFα and IL-1β and the chemokine CXCL8
bind their respective cell surface receptors, S100A11 expression is induced which, once secreted
extracellularly, binds to the RAGE cell surface receptor and induces expression of
proinflammatory genes through the p38-MAPK signaling (Zhang et al. 2021). Furthermore,
S100A11 binding to RAGE induces production of chemokine CCL2 (also known as monocyte
chemoattractant protein-1), which is a ligand that binds to the chemokine receptor CCR2
(Safronova et al. 2019). Upregulation of the S100A11 gene by CD4+CCR2+CCR5+ T cell subset
in children with MS may suggest an enhanced autocrine and/or paracrine role of CCL2, which
once bound to CCR2, leads to chemotaxis of this subset, as well as recruits other immune cells
able to respond to CCL2 (ie, myeloid and other lymphoid cells). CCL2 regulates cellular adhesion,
autophagy and survival of lymphoid cells and could act as a therapeutic target in MS through the
regulation of the S100A11 gene.
PAFAH1B1 (Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit) is highly specific
for platelet-activating factor (PAF) and acts as a chemoattractant in mediating inflammation. This
was also one of the differentially expressed genes in PBMC samples of untreated MS patients as
compared to controls in a prior study (Bomprezzi et al. 2003). PAF decreases production of antiinflammatory cytokines (IL-10) from T cells and induces Th17 differentiation (Drolet et al. 2011).
The upregulation of this gene in the CD4+CCR2+CCR5+ T cells may contribute to making this
subset more resistant to Treg suppression and preferentially upregulate genes that lead to Th17
differentiation instead. PAF is also recognized as a HIV-induced neurotoxin secreted in the
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infected brain allowing for the use of PAF antagonists to regulate expression of chemokine
receptors such as CCR5, the chemokine receptor implicated in HIV-1 pathogenesis (Eggert et al.
2009; Kelesidis et al. 2015). Interestingly, when Sato et al. first described the expression of CCR2
and CCR5 on CD4 T cells, their surface expression correlated with secretion of IL-17 and IFNy,
respectively [i.e., CCR2+CCR5- are IL-17 producers (Th17-like cells) and CCR2-CCR5+ are IFNγ
producers (Th1-like cells)] (Sato, Aranami, and Yamamura 2007). We have already established
that our disease implicated subset expresses simultaneously both chemokine receptors and
secretes both IFNy and IL-17, upon short-term stimulation. Further work is needed (including
functional assays such as established Treg suppression assays) to determine whether PAF and
its antagonists mediate resistance to Treg suppression in this subset, as well as their potential
effects on the expression of CCR5 (which could be associated with a skew toward Th1 and/or
Th17 responses).
CCL20 (C-C motif ligand 20) chemokine, which is a small polypeptide that attracts various types
of leukocytes to sites of inflammation, has been found to be increased in the serum of untreated
MS patients as compared to controls, thus is considered to play a role in MS pathogenesis
(Jafarzadeh et al. 2014). CCL20 acts as a chemoattractant for CCR6-expressing cells, including
Th17 cells. Th17 cells express both CCR6 and its ligand CCL20, suggesting that Th17 cells might
mediate their own recruitment to inflamed tissues in an autocrine manner and induce T cell
recruitment in the CNS (Maddur et al. 2012).

From our recent CITE-seq dataset,

CD4+CCR2+CCR5+ T cell subset expresses moderate levels of the CCR6 chemokine receptor,
suggesting that just as in the case of CCL2, CCL20 can be secreted in an autocrine manner, bind
to its cell surface receptor, and induce its recruitment to the CNS. Indeed, Zhang et al suggested
that CD4+CCR2+CCR5+ T cells express multiple chemokines (including CCR6, CXCR3 and
CCR4) which make them potentially the best migrators toward proinflammatory chemokines
(Zhang et al. 2010; Huang et al. 2020) A discovery study assessing plasma CCL20 in healthy
controls, patients with MS and other neurological diseases, reported that this chemokine is
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associated with MS severity score. This association was not validated in the replication cohort, in
part due to the higher proportion of early disease cases. Although disease severity in pediatriconset MS may be heterogenous, directly measuring the levels of this chemokine may serve as a
blood biomarker and help in monitoring pediatric MS patients in routine clinical care settings as a
proxy to pathogenic processes of inflammation, as well as potentially distinguish MS from other
CNS demyelinating disorders.
Among the autophagy and cell survival genes upregulated in this cell subset of pediatric MS
patients is SQSTM1 (Sequestosome 1), which is a multifunctional gene encoding for a scaffolding
protein that acts as a soluble autophagy receptor by binding to ubiquitinated cargo and lead to its
degradation. In the blood of MS samples, some autophagy related genes (ATGs) involved in
several steps of the autophagy process are differentially expressed, with some being upregulated
while others downregulated (Misrielal et al. 2020). Autophagy response in relapsing-remitting MS
patients is significantly increased and this higher autophagy rate may play a role in MS
pathogenesis (Hassanpour et al. 2020). Since pediatric MS patients generally have a relapsingremitting course, we would expect their autophagy response to be increased. Monitoring the
levels of autophagy and related processes in early onset MS may help track disease activity.
2. Differentially expressed genes among overall memory CD4 T cells of pediatric MS
Prior studies assessing of T cells in patients with MS suggest that abnormalities are unlikely to be
limited to the CCR2+CCR5+ memory subset. We postulated that children with MS may harbor
broader abnormalities in their memory T cells which, in particular, may exhibit increased levels of
transcripts for STAT1/Tbet and STAT3/RORγt that lead to the differentiation of Th1 and Th17
cells, respectively (Hohlfeld et al. 2016a). Although these specific markers were not implicated
among the top 20 differentially expressed genes in the circulating T cells of pediatric MS patients,
another member of the signal transducer and activator of transcription (STAT) family of
transcription factors STAT4 emerged. This gene encodes for a transcription activator, which is
essential in mediating responses of several cytokines, including IL-12 and IL-23 in lymphocytes
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(which regulate Th1 and Th17 cells, respectively) and plays a role in signaling via the type-1
interferon receptor (Martinez et al. 2008). Polymorphisms in this gene are implicated in the EAE
animal model and adult MS patients, as well as other autoimmune diseases (Rodriguez et al.
2006; Nageeb et al. 2018) Another gene whose expression we found upregulated in memory T
cells of children with MS encodes for PRMT1 (protein arginine methyltransferase 1) which plays
an essential role in Th17 differentiation by controlling the recruitment of transcription factors
STAT3 (associated with Th17) and STAT5 (associated with Tregs) (Bedford and Clarke 2009;
Sen et al. 2018). Modification of PRMT1 associates with RORγt and allows for stabilization of
stimulatory STAT3 and subsequently releases the inhibitory STAT5 from the IL-17 locus. This
leads to activation of IL-17 gene, which in turn promotes Th17 differentiation and reciprocally
inhibits expansion of Foxp3+ regulatory T cells (mediated by IL-2-induced STAT5) in vitro, as well
as in vivo during induction of EAE (Sen et al. 2018). Pharmacological inhibition of PRMT1
decreases generation of Th17 cells in EAE mice, suggesting that this gene could be a novel
target to diminish pathogenic Th17 cell responses and shifting the balance toward regulatory T
cells in MS. We have previously reported that a disruption in the balance between T effector and
regulatory limbs of the immune system is a distinguishing feature between children with MS and
controls (Mexhitaj et al. 2019). Upregulation of PRMT1 in children with MS could theoretically
contribute as one of the mechanisms leading to preferential Th17 differentiation, as opposed to
Tregs, contributing to early MS development.
Another differentially expressed gene in memory T cells of pediatric-onset MS is CCR6 (C-C
chemokine receptor type 6), which encodes for the chemokine receptor CD196, primarily
upregulated in Th17 cells. Upregulation of this chemokine receptor allows for migration of
immune cells across the blood blain barrier where they have been found to be increased in the
CSF of MS patients (Cao et al. 2015; Restorick et al. 2017). Also upregulated in pediatric MS
memory T cells is JAM3 (junctional adhesion molecule 3) that plays a central role in leukocyte
extravasation by facilitating transmigration through the endothelium.
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It is found both in tight

junctions of brain endothelial cells, as well as on T cells where its expression influences their
transmigration (Liang et al. 2002; Cook-Mills and Deem 2005). JAMs are also part of the VCAM1/CD106 signaling pathway, which promotes the production of matrix metalloproteinases (MMPs),
in turn degrading junctional proteins of the blood brain barrier (BBB).
We indeed considered that T cells of pediatric MS patients may express increased levels of
transcripts associated with matrix degrading proteins such as MMPs which, once secreted, can
contribute to the disruption of the blood brain barrier (BBB) and facilitate the transmigration of
pro-inflammatory cells into the CNS (Sato et al. 2012; Mirshafiey et al. 2014; Trentini et al. 2016).
While no genes encoding for specific MMPs emerged as top differentially expressed genes in
pediatric MS memory CD4 T cells, we observed an upregulated gene LINCO1128 (long
intergenic non-protein coding RNA 1128) which encodes for a long non-coding RNA (lncRNA).
This lncRNA physically binds to microRNAs (miRNAs) to reduce their inhibition and subsequently
allow for MMP expression (Yao and Chen 2020). lncRNAs have been shown to be upregulated in
GWAS studies of patients with MS and may play a role in several aspects in the disease (Han et
al. 2019). MMP activity depends on the balance between MMPs and their inhibitors. Upregulation
of the lncRNA in T cells of pediatric MS patients may have the ability to enhance MMP expression
helping them overcome inhibition and consequently degrade and invade the BBB. Sato et al
reported that the CD4+CCR2+CCR5+ T cell subset was increased in frequency in the CSF of adult
MS patients during relapse (Sato et al. 2012). Once stimulated in vitro, this subset produced
MMP9 and showed higher invasive potential across an in vitro BBB model compared with other T
cells. We identified the CCR2+CCR5+ T cell subset among the memory CD4+ T cell population (as
cluster #1) (Figure 4.3. A, B). This subset showed upregulated expression of several other
chemokine receptors (CCR4, CCR6 and CXCR3), as well as CD49d/CD29, constituting the VLA4 (very-late antigen 4) adhesion molecule, a receptor for the adhesion protein VCAM-1 in
endothelial cells of BBB. MMPs secreted by T cells have also been shown to cleave myelin basic
protein (MBP), which is considered one of the autoantigens in MS (Shiryaev et al. 2009).
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In that regard, one of the differentially expressed genes within the memory CD4 T cell population
of pediatric MS patients encodes for MBP. MBP has various isoforms generated by alternative
splicing (Denise et al. 2014), including isoform 1 (golli-MBP, a non-classic group of MBP isoforms
expressed in the developing neural system and in immune cells) and isoform 5 (classic MBP, the
major component of the CNS myelin sheath) (Campagnoni et al. 1993). Golli-MBP, which is found
in peripheral immune cells, is structurally related to classical MBP and it has been considered as
a potential trigger of MBP reactivity in MS (Pitchekian-Halabi et al. 1996; Xu et al. 2016).
However, some studies suggest that peripheral golli-MBP, which is predominantly found in the T
cell lineage, regulates T cell activation through association with the plasma membrane after TCR
stimulation to modulate Ca+2 ion influx (Feng et al. 2006; Feng 2007). Golli-deficiency leads to
increased levels of intracellular Ca+2 ions upon TCR stimulation with antigen, which causes T cell
activation (Xu et al. 2016). The upregulation of golli-MBP in the periphery may relate to a role for
this MBP isoform as an autoantigen, but also as a signaling molecule that regulates the
propensity of aberrant activation described in peripheral autoreactive T cells of patients withh
MS. Ca+2 ion regulation itself may be relevant in MS pathogenesis, as calcium homeostasis in MS
patients is reportedly disturbed. Memory-regulatory T cells in MS patients have been shown to
be less efficient in blocking calcium signals in autoreactive T cells, as compared to healthy
subjects (Schmidt, Oberle, and Krammer 2012; Schwarz et al. 2013). The disruption of the
balance between these memory-regulatory T cells (which have lost their downregulatory activity)
and the naïve regulatory T cells could potentially be one of the reasons why Tregs in children with
MS may become defective, as we and others have shown (Schwarz et al. 2013; Mexhitaj et al.
2019) .
Children with MS have been shown to exhibit premature immunosenescence (early aging) as a
possible result of thymic involution, leading to a decrease in naïve T cell frequencies,
differentiation, maturation and function (Dema et al. 2021). These children show decreased ratio
of naïve vs. memory T cells to levels that are typically seen in healthy controls who are ~30 years
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older, as well as reduced suppresive capacity of their Treg function (Balint et al. 2013). Presence
of premature senescence and reduced suppressive capacity of Tregs, together with an
overpropensity for extrathymic T cell proliferation may lead to expansion of pathogenic selfreactive T cells, that could potentially contribute to MS pathogenesis based on abnormal
peripheral balance between effector and regulatory T cells (Bar-Or and Muraro 2013). Persistant
T cell proliferation leads to impared telomerase activity causing progressive telomere shortening
with each division. When DNA reaches a critial length, telomeres initiate a DNA damage
response and promote cellular senescence. Among the differentially expressed genes in
memory-like CD4 T cells of children with MS was the regulator of the NOLC1 (RNA polymerase
Nucleolar and Coiled-Body Phosphoprotein 1). Its overexpression has been shown to interact
with and promote the accumulation of telomere TRF2 (repeat-binding factor 2) in the nucleolus,
which otherwise shelters and protects the telomeres, dissociating it from telomeres and thus
inducing DNA damage (Yuan, Li, and Tong 2017).
Aside from telomere length reduction, oxidative stress has also been suggested as premature
ageing marker in MS (Guan et al. 2015; Habib et al. 2020). Oxidative stress originating from
genotoxic stress, reactive oxygen species or disruption in cellular metabolism have been
implicated in the pathogenesis of MS. Several of the differentially expressed genes associated
with cellular stressors are upregulated in the memory-like CD4 T cells of children with MS. One of
them is the DYRK3 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 3) gene
encoding for a protein kinase which, in its inactive, form promotes assembly of stress granules
(SG; which are dense aggregates of proteins and non-translating RNAs) during cellular stress. In
the recovery phase, this protein kinase becomes activated by autophosphorylation and it
dissassembles the stress granules, allowing for control of metabolic processes (ie, mRNA
biogenesis, protein synthesis further allowing for translation restoration and cell growth) (Mediani
et al. 2021). SG have been found to be present in neuronal cells of patients with MS and other
neurodegenerative diseases (Salapa et al. 2018; Salapa et al. 2020). The role of SG in peripheral
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lymphocytes suggests that they may assemble upon continous TCR stimulation where they have
an active role in controlling particular translational programs (ie, regulate cytokine production,
metabolism, immune checkpoints, cellular proliferation, differentiation and effector functions)
(Curdy et al. 2020). Active post-translational mechanisms control mRNA translation during T cell
activaton by regulating the mRNA through stress sensor kinases, which are upregulated in
stimulated T cells (Curdy et al. 2020). The upregulation of this gene in the memory CD4 T cell
population of children with MS, suggests that there may be cyclical inactivation and activation of
this kinase throughout disease with stress granules assembled and dissassembled, respectively,
providing control of protein synthesis. Restoring translation in T cells depends on the nature of
the stress, the cell type (ie, memory, effector or terminally differentiated) and the cell’s metabolic
state.
An important change that arises with T cell activation and differentiation is metabolic reprogramming (Chapman, Boothby, and Chi 2020). Some of these metabolic processes include
sphingolipid biosynthesis and reduction of adenosine, both processes which increase the state of
inflammation and are implicated in MS pathogenesis. Sphingolipids are present in the plasma
membrane and are involved in structural organization of lipid rafts, signal transduction, activation,
proliferation and differentiation of T cells (Davies, Fassbender, and Walter 2013). Subtypes of
sphingosine-1-phosphate (S1P) receptors are upregulated in MS patients and EAE animal
models (Foster et al. 2009; Van Doorn et al. 2010). The non-selective S1P receptor modulator
fingolimod (FTY720) was the first in its class approved for treatment of MS, and others have since
been approved. The mode of action of this family of disease modifying treatments is thought to in
part involved in targeting S1P receptors in T cells and prevent egress of the T cells from
secondary lymphoid organs, presumably resulting in a reduction of autoreactive T cells in
circulation (Ontaneda and Cohen 2011). The KDSR (3-Ketodihydrosphingosine Reductase)
gene is upregulated in memory T cells of children with MS. This gene has been shown to play a
role in redox reactions and sphingolipid biosynthesis, as well as upregulation of activated Th17
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cells (Tuomela et al. 2012). S1P has been shown to enhance the development of Th17 cells from
antigen-challenged transgenic S1P-overexpressing CD4 T cells in wild-type mice, suggesting that
the role of the modulator FTY720 is able to suppress Th17-mediated inflammation (Liao, Huang,
and Goetzl 2007). Although several other disease modifying treatments are used for MS, thus far
fingolimod is the only one approved for use in pediatric MS, associated with a lower rate of
relapse and less accumulation of lesions on MRI (Chitnis et al. 2018; Fadda, Armangue, et al.
2021).
Another metabolic process that is implicated in MS pathogenesis is reduction of adenosine
(Safarzadeh et al. 2016; Pasquini et al. 2021). Stressed cells release ATP and ADP during
chronic inflammation, which is then hydrolysed to AMP through the co-expression of CD73 and
CD39 found in the plasma membrane of Treg cells. Tregs generate immunosuppresive
adenosine, which signals via the A2A receptor of T effector cells to prevent their proliferation and
effector functions (Schmidt, Oberle, and Krammer 2012). This suggests that in a disease state
such as MS, dysfunctional Tregs may generate lower levels of adenosine to suppress T effector
cell activation and proliferation, these effectors express lower levels of adenosine receptor, or any
other proteins that may prevent adenosine from binding to its receptors. Interestingly, a
differentially expressed gene among memory CD4+ T cells of children with MS is AMPD2 (AMP
deaminase 2), which has been shown to counteract the anti-inflammatory extracellular adenosine
(which otherwise serves as an important immunomodulator during inflammation) by causing AMP
deamination to IMP thus reducing adenosine (Ehlers et al. 2021).

T effector cell surface

expression of AMPD2 and Treg co-expression of CD73 and CD39 and their role in ATP
adenosine balance were recently evaluated in PBMC of patients with rhematoid arthritis, who
exhibited higher levels of AMPD2 expression as compared to healthy controls (Ehlers et al.
2021). This could provide a possible way of measuring cell surface AMPD2 expression in CD4 T
cells of children with MS, which we would expect to be higher as compared to controls. Identifying
cell surface expression of AMPD2 in the CD4 T cells of children with MS and inhibiting its
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upregulation, would be expected to skew the production of adenosine via the immunomodulatory
CD39-CD73 system of Tregs and may provide a possible protection mechanism from abnormal
inflammation in early onset MS.
The role of adenosine could have other implication for MS. Intrestingly, we found upregulation of
some tumor suppresor genes within the memory CD4 T cells of pediatric MS, pointing to proapoptotic activity. Two of these tumor suppressor genes have been shown to be upregulated in
regulatory T cells, suggesting that this pro-apoptotic feature could lead to a possible decrease in
number of these cells in MS, shifting the balance toward effector T cells, contributing to chronic
inflammation. However, it was recently speculated by Maj et al that regulatory T cells are more
prone to apoptotic cell death (in the context of cancer) and that this pro-apoptotic activity gives
them a greater immunosuppresive capacity (Maj et al. 2017). That is because “stressed out and
dying” Tregs, just like other stressed T cells, release ATP which is converted through the coexpression of CD39-CD73 into the immuno-suppressive adenosine. Adenosine is able to bind to
A2A receptors on effector T cells, leading to production of cAMP which activates protein kinase
and inhibits TCR signaling and further activation (Beier 2018). Thus, increase of these tumor
suppresor genes in the memory-like CD4 T cells of children with MS, may suggest an attempt of
Tregs to become more immunosuppressive in a proinflammatory environment.
Finally, our memory CD4 T cell dataset points to an upregulation of vesicle-mediated transport,
endosomal recycling and autophagy-related (ATG) genes in pediatric MS, corroborating GWAS
studies which point to a connection of several ATG genes with inflammation and autoimmune
disorders, including MS (Mahil et al. 2016; Muller et al. 2017). Autophagy plays a critical role in
multiple immune processes, such as degradation of scenesent or defective proteins and
organelles, autoantigen presentation, cytokine production and survival of lymphocytes (Yin et al.
2018; Misrielal et al. 2020). Autophagy can be induced by inflammatory stimuli and in the attempt
to maintain cellular homeostasis it degrades damaged cellular products, recycles some of the
metabolites composing these cellular components, prevents production of reactive oxygen
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species (ROS), eliminates damaged mitochondria and thus promotes cell survival (Hassanpour et
al. 2020). In MS, autophagy appears enhanced in peripheral T cells, B cells and dendritic cells
possibly by preventing formation of ROS and elimination of damaged mitochondria. Continous
CNS antigen processing and presentation by dendritic cells to autoreactive CD4 T cells may
result in prolonged survival of activated T cells, their proliferation and secretion of proinflammatory cytokines (Misrielal et al. 2020). It is interesting to speculate whether, someday,
pharmacological interventions that reduce or inhibit autophagy-related processes in autoreactive
T cells may prove useful for limiting the initial peripheral activation of the immune responses in
conditions like MS.
MOG-associated disease (MOGAD) is now considered another CNS demyelinating condition
characterized by the presence of MOG antibodies in the serum of affected patients, which causes
preferential inflammation in the optic nerve, but also elsewhere in the CNS (Fadda, Armangue, et
al. 2021). While our primary goal was to explore abnormal T cell expression profiles in children
with MS, with children diagnosed with MOGAD serving as other CNS inflammatory disease
controls, we recognize the opportunity to get a preliminary look into what may distinguish T cells
of children with MOGAD from other forms of CNS inflammation, including MS. MOG is a protein
expressed specifically on the surface of the myelin sheath and oligodendrocytes in the CNS,
which means that it can readily become a target of both humoral and cellular immune responses
in inflammatory demyelinating diseases (Peschl et al. 2017). MOG directed antibodies are
present in the blood of patients who may have a single (monophasic) or multiple (relapsing) CNS
demyelinating event(s) and defines them as having MOGAD. Patients who are persistently
seropositive for MOG are at risk of recurring events. Our findings suggest that, as compared to
pediatric-onset MS, there is a distinct pattern of differentially expressed genes in the CD4 T cells
of pediatric MOGAD children, suggesting enhanced Th1 anti-viral and Th2 responses.
Post-infectious or post vaccination autoimmune processes have been proposed to contribute to
pathophysiologic mechanisms in MOGAD (Kakalacheva et al. 2016; Lee et al. 2021; Woodhall et
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al. 2020). Approximately 50% of MOGAD patients are reported to have had a recent exposure
after vaccination, due to influenza or infectious mononucleosis (Jarius, Ruprecht, Kleiter, Borisow,
Asgari, Pitarokoili, Pache, Stich, Beume, Hummert, Trebst, et al. 2016; Lee et al. 2021). Infectionassociated relapses in MOGAD have also been reported (Cobo-Calvo et al. 2018). Differentially
expressed genes in CD4 T cells of pediatric MOGAD patients include ones encoding proteins
associated with anti-viral cellular responses. One of the upregulated genes in children with
MOGAD is TRIM22 (Tripartite Motif Containing 22), which encodes for a broad anti-viral host
factor to influenza A, HBV, HVC and HIV (Hattlmann, Kelly, and Barr 2012). Viral DNA/RNA
triggers type I interferons, which after binding to the interferon receptor, activate STAT1/2 and
induce expression of TRIM22 restricting viral infections (ie, by inhibiting viral particle production,
targeting nucleoprotein for degradation and suppressing activity of virus core promoter, etc) (Lian
and Sun 2017). Another upregulated gene, GBP5 (Guanylate Binding Protein 5), which encodes
for an interferon-induced GTPase, can assemble into larger macromolecules that execute strong
host defense mechanisms, shown to inhibit influenza A virus replication through the activation of
interferon signaling and proinflammatory factors (Feng et al. 2017). Moreover, the geneexpression profile of peripheral blood from patients with chronic active EBV included upregulation
of cytosolic GBP5 associated with the survival and proliferation of EBV-infected T cells (Tripal et
al. 2007; Ito et al. 2008). It is possible that T cells associated with viral antigens can provide the
necessary stimulus for bystander activation and co-stimulation of autoreactive T and B cells,
respectively. The differential expression of genes that confer resistance to viral infection and
survival of T cells in children with MOGAD, raises the possibility that a host-response to an
infection may reach a threshold that is sufficient to activate MOG-specific B cells and produce
antibodies against MOG, leading to an increase of MOG antibody titers in the serum and
eventually disease relapse.
It has recently been reported that after stimulation with human recombinant MOG, PBMC of
children with MOGAD exhibit enhanced Th2 and Th17 responses, as well as decreased
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regulatory T cell responses (in relapsing MOGAD), suggesting a probable loss of tolerance
toward MOG autoantigen, which may contribute to relapses (Horellou et al. 2021). Th2 responses
have mostly been considered as an immunological response to allergic reactions due to
environmental triggers. However, it is being recognized that Th2 responses and some of their
mediators play a role in autoimmune CNS demyelinating conditions (Costanza 2019). Th2 cells
contribute to the development of antibody responses by secreting several cytokines (IL-4, IL-5
and IL-13, among others) that influence both plasma cell differentiation and eosinophil activation.
One of the differentially expressed genes within the memory CD4 T cells in pediatric MOGAD is
MFSD10 (Major Facilitator Superfamily Domain Containing 10), which encodes for a plasma
membrane anion efflux pump (Ushijima et al. 2008; Perland et al. 2017). MFSD10 is now
recognized as an eosinophil-specific cell surface maker, which serves as a critical target for
down-regulation of eosinophil accumulation in allergic diseases, selectively suppressing antigenspecific Th2 responses (Motoi et al. 2012; Nishimura et al. 2014). Eosinophils can act as APCs
and are involved in the initiation and maintenance of Th2 cell responses (Spencer and Weller
2010; Costanza 2019). Presence of eosinophils in lesions and the cerebrospinal fluid is more
prominent in neuromyelitis optica spectrum disease (NMOSD), which is another CNS
demyelinating disorder, but rarely in MOGAD patients (Costanza 2019; Ambrosius et al. 2020).
Prior to our dataset, the MFSD10 gene has not been shown to be upregulated in T lymphocytes.
Its apparent upregulation in the memory CD4 T cells of pediatric MOGAD would be a novel
observation which, if replicated, may suggest a possible link between enhanced peripheral (rather
than intrathecal) Th2 responses and antibody production upon recognition of MOG autoantigen
which could be presented to T cells not only by DCs and B cells, but also by eosinophils.
Additional genes related to Th2 responses were upregulated in the CD4 T cells of children with
MOGAD. COTL1 (Coactosin Like F-Actin Binding Protein 1), which encodes for an actin-binding
protein and regulates actin cytoskeleton during cell trafficking, also interacts with 5-lipoxigenase,
the first committed enzyme in leukotriene biosynthesis in leukocytes (Radmark and Samuelsson
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2009). Leukotrienes are immune-regulating lipids, whose biosynthesis helps in the oxidative
metabolism of arachidonic acid. These lipids have a pathogenic role in inflammatory Th2mediated diseases, such as asthma, and

may also contribute to inflammation in

neurodegenerative diseases (Haeggstrom 2018). Some MOG-IgG positive patients have other
coexisting autoimmunity, including RA (Jarius, Ruprecht, Kleiter, Borisow, Asgari, Pitarokoili,
Pache, Stich, Beume, Hummert, Ringelstein, et al. 2016). Indeed, a polymorphism of the COTL1
gene has been associated with autoimmune disease and has been highly expressed in plasma of
RA patients as compared to healthy controls (Jin et al. 2009; Liu and Chen 2021). Another gene
IFITM1 (Interferon-Induced Transmembrane 1), which is involved in interferon gamma signaling
and displays anti-viral activity against various infections, has been implicated in skewing the
balance toward Th2 differentiation (Yanez, Ross, and Crompton 2020). IFTM proteins are
involved in maintaining the balance between Th1 and Th2 differentiation, but their deletion shifts
the balance towards Th1 and reduces the severity of Th2 inflammation in a mouse asthma model
(Yanez et al. 2019). Upregulation of this gene within the CD4 T cells of children with MOGAD,
may result in IFITM1 playing a role, on one hand, in cellular resistance to infections but also a
mediator of CD4 T cell differentiation, shifting balance toward Th2 responses.
In summary, the specific aims of this study were to follow up with a more detailed geneexpression level analysis of previously implicated CCR2+CCR5+ T cell subset in children with MS
and controls, and then explore gene expression profiles that may be differentially regulated
between the CD4 T cell populations in well-characterized and well-ascertained children with MS,
MOGAD, non-MS/non-MOGAD and healthy controls. We identified several novel aspects of the
CCR2+CCR5+ T cell profiles in children with MS. The clearest distinctions between cohorts were
observed as clusters of differentially expressed genes within memory CD4 T cells of pediatriconset MS and MOGAD. Our findings need to be reproduced in larger groups of subjects and
further work with MOGAD patients may also provide interesting insights into what distinguishes
relapsing remitting from monophasic CNS inflammation. This study has several limitations in
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addition to the relatively small numbers. Although multiplexing was useful in reducing
experimental batch effects, we cannot exclude potential variations across batched experiments.
Similar to other transcriptomics studies in adult-onset MS and controls, we appear to see subtle
but distinguishable gene expression differences between healthy and MS subject in peripheral
blood cells. Gene expression differences between pediatric MS patients and controls were
modest, possibly due to disease heterogeneity and the only practical choice of research
specimens (PBMC), as opposed to more disease-relevant tissues which are not as accessible.
Further studies including cerebrospinal fluid (CSF) analyses, which our lab is pursuing, are
needed to determine the signatures in other immune cell types and if gene expression in the
periphery truly represent processes in the CNS. Indeed, we anticipate that investigating single
cell proteogenomic profiles of immune cells in the CSF and blood of pediatric MS patients would
add tremendous value to elucidating the complex cellular immunology of MS. Access to CSF cells
and the established capacity to perform single cell proteogenomic will be the next step to provide
deeper insights into the pathogenesis of both MS and MOGAD, as well as potentially identify
biomarkers that may distinguish between these two CNS demyelinating diseases. Though
challenging, serial follow-up and larger patient cohorts will be helpful as well as integration of
immunological measures with detailed clinical and neuroimaging outcomes.
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Tables
Table 4.1: Pediatric Participant Demographics
ADS presenting

Age at blood

Follow up available

Sex

phenotype

sampling (years)

after ADS (years)

MS-01

F

Monofocal

15.4

4.0

MS-02

M

Monofocal

16.6

4.0

MS-03

F

Monofocal

12.0

9.0

MS-04

M

Monofocal

12.9

9.0

MS-05

F

Monofocal

14.5

9.0

MS-06

F

Monofocal

15.8

9.0

14.5 (+/-1.8)

7.3 (+/-2.5)

Diagnosis

4F:2M
monoMOGAD-01

F

Monofocal

12.8

4.0

monoMOGAD-02

M

Polyfocal

17.9

8.0

monoMOGAD-03

F

ADEM

7.7

9.0

relapseMOGAD-01

F

ADEM

6.9

9.0

relapseMOGAD-02

M

Monofocal

15.6

7.0

relapseMOGAD-03

M

Monofocal

7.9

10.0

11.5 (+/-4.7)

7.8 (+/-2.1)

3F:3M
monoADS-01

M

Monofocal

17.3

8.0

monoADS-02

M

Monofocal

16.8

7.0

monoADS-03

F

Monofocal

14.3

9.0

monoADS-04

M

ADEM

12.3

9.0

monoADS-05

F

Monofocal

11.4

9.0

monoADS-06

F

Monofocal

9.9

8.0

13.7 (+/-3)

8.3 (+/-0.8)

3M:3F
HC-01

F

N/Ap

15.0

N/Ap

HC-02

F

N/Ap

13.5

N/Ap

HC-03

M

N/Ap

13.9

N/Ap

HC-04

M

N/Ap

17.0

N/Ap

HC-05

F

N/Ap

15.5

N/Ap

HC-06

F

N/Ap

16.0

N/Ap

130

4F:2M
Abbreviations:

ADEM=acute

15 (+/-1.3)
disseminated

encephalomyelitis;

ADS=incident

acquired

demyelinating syndrome; F=female; HC=healthy control; M=male; MonoADS=monophasic
(mono)ADS

(MOG-monoADS);

MS=multiple

sclerosis;

MOGAD=myelin-oligodendrocyte

glycoprotein antibody-associated disease (monophasic or relapsing MOGAD or MOG +); N/Ap=not
applicable.
Throughout the analysis and figures, the subjects are identified as HC, MOG-, MOG+, and MS,
respectively. None of the children had ever received immune modulatory treatments or steroids
within 30 days of blood procurement.
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Table 4.2: Hashtag and Oligo-Conjugated Antibody List
Volume
of Ab
Optimal

Hashtags

Volume of

(ul)/

Concentration

Ab

200,000

Catalog

Stock

for Staining

(ul)/106

cells/50

Number

Concentration

(ug/ml)

cells/50ul

ul

TotalSeq™-B0251 anti-human Hashtag 1

394631

0.5mg/ml

10

1

0.2

TotalSeq™-B0252 anti-human Hashtag 2

394633

0.5mg/ml

10

1

0.2

TotalSeq™-B0253 anti-human Hashtag 3

394635

0.5mg/ml

10

1

0.2

TotalSeq™-B0254 anti-human Hashtag 4

394637

0.5mg/ml

10

1

0.2

TotalSeq™-B0255 anti-human Hashtag 5

394639

0.5mg/ml

10

1

0.2

TotalSeq™-B0256 anti-human Hashtag 6

394641

0.5mg/ml

10

1

0.2

TotalSeq™-B0257 anti-human Hashtag 7

394643

0.5mg/ml

10

1

0.2

TotalSeq™-B0258 anti-human Hashtag 8

394645

0.5mg/ml

10

1

0.2

Optimal

Volume

Concentration

Oligo-conjugated antibodies

of Ab

for Staining

Volume of

(ul)/

(ug/ml) per

Ab

200,000

Catalog

Stock

Buus et al

(ul)/106

cells/50

Number

Concentration

2020

cells/50ul

ul

TotalSeq™-B0034 anti-human CD3

300477

0.5mg/ml

0.5

0.05

0.01

TotalSeq™-B0072 anti-human CD4

300565

0.5mg/ml

0.5

0.05

0.01

TotalSeq™-B0046 anti-human CD8

344757

0.5mg/ml

0.1

0.01

0.002

TotalSeq™-B0053 anti-human CD11c

371523

0.5mg/ml

0.1

0.01

0.002

TotalSeq™-B0051 anti-human CD14

367145

0.5mg/ml

2.5

0.25

0.05

TotalSeq™-B0083 anti-human CD16

302063

0.5mg/ml

2

0.2

0.04

TotalSeq™-B0050 anti-human CD19

302263

0.5mg/ml

0.5

0.05

0.01

TotalSeq™-B0100 anti-human CD20

302361

0.5mg/ml

0.5

0.05

0.01

TotalSeq™-B0180 anti-human CD24

311145

0.5mg/ml

3

0.3

0.06

TotalSeq™-B0085 anti-human CD25

302647

0.5mg/ml

3

0.3

0.06

TotalSeq™-B0154 anti-human CD27

302851

0.5mg/ml

2.5

0.25

0.05

TotalSeq™-B0386 anti-human CD28

302961

0.5mg/ml

1.25

0.125

0.025

TotalSeq™-B0369 anti-human CD29

303033

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0124 anti-human CD31

303145

0.5mg/ml

0.1

0.01

0.002

TotalSeq™-B0389 anti-human CD38

303547

0.5mg/ml

2.5

0.25

0.05

TotalSeq™-B0176 anti-human CD39

328241

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0031 anti-human CD40

334352

0.5mg/ml

2

0.2

0.04

TotalSeq™-B0063 anti-human CD45RA

304161

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0087 anti-human CD45RO

304257

0.5mg/ml

2.5

0.25

0.05

TotalSeq™-B0576 anti-human CD49d

304347

0.5mg/ml

1

0.1

0.02
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TotalSeq™-B0047

anti-human

CD56

362561

0.5mg/ml

4

0.4

0.08

anti-human

CD57

393323

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0147 anti-human CD62L

304849

0.5mg/ml

0.1

0.01

0.002

TotalSeq™-B0146 anti-human CD69

310949

0.5mg/ml

0.2

0.02

0.004

TotalSeq™-B0577 anti-human CD73

344033

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0359 anti-human CD83

305343

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0006 anti-human CD86
TotalSeq™-B0156

(NCAM)
TotalSeq™-B0168

Recombinant Antibody

305445

0.5mg/ml

1

0.1

0.02

anti-human

CD95

305653

0.5mg/ml

2

0.2

0.04

anti-human

CD103

350235

0.5mg/ml

0.1

0.01

0.002

TotalSeq™-B0064 anti-human CD123
TotalSeq™-B0390

(Fas)
TotalSeq™-B0145
(Integrin αE)
306047

0.5mg/ml

1

0.1

0.02

anti-human

CD127

351354

0.5mg/ml

2.5

0.25

0.05

anti-human

CD134

350037

0.5mg/ml

1

0.1

0.02

anti-human

CD138

356543

0.5mg/ml

3

0.3

0.06

anti-human

CD141

344127

0.5mg/ml

2.5

0.25

0.05

anti-human

CD152

369629

0.5mg/ml

1

0.1

0.02

anti-human

CD154

310851

0.5mg/ml

2

0.2

0.04

TotalSeq™-B0149 anti-human CD161

339949

0.5mg/ml

2

0.2

0.04

TotalSeq™-B0140

(IL-7Rα)
TotalSeq™-B0158
(OX40)
TotalSeq™-B0055
(Syndecan-1)
TotalSeq™-B0163
(Thrombomodulin)
TotalSeq™-B0151
(CTLA-4)
TotalSeq™-B0032
(CD40L)

anti-human

CD183

353751

0.5mg/ml

1

0.1

0.02

anti-human

CD185

356943

0.5mg/ml

1

0.1

0.02

CD192

CUSTOM

0.5mg/ml

2

0.2

0.04

CD194

359427

0.5mg/ml

1.5

0.15

0.03

CD195

CUSTOM

0.5mg/ml

2

0.2

0.04

anti-human

CD196

353445

0.5mg/ml

3

0.3

0.06

anti-human

CD197

353249

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0171 anti-human/mouse/rat

313551

0.5mg/ml

2

0.2

0.04

(CXCR3)
TotalSeq™-B0144
(CXCR5)
TotalSeq™0242

anti-human

(CCR2)
TotalSeq™-B0071

anti-human

(CCR4)
TotalSeq™-0141

anti-human

(CCR5)
TotalSeq™-B0143
(CCR6)
TotalSeq™-B0148
(CCR7)

CD278 (ICOS)

133

TotalSeq™-B0179 anti-human CX3CR1

138435

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0159 anti-human HLA-DR

307661

0.5mg/ml

0.5

0.05

0.01

TotalSeq™-B0250

361109

0.5mg/ml

1

0.1

0.02

372727

0.5mg/ml

2

0.2

0.04

TotalSeq™-B0375 anti-human IgG Fc

410729

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0384 anti-human IgD

348247

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0136 anti-human IgM

314549

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0224 anti-human TCR α/β

306747

0.5mg/ml

1

0.1

0.02

TotalSeq™-B0139 anti-human TCR γ/δ

331233

0.5mg/ml

0.5

0.05

0.01

TotalSeq™-B0581

351737

0.5mg/ml

2

0.2

0.04

anti-mouse/human

KLRG1 (MAFA)
TotalSeq™-B0089

anti-human

TIGIT

(VSTM3)

anti-human

TCR

Vα7.2
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Table 4.3: Upregulated Genes in CD4+CCR2+CCR5+T Cells of Children with MS

Upregulated genes in CD4+CCR2+CCR5+T cells
of children with MS
Gene symbol

Gene Name
S100

S100A11

Gene function

calcium

Ca+2 ion sensor and binding protein;

protein

signal transduction, chemoattractant

binding

agent

A11

in

inflammatory

disease,

induces CCL2 production

SIGNAL
TRANSDUCTION
&

PAFAH1B1

CHEMOTAXIS

Platelet-activating

Platelet-activating

factor

factor

acetylhydrolase; chemoattractant in

acetylhydrolase,

inflammation, decrease production of

isoform Ib, alpha

IL-10 and upregulation of Th17

subunit

CCL20

C-C motif ligand

Chemokine; chemotactic activity for

20

lymphocytes that attracts Th17 cells
into the CNS

Sequestosome 1

AUTOPHAGY

Scaffolding/adaptor

activity;

autophagy receptor that regulates

SQSTM1

NF-κB

activation

and

prevent

apoptosis

&
G

CELL SURVIVAL
GNL3

Protein

Nucleolar 3

GTPase;

transcription

implicated

in

progression

135

cell

activator

growth

and

Table 4.4: Differentially Upregulated Genes in Memory CD4 T Cells of Children with MS

Differentially upregulated genes in memory CD4 T cells of
children with MS
Gene symbol

Gene Name
Myelin Basic Protein

Gene function
myelin

component

autoantigen;

inducer

&

MS

of

T-cell

proliferation

MBP

Ca+2 ion influx regulator; regulator
of T cell activation
Protein Arginine

positive regulator of Th17 cell

Methyltransferase 1

proliferation

(stabilize

STAT3/RORγt);

PRMT1

decrease

of

Foxp3+ Treg cells (destabilize
STAT5/IL-2)

IMMUNE
RESPONSE

STAT4

signal transducer and

Th1

and

activator of transcription

transcription factor; promote IL-12

4

and IL-23 production, respectively

TNF Receptor

TNF receptor associated factor;

Associated Factor 3

regulates pathways leading to
production

TRAF3

interferons;

Th17

of

differentiation

cytokines
induces

and
signal

transduction of CD40

TMEM8A

ZHX2

TRAFFICKING &

CCR6

EXTRAVASATION
ACTIVITY

HEG1

Transmembrane

transmembrane protein; maintain

Protein 8A

resting state of T cells

Zinc Fingers and

stem cell regulator; involved in

Homeoboxes 2

hematopoietic cell development

C-C chemokine

chemokine

receptor type 6

migration & Th17 differentiation

Heart Development

Ca+2 ion binding activity; promote

Protein with EGF Like
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receptor;

leukocyte

ARHGAP31

JAM3

Domains 1

activation and migration

Rho GTPase Activating

GTPase activity; promotes cell

Protein 31

trafficking and migration

junctional adhesion

part of vcam-1/cd106 signaling;

molecule 3

leukocyte extravasation; bloodbrain barrier and immune cell
transmigration

LINC01128

Long Intergenic Non-

long non-coding RNAs; promote

Protein Coding RNA

matrix

1128

(MMPs)

metalloproteinases
activity

to

induce

degradation of blood brain barrier

KDSR

3-

sphingolipid metabolic process;

Ketodihydrosphingosine

oxidation-reduction process; Th17

Reductase

cell differentiation

AMP deaminase 2

metabolism/energy; reduction of
adenosine leading to increased
state of inflammation; reduced

AMPD2

Treg function to suppress T cell
activation

METABOLISM,

AP1S3

Adaptor Related Protein

vesicle

mediated

Complex 1 Subunit

promote autophagy

transport;

Sigma 3

AUTOPHAGY &
SENESCENCE
RAB11FIP1

RAB11 Family

endosomal

recycling

process;

Interacting Protein 1

membrane

trafficking

recycling

trans-Golgi network

FAM241A

Family With Sequence

golgi-apparatus

Similarity 241 Member

macrophage

A

gene

Nucleolar and Coiled-

DNA damage response; telomere

Body Phosphoprotein 1

shortening

NOLC1

senescence

137

protein;

polarization-related

and

cellular

Dual
DYRK3

RBMS1

Specificity

Tyrosine

genotoxic

Phosphorylation

assembly/disassembly of stress

Regulated Kinase 3

granules during cellular stress

RNA

tumor suppressors; promote cell

Binding

Single

Motif

Stranded

Interacting Protein 1
V-Set

TUMOR
SUPPRESORS

VSIG1*

and

Immunoglobulin

Ras

Association

Domain Family Member
2

138

cycle

arrest

stress,

and

apoptosis;

*upregulated in Treg cells

Domain Containing 1

RASSF2*

protein kinase activity; promotes

Table 4.5: Differentially Upregulated Genes in Memory CD4 T Cells of Children with
MOGAD

Differentially upregulated genes in memory CD4 T cells of
children with MOGAD

Gene symbol

Gene Name
Tripartite Motif Containing 22

Gene function
transcription

factor

and

corepressor activity; broad anti-

TRIM22

viral host factor

METABOLISM

GALNT3

& TH2

Polypeptide N-

Ca+2

Acetylgalactosaminyltransferase

transferase activity; metabolism

3

and

ion

binding

anti-viral

and

immunity;

glycosylation of MOG

RESPONSES
Guanylate Binding Protein 5

GTPase

activity;

cytokine

signaling; strong host defense
mechanisms; associated with

GBP5

survival of EBV-infected T cells
in chronic EBV infection

IFITM1

Interferon-Induced

signal

transducer

activity;

Transmembrane 1

interferon gamma signaling and
potential skewing toward Th2
immunity

ANTI-VIRAL
TH1

Major Facilitator Superfamily

transmembrane

Domain Containing 10

activity;

confer

resistance

MFSD10

RESPONSES

to

eosinophil-mediated

transporter
cellular
apoptosis;
Th2

immunity

COTL1

Coactosin Like F-Actin Binding

actin-binding activity; involved

Protein 1

in leukotriene biosynthesis and
Th2 immunity
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Figures
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Figure 4.1: CITE-seq proteogenomic approach reconstructs circulating leukocytes in
pediatric cohort.
(A) Uniform Manifold Approximation and Projection (UMAP) plot representing 12 color-coded
clusters identified in merged transcriptomes and proteomes of blood cells (~120,000 cells) of
healthy controls (n=6), monophasic (n=6), MOG-associated diseases (n=6) and multiple sclerosis
(n=6) pediatric patients. Following Louvain clustering, clusters were assigned to either CD4 T,
CD8 T, CD8 T MAIT, B, Antibody-secreting cell (ASC), NK CD56dim, NK CD56bright, CD14
Mono, CD16 Mono, pDC, DC, or Platelet identities based on expression of marker genes and
ADT expression patterns. (B) Violin plots used to confirm the identity of major immune cell types
(CD4 and CD8 T cells, monocytes, NK and B cells) based on antibody-derived tags (ADTs)
surface expression level (C) Heatmap depicting average ADT expression of selected surface
markers used to identify major immune cell populations. Expression values were normalized per
ADT with -1 reflecting the lowest expression and 3 reflecting the highest expression. (D) Dot plot
depicting selected marker genes in cell clusters. Dot size encodes percentage of cells expressing
the gene, color encodes the average per cell gene expression level. Cluster key; CD4 and CD8
T cells; B cells; NK, CD56 dim and CD56 bright natural killer cells; CD14 and CD16 Mono,
classical CD14-expressing and non-classical CD16-expressing monocytes; CD8 MAIT, CD8
mucosal associated invariant T cells; DC, dendritic cells; pDC, plasmacytoid dendritic cells; ASC,
antibody producing cells and platelets.
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Figure 4.2: Profiling of identified clusters and circulating cell composition for the four
conditions.
(A) Colored-UMAP plots of immune cell clusters identified in merged transcriptomes and
proteomes of blood cells (~60,000 single cells/condition): HC, healthy control; MOG-, monophasic
acquired demyelinating syndrome myelin oligodendrocyte glycoprotein antibody negative; MOG+,
myelin oligodendrocyte glycoprotein antibody positive; MS, multiple sclerosis (n=6/condition). (B)
Differential abundance plots of the frequency of 12 major immune cell populations across
different groups.

143

144

Figure 4.3: Naïve-like and memory-like sub-clusters in CD4 T cells in pediatric cohorts.
(A) UMAP of total CD4 T cells identifying 10 sub-clusters (numbered 0-9) in HC, healthy control;
MOG-, monophasic acquired demyelinating syndrome myelin oligodendrocyte glycoprotein
antibody negative; MOG+, myelin oligodendrocyte glycoprotein antibody positive; MS, multiple
sclerosis (n=6/condition). (B) Heatmap of surface markers on the 10 identified subpopulations of
CD4 T cells as measured by ADT expression. Expression values were normalized per ADT with 1 reflecting the lowest expression and 1.5 reflecting the highest expression. (C) UMAP plots of
ADT expression of naïve-like and memory-like markers for CD4 T cells based on CD45RA,
CD45RO, CCR7b and CD62L expression. (D) Differential abundance plots of the frequency of
CD4 naïve-like and memory-like T cell populations based on ADT expression across the 4
different conditions. Differential abundance testing was performed utilizing a t-test for
compositional abundances within the CD4 T cell compartment.
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Figure 4.4: Differentially expressed genes in CD4+CCR2+CCR5+ T cells in pediatric-onset
MS and other CNS inflammatory disease controls. * Designates relapsing MOGAD.
(A) Group summary of frequency of CCR2+CCR5+ population within CD4 T cells as determined
by flow cytometry; HC, healthy control; MOG-, monophasic acquired demyelinating syndrome
myelin oligodendrocyte glycoprotein antibody negative; MOG+, myelin oligodendrocyte
glycoprotein antibody positive; MS, multiple sclerosis (n=6/condition). Statistical analysis was
performed by a mixed-effect model (1-way ANOVA) followed by Tukey’s multiple comparison test
(adjusted p value, *p<0.05, **p<0.001, ***p<0.0001) (B) UMAP plot of CD4 T cell population
expressing CCR2 and CCR5 as measured by ADT levels, co-localized in cluster#1 from (Figure
4.3. A, B). (C) Heatmap of differentially expressed genes within CCR2hiCCR5hi population across
different conditions (and donors). Genes with an adjusted p-value lower than 0.05 were labelled
as differentially expressed and clustered in rlog-gene-expression-scaled space to determine
expression patterns across all 4 conditions. Upregulated genes in the CCR2hiCCR5hi within
memory CD4 T cells of pediatric-onset MS were classified into two main categories, including (i)
chemotaxis and (ii) cell survival.

147

148

Figure 4.5: Distinct pattern of differentially expressed genes in memory CD4 T cells in
pediatric-onset MS and other CNS inflammatory disease controls. * Designates relapsing
MOGAD.
(A) Heat map of differentially expressed genes within memory CD4 T cells across the four
conditions in all subjects: HC, healthy control; MOG-, monophasic acquired demyelinating
syndrome myelin oligodendrocyte glycoprotein antibody negative; MOG+, myelin oligodendrocyte
glycoprotein antibody positive; MS, multiple sclerosis (n=6/condition). Genes with an adjusted pvalue lower than 0.05 were labelled as differentially expressed and clustered in rlog-geneexpression-scaled space to determine expression patterns across all 4 conditions. (B)
Upregulated genes in pediatric-onset MS were classified into four main categories, including (i)
immune cell response, (ii) trafficking and extravasation activity (iii) metabolism and senescence
and (iv) tumor suppressors. (C) Upregulated genes in children who had monophasic and
relapsing MOG-associated disease (MOGAD) were classified into two main categories, including
(i) metabolism Th2 responses and (ii) anti-viral Th1 responses.
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CHAPTER 5: GENERAL DISCUSSION AND CONCLUSION
MS is an inflammatory disease of the CNS leading to accumulating neurological disability.
Although available therapies can limit new relapsing injury, they tend to broadly target the
immune system hence leading to adverse effects that limit long-term use. T cells are implicated in
MS relapses, though the subsets and their antigenic targets remain largely unknown. Elucidating
these could guide development of more selective and safer treatments. We focus on pediatriconset MS which, though rare, offers us a unique window into early biological events and disease
targets. For this work we studied cryopreserved peripheral blood mononuclear cells from patients
followed from time of an initial presentation with acquired demyelinating syndrome (ADS) with
careful prospective ascertainment of diagnosis, allowing us to compare immune cell profiles of
children developing MS with profiles of children with other CNS inflammatory demyelinating
disorders, as well as healthy controls. My thesis work examines for the first time in the peripheral
compartment of pediatric-onset MS: [1] the phenotypic and functional response profiles of both
Teff and Treg, as well as implicate in these children a CD4 T effector T cell subset that coexpresses the ‘CNS-homing’ CCR2 and CCR5 chemokine receptors, which circulates on average
at a higher frequency and upon stimulation shows enhanced expression of the pro-inflammatory
cytokines (Mexhitaj et al. 2019) [2] evaluate spontaneous activation and antigen-specificities of T
cells (including the implicated CD4+CCR2+CCR5+ T cells) to CNS (myelin) and EBV antigens, as
well as evaluate how these abnormal T-cell responses are impacted in patients undergoing
treatment with an effective MS therapy, and [3] explore the single cell proteogenomic profile of T
cells (with a focus on the implicated CD4+CCR2+CCR5+ T cells and other memory T cell subsets).
Taken together, the data in this dissertation expand our knowledge of T cell profiles and
responses in these unique patient cohorts, as well as provide insights into the potential
interactions with other cell types and their targets involved in early MS pathogenesis. Our hope is
that this work may help ultimately develop better biological measures of disease state and/or
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activity and potentially contribute to the development of more selective treatments. In this chapter,
I summarize key findings, address questions that arose with these discoveries and how they
relate to existing literature, as well as put forward future avenues for translational and clinical
research in MS.
Overview of findings
In this thesis work, we report abnormal frequencies and pro-inflammatory functions of a distinct
subset of CD4 T cells (previously implicated in adults with MS) in children with MS compared to
both healthy and other CNS inflammatory disease controls. In support to prior reports in adults
with MS, we identify abnormalities in the function of pediatric MS regulatory T cells, as well as
decreased susceptibility to suppression of the disease-implicated pro-inflammatory T cells. Based
on this first integrated analysis and serial assessment of both effector and regulatory T cell
populations, we suggest that MS can manifest when the balance between the effector and
regulatory limbs of the immune response in individual children is disrupted, whether the
abnormality is predominantly due to exaggerated pro-inflammatory responses of their distinct
effectors, insufficient regulation by their regulatory cells, or lesser combinations of both. We
propose that measurement of the Teff/Treg ratio (rather than each measure separately) will better
distinguish MS patients from controls (Chapter 2). Upon further characterization of the T cell
response profile, as well as disease relevance of our implicated T cell subset in pediatric MS, we
report that we consistently capture a higher magnitude of auto-activation (possibly similar to the
one previously described in adults with MS), providing us a glimpse of the peripheral abnormality
of CD4 T cell responses in early MS. This autoactivation appears to be overlaid by the more
variable presence of CNS myelin and EBV-reactivities in children with MS. Moreover, these
abnormal T-cell responses were impacted in patients undergoing treatment with an effective MS
therapy (Chapter 3). Finally, we report on the first ever comprehensive proteogenomic analysis in
pediatric MS, as well as MOGAD which provides helpful comparisons to children with other
inflammatory diseases as well as healthy controls. Some of the identified upregulated genes in
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pediatric-onset MS may have implications for studying mechanisms involved in early MS
pathogenesis, as well as serve as potential targets that could ultimately lead to potentially novel
biomarkers and therapeutic targets (Chapter 4).
Implications for an integrated analysis of both effector and regulatory T cells in the
peripheral compartment of children with MS
Using an integrated analysis of both the effector and regulatory limb within same individuals
shows that children with MS exhibit, on average, deficient regulatory capacity of circulating
CD25hiCD127loTregs (expressing lower levels of FoxP3 expression) and that the disease
implicated Teff are relatively resistant to Treg suppression (Mexhitaj et al. 2019). However,
molecular mechanisms that underly Teff resistance to Treg and/or Treg capacity to suppress Teff
are not fully understood as they are context-dependent (ie, on disease type, immune reaction,
activation state of Tregs and the target they need to suppress) (Schmidt, Oberle, and Krammer
2012). Tregs can suppress Teff activation and proliferation via different mechanisms through; (1)
upregulation of FoxP3, (2) cell-cell contact to rapidly suppress TCR-induced Ca+2 ion signaling in
Teff, (3) secretion and production of soluble factors (ie, IL-10, IL-35, and TGFβ cytokines,
deamination of ATP to adenosine), (4) competition for IL-2 consumption and (5) indirectly
downregulate co-stimulatory molecules on APCs or through release of cAMP, among others
(Vignali, Collison, and Workman 2008; Schmidt, Oberle, and Krammer 2012; Barbi, Pardoll, and
Pan 2014; Baecher-Allan, Kaskow, and Weiner 2018). Moreover, T cells do not contribute to
autoimmune disease in isolation. Therefore, local secretion of other cytokines (such as IL-6, IL17, TNFα) by other cells (such B cells, APCs and other T cells) reduces Treg suppression
capacity and affect the ability of Teff to be suppressed by Tregs (Barr et al. 2012; Schneider et al.
2013; Baecher-Allan, Kaskow, and Weiner 2018). Although challenging to design assays that
take into consideration all these factors, examining further these interactions is imperative to
obtain a more comprehensive view of how imbalance affects disease initiation and progression in
pediatric- and adult-onset MS.
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An integrated analysis allows for evaluation of the balance between effectors and regulators
operating in the same patients. We report in Chapter 2 that an abnormal Teff:Treg balance
better distinguishes children with MS from controls and serial assessment of this ratio seems
relatively stable characteristic of individual subjects. Based on our integrated analysis, we
suggest that MS can manifest when the balance between the effector and regulatory limbs of the
immune response in individual children is disrupted, whether the abnormality is due to
exaggerated Teff pro-inflammatory responses, insufficient regulation by their Tregs, or lesser
combinations of both. ‘Normal’ immune balance can be seen across quite a broad range of
regulatory and effector states. However, the further away from that balance on either side would
lead to abnormalities in each individual (Mexhitaj et al. 2019). An increase in effector functions
would lead to an autoimmune disease like MS, while an increase in regulatory functions and
insufficient effectors, would make that individual susceptible to cancer or infection. Indeed, we
now have biological proof of principle that using check-point inhibition to treat cancers effectively
by enhancing the immune system response (ie, blocking inhibition of PD-1 or CTLA-4) introduces
side effects in patients who now have autoimmune diseases (Ramos-Casals et al. 2020).
Therefore, when considering therapies for autoimmune disease, we need to keep in mind the
implications of disrupting the balance toward the opposite direction (Figure 5.1).
Implications for spontaneous activation and T-cell responses to CNS (myelin) and EBV
(and possible novel antigens) in children with MS
Studies in adults with MS, in whom biological onset of disease starts many years before clinical
observation and immune cell assessment have contributed to a challenge in identifying
abnormalities as initiators or propagators of MS. Finding targets of interest would be possible
early in the disease process. However, efforts to develop therapies are unlikely to be beneficial as
these abnormalities develop as a consequence of inflammatory injury, increasing the disease
burden. In Chapter 3, we assessed T-cell responses to simultaneously CNS myelin and EBV
antigens and found exaggerated peripheral CD4 T cell responses (including in the disease153

implicated CD4+CCR2+CCR5+ T cell subset) to these antigens in pediatric-onset MS as
compared to controls. We report that these CD4 T cell responses were superimposed on a higher
magnitude of auto-activation, intrinsic in children with MS. Furthermore, using similar assay and
readouts, these T cell responses appear to be even more exaggerated in adult-onset MS.
Previous findings implicated increased auto-reactive T cell responses to CNS antigens in
pediatric-onset MS (Correale and Tenembaum 2006; Banwell et al. 2008). These enhanced T cell
responses were found to be dependent of age or disease duration since higher auto-reactivities
were observed in samples from adult-onset MS, when using similar assay readouts to samples
from pediatric-onset MS (Banwell et al. 2008). This suggests that CD4 T cells in children with MS
are primed and have a lower threshold for activation, which allows them to respond to selfantigens repeatedly, possibly through epitope spreading. A previous study used antigen
microarrays that included CNS-related proteins and other autoantigens to assess serum antibody
reactivities in children with MS and those remaining monophasic, in a discovery and a validation
cohort (Quintana et al. 2014). The findings suggest that at clinical presentation, samples form
children with MS revealed similar patterns of auto-antibody responses as from those who
remained monophasic, but in 3 months after follow-up, samples from children with MS reacted
against a broader panel of CNS antigens (including myelin antigens). This suggests that an active
process of epitope spreading occurs in the early stages of MS. However, it is not yet known
whether these CNS auto-reactive antibody contribute to CNS injury, or if they emerge due to
ongoing CNS injury. Even though, enhanced T cell and humoral responses are present early in
the disease onset as compared to controls, studying children with MS constitutes a lower disease
burden as compared to adults with MS, allowing investigation of early disease mechanisms and
targets. Since both CNS and EBV responses are superimposed on spontaneous activation of T
cells, future studies are warranted in assessing the transcriptomics and functional profile of these
cells, explore their TCR specificities and investigate their self-antigenic targets.
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While myelin antigens have been thought to be predominant targets of the aberrant immune
response in MS, several studies implicate other targets, such as axoglial and axonal antigens
(Dhaunchak et al. 2012) (Singh et al. 2015). The axoglial apparatus, which is the anatomic site
where the paranodal loops of oligodendrocytes bind to the underlying axons, represents a
potential early target of MS pathology (Bar-Or et al. 2016). Adhesion and signaling molecules are
enriched at the axoglial interface and injury to that site implies disturbed intracellular
communication. A previous cerebrospinal fluid (CSF) proteomic study implicated novel axo-glial
apparatus molecules, rather than compact myelin antigens, as early injury targets in MS, but not
in monophasic children (Dhaunchak et al. 2010; Dhaunchak et al. 2012). Generating peptide
pools of overlapping combinatorial peptide libraries on some of the most implicated proteins from
our previous pediatric MS work (Dhaunchak et al. 2012) would be a next step in assessing
whether T cells (and previously disease-implicated T cells subsets) would harbor abnormal proinflammatory response profiles that extend beyond CNS myelin and EBV targets.
Implications for treatment of children with MS
We also report, in a ‘proof of principle’ experiment with samples from adults-onset MS, that
treatment with anti-CD20 therapy decreased both auto-activation, as well as CNS and EBV-T cell
reactivities, suggesting that an effective MS treatment decreases these peripheral responses,
preventing T cell accumulation in the CNS and as a result reduce relapses. Our findings
corroborated previous reports in adults with MS and further attribute B cells an APC role, which
implicated T:B cell interactions in vivo (Jelcic et al. 2018). To confirm these results in vitro, future
experiments would require isolation of B cells from PBMC of pediatric MS patients and assess T
cell responses (auto-activation or EBV, CNS myelin and novel antigens). Ocrelizumab is not an
approved therapy for pediatric-onset MS, but fingolimod is. Although, samples from children preand post-treatment with fingolimod are rare in our cohort, it would be of interest to assess
whether the observed auto-activation and antigenic (CNS and viral) T cell responses would
diminish. We would expect this to be the case, since fingolimod traps immune cells in secondary
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lymphoid nodes, preventing their egress in circulation. However, treatment with fingolimod would
not deplete all B cells from circulation, which suggests, based on previous data, that there would
be slightly higher T cell responses (in the absence or presence of antigens) as compared to
samples from patients treated with ocrelizumab (Jelcic et al. 2018). To determine how disease
progression affects auto-activation, as well as self and foreign antigen-specific responses, it will
be useful to assess serial timepoints in both pediatric- and adult-onset MS, including during
relapse and remission.
Implications for proteogenomic profiling in the circulation (and intrathecal compartment)
of children with MS and other CNS inflammatory disorders
The goal of using a cutting-edge technique that could simultaneously assess transcriptomics and
proteomic readouts, was to first follow up with a more detailed gene-expression level analysis of
previously implicated CD4+CCR2+CCR5+ T cells in children with MS and controls, as well as
explore gene expression profiles that may be differentially regulated between the overall memory
CD4 T cell populations in well-characterized and well-ascertained children with MS, MOGAD,
non-MS/non-MOGAD and healthy controls. In Chapter 4, we identified novel aspects of the
CD4+CCR2+CCR5+ T cell profiles in children with MS, including expression levels of other
trafficking molecules (eg, CCR6 and CXCR3) and cell adhesion molecules [eg, VLA-4
(CD49d/CD29)]. Several genes involved in chemotaxis and trafficking were differentially
expressed in the T cells of pediatric MS patients and their role needs to be explored further in the
context of MS. In Chapter 2, we report this subset to be resistant to Treg suppression and
expected to show decreased levels of transcripts associated with molecules that receive signals
from regulatory cells and increased levels of molecules that inhibit Treg capacity to suppress it. In
this chapter, differentially expressed genes in this subset in pediatric MS showed to be
associated primarily with (i) chemotaxis and (ii) cell survival, but with implications for Th1/Th17
and Treg differentiation.
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The clearest distinctions between cohorts were observed as clusters of differentially expressed
genes in memory CD4 T cells of pediatric-onset MS and MOGAD. Upregulated genes in children
with MS included genes associated with T effector responses (Th1 and Th17), chemotaxis,
altered metabolism and senescence, which have been previously implicated in gene expression
studies in adults with MS (Lindberg et al. 2008). Upregulated genes in children with MOGAD
included genes associated also with mostly Th1 and Th2 responses. Our findings need to be
reproduced in larger groups of subjects, in which further work with MOGAD patients may also
provide interesting insights into what distinguishes relapsing remitting from monophasic CNS
inflammation. Although the primary focus for this thesis was the characterization of CD4 T (and
the implicated CCR2+CCR5+ T cell subset), future projects in the lab will benefit from this rich
dataset that has emerged to enable assessment of other cells of interest in MS (including B cells
and myeloid cells) to test and generate new hypothesis.
Further studies including studies of non CD4 T cells in the existing datasets, as well as future
cerebrospinal fluid (CSF) studies, which our lab is pursuing, are needed to determine MS immune
signatures as well as help assess the extent and ways more fully in which gene expression
profiles of circulating cells and CSF cells are similar or different. Sampling the CSF by lumbar
puncture represents the only feasible method to characterize soluble and cellular mediators of
inflammatory diseases of the CNS more directly. A recent integrated single cell analysis of blood
and CSF leukocytes in adult-onset MS shows that these two compartments are distinct, in terms
of cellularity and transcriptomics (Schafflick et al. 2020). Indeed, we anticipate that investigating
single cell proteogenomic profiles of immune cells in the CSF and blood of pediatric MS patients
would add tremendous value to elucidating the complex cellular immunology of MS. Access to
CSF cells and the established capacity to perform single cell proteogenomic will be the next step
to provide deeper insights into the pathogenesis of both MS and MOGAD, as well as potentially
identify biomarkers that may distinguish between these two CNS demyelinating diseases.
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Significant progress on this goal has involved my work to establish a high quality ‘point of care’
pipeline for expeditious CSF handling, processing, and analysis. This pipeline of CSF sample
procurement from (pediatric and adult MS) clinic to the lab is critical for comprehensively studying
and comparing CNS-infiltrating T cells by both flow cytometry and RNA expression profiling, in
MS patients and controls. Establishing such a clinical-lab interface and standardized operating
procedure (SOP) for high quality CSF cell interrogation is a first at Penn and CHOP. This is a key
effort to carry out combined flow cytometry and RNA-seq analyses of CSF cells. Obtaining blood
from the same patients at the same time will enable study of T cells within peripheral blood and to
further characterize disease-implicated T cells in both intrathecal and peripheral compartments at
the phenotypic, transcriptional, and functional levels. My effort on this pipeline development
involved 3 steps: (i) establishing the clinical-research interface; (ii) optimizing CSF flow cytometry
protocols; (iii) optimizing CSF scRNA-seq protocol (iv) and handling CSF processing. These were
initially developed at the adult clinical-research interface, and now are adapted to the pediatric
context, paving the way to functional phenotype CSF and blood in patients with MS and other
conditions, across the age-span. Moreover, I have established a standardized method of
preserving CSF cells for immunophenotyping by flow cytometry at a centralized facility that could
be incorporated across multiple sites and multiple clinical trials studying neuroinflammatory
diseases, such as MS. This protocol, which describes different ways of processing (ie, fresh, fixed
and frozen) and staining CSF, is now implemented at an NIH-funded multicentric study of MS
(BEAT-MS: ClinicalTrials.gov Identifier: NCT04047628) and will be submitted as a methods
manuscript.
Conclusion
Collectively, this body of work emphasizes the complexity of a multifaceted disease such as MS
and the tightly intertwined relationship between components of the immune system. The data
presented here implicates for the first time the CD4+CCR2+CCR5+ T cells and their proinflammatory profile in pediatric-onset MS, determines this subset’s transcriptome expression
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profile and its antigenic specificities to CNS (myelin) and viral antigens. Further, the datasets
generated as part of this work provide novel insights into early disease mechanisms of MS as
compared to other CNS demyelinating diseases, opening avenues for a more comprehensive
investigation of the specific immune targets and the cell types involved in MS. We anticipate that
these efforts will help with early detection of the disease and ultimately may lead to the
development of useful biomarkers and more selective treatments (Figure 5.2).
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Figures

CheckPoint
Inhibition

Figure 5.1: A normal immune state requires balance between effector and regulatory
immune functions.
A normal state of immune balance can exist across a broad range of Teff and Treg functions.
Imbalances between Teffs and Tregs can manifest as emergence of an autoimmune disease
such as multiple sclerosis (when Teff>>>Treg) or the development of cancer or uncontrolled
infection (when Teff <<<Treg). Check-point inhibition to treat cancers effectively by enhancing the
immune system response introduces side effects in patients who develop autoimmune diseases.
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Figure 5.2: Dissertation’s contribution to the field of pediatric multiple sclerosis and additional contribution to the field from past
and future studies.
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Appendix 2.1: Supplementary methods
The Canadian Pediatric Demyelinating Disease Study (CPDDS): has recruited children with
incident presentations of acute demyelinating syndromes (ADS) at 23 sites across Canada since
September 2004. ADS presentations are classified as having neurological features that are either
monofocal, polyfocal or consistent with acute disseminated encephalomyelitis (ADEM) (Banwell
et al., 2011). All children are followed prospectively with standardized serial clinical assessments
and brain MRIs to ascertain the diagnosis of MS (based on development of new clinical or
imaging disease activity according to the McDonald 2010 criteria (Polman et al., 2011)), versus
children whose diagnosis remains that of monophasic illness (representing an ‘other CNS
inflammatory disease’ control group). Serial isolation of biological samples including (when
possible) peripheral blood mononuclear cells (PBMC) is also carried out for all participants
providing assent or consent. Healthy controls (HCs) comprised children with no known neurologic
diseases or medical conditions recruited through community advertisement.
Criteria used to select participants from the CPDDS for the current study
Children with MS and monophasic (mono)ADS were selected from the CPDDS for this immune
study as ‘convenience cohorts’ based on the following criteria: (1) all children for whom at least 2
aliquots of cryopreserved PBMC were available, were considered; (2) samples were selected to
minimize confounding by treatment (no prior history of immune-modulating therapy use, and no
steroid exposure within at least 1 month of blood procurement whenever possible); (3) samples
from participants with a personal or family history of MS or other autoimmune disease were
excluded; (4) though we did not try to formally limit samples to ‘remission state’ (since presence
of sub-clinical disease activity cannot be excluded), we avoided using samples obtained at time of
a clinically evident relapse. None of the samples used in this study were obtained within 2 months
of vaccination, or in presence of inter-current infection, allergies requiring treatment or in context
of any other active medical condition, which all pediatric subjects and parents/guardians were
routinely asked about. We were not able to control the time of day in which samples were
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obtained from the children since these were all obtained as part of a clinically indicated blood
draw. However, we routinely document the time of blood draws as part of the CPDDS protocol
and there were no systematic differences in the timing of blood draws between the groups (data
not shown).
We chose not to formally age- and sex-match selected children with MS and monoADS disease
since children with monoADS are known to be younger at presentation on the average than those
with MS, and we wished to avoid overmatching. Selection of participants for the current study
(Table 2.1) based on these criteria resulted in cohorts of children with MS (n=21; F:M = 14:7; age
at ADS: 12.8 ± 2.4 years; age at sampling: 14.1±2.3) and monophasic disease (n=26; F:M =
15:11; age at ADS: 9.6 ± 3.2 years; age at sampling: 12.3±2.9) that were well-representative of
the overall MS and MonoADS cohorts in the CPDDS study (Banwell et al., 2011).
We selected the healthy control cohort (Table 1; n = 22, F:M = 11:11, age at sampling 14.4 ± 2.1
years) to provide a better age-match for the children with MS and, though our cohorts were
overall reasonably well-balanced, we also explicitly evaluated the association between age, sex
and the outcomes of interest in these cohorts to ensure that differences detected in immune
response across groups were not likely to be confounded by age or associated puberty. Specific
assays were carried out based on sample availability (detailed in Table 2.1) with more limiting
samples reserved for functional immunophenotyping (FIP) and/or serial immune phenotyping
(SIP) by flow cytometry and more permissive samples used for Treg suppression assays (Reg)
and for effector resistance (ER) assays.
Identifying T cell subsets of interest, developing, and validating functional-phenotyping assays
using multiparametric flow cytometry panels and cryopreserved PBMCs
We reviewed PubMed literature involving studies of effector T cell (Teff) subsets in MS and other
autoimmune diseases and the literature pertaining to regulatory T cells (Treg) in these conditions.
The search period was between Jan 1, 1990 to June 1, 2016, and was restricted to publications
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in English. Search terms were “multiple sclerosis”, “CD4 T cells”, “CD8 T cells”, “regulatory T cells
(Tregs)”, “T helper (Th)”, “Th1”, “Th17”, “mucosal associated invariant T (MAIT) cells”, “recent
thymic emigrant (RTE) T cells”, “RTE-Tregs”, “CD39+ Tregs”, “chemokine receptor (CCR) 2”,
“CCR5”, “CCR6”, “blood brain barrier (BBB)” and “autoimmune disease”. The final reference list
was generated based on relevance to the topics covered in the review. Appendix 2.3.1
summarizes effector T cell (CD4+ and CD8+) subsets previously implicated in MS or in other
human autoimmune diseases. We developed multi-parametric flow cytometry panels capable of
assessing both surface markers and activation-induced intracellular-cytokine expression within
the selected effector T cell (Teff) and regulatory T cell (Treg) subsets (Appendices 2.3.2 and
2.3.3). Assays were first developed using freshly isolated PBMC from adults, then miniaturized to
address the limited cell numbers available from the volume of blood obtained from children, and
finally validated for use in cryopreserved PBMC that were processed using the same SOPs
implemented in the CPDDS.
To optimize comparisons across groups, PBMC aliquots from a balanced number of children with
MS, monophasic-ADS or HC of similar age and sex, that passed quality control assessment for
yield and viability, were batch-analyzed in each experiment. Briefly, individual vials of cryopreserved PBMC were rapidly thawed at 37oC and cells were then washed in RPMI
supplemented with 5% fetal calf serum (FCS) and rested in a fixed volume for 2 hours in an
incubator at 37°C. Aliquots were used to count cells and assess for both yield (calculated relative
to number of cells originally cryopreserved in that vial) and viability (based on trypan blue
exclusion). Only samples meeting pre-defined criteria of at least 80% yield and at least 80%
viability were studied further. Rested cells that passed quality control were then washed once in
RPMI and left either unstimulated or stimulated (for intracellular cytokine staining) for 4 hours with
phorbol myristate acetate (PMA) and ionomycin (10 ng/ml and 500 ng/ml, respectively; both
Sigma- Aldrich, St Louis, MO, USA) and Golgi stop (10 mM; Sigma-Aldrich). After stimulation,
cells were washed in phosphate buffered saline (PBS) and stained with Live/Dead Fixable Dead
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Cell violet stain (Molecular Probes, Invitrogen) to exclude dead cells. Cells were then surface
stained for subset markers, then fixed, permeabilized (Fix/Perm buffer; eBioscience), and stained
for intracellular markers with optimized concentrations of appropriate fluorochrome-conjugated
monoclonal antibodies and appropriate isotype-controls (listed in Appendices 2.3.2 and 2.3.3). All
samples were acquired on LSR-Fortessa (BD Biosciences) and analyzed using FlowJo software
v10.7 (Tree Star, Ashland, OR, USA). The basic strategy for gating on CD4+ and CD8+ T cell
subsets is shown in Supplementary Figure 1. Individual stains were not included in group analysis
in rare instances that intracellular cytokine staining artefact precluded reliable interpretation.
Cross-over Treg suppression and Teff resistance assays
After thawing, PBMC were labeled with Live/Dead Stain-Aqua (LDS-Aqua) and stained for CD3,
CD4, CD25, CD127, CCR2 and CCR5, then sorted (Appendix 2.2.4) using FACSAria III (BD
Biosciences) as CD4+CD25hiCD127low T cells (a phenotype commonly used to estimate
regulatory T cells; Tregs); and responder cells including CD4+CD25-CD127+ cells (traditional
responder T cells); or CD4+CCR2+CCR5+ effector T cells. Subset purities above 95% were
routinely confirmed (Appendix 2.2.4 B). Treg suppression assays were then performed in a
‘cross-over’ design to assess on one hand the suppressive capacity of Tregs isolated from the
different pediatric cohorts to suppress the same responder cells, and to assess the capacity of
responder cells isolated from the different pediatric cohorts to resist suppression by the same
Treg. Briefly, responder cells (either CD4+CD25-CD127+ traditional responder T cells or
CD4+CCR2+CCR5+ effector T cells) were added at a constant number (1.2 x 104) into wells of
U-bottomed 96 well-plates (Corning, Corning, NY) pre-coated with plate-bound anti- CD3 (1
mg/ml; clone UCHT1) and anti-CD28 (1 mg/ml; clone CD28.2; both from Beckman Coulter) to
achieve Treg/Tresp ratios of 0:1, 1:2, 1:4 and 1:8, in RPMI 1640 medium supplemented with 5%
FCS and 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine. Cultures were kept for
5 days at 37°C, then pulsed with [3H] thymidine (1 mCi; PerkinElmer, Cambridge, U.K.) and
incubated for an additional 16 hrs. Cells were then harvested and assessed for thymidine
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incorporation using a liquid scintillation beta counter (Trilux Microplate Scintillation Counter; Life
and Analytical Sciences, Finland). Cell proliferation was expressed as counts per minute (cpm).
Percent suppressive capacity of Tregs.
Appendix: 2.2: Supplementary figures

Appendix 2.2.1: General flow cytometry gating strategy. Thawed PBMC were
labeled with Live/Dead Stain- Aqua (LDS-Aqua) and then stained with the different
antibody panels (Supplementary Tables 3 and 4). For all analyses, cells were first gated
for singlets (FSC-H vs. FSC-A) with exclusion of debris (SSC-A vs. FSC-A) and viable
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cells were identified using LDS-Aqua and gating on LDS-Aqua-/low cells. CD3+ T cells,
and subsequently CD4+ and CD8+ T cell subsets were identified with further subsets
quantified perindividual panel.
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Appendix 2.2.2: Frequencies and pro-inflammatory cytokine responses of overall CD4+
and CD8+ T cell subsets. Cryopreserved PBMC were rapidly thawed, briefly activated and
stained for relevant surface and intracellular molecules, as detailed in methods. PBMC were then
gated on singlet, viable, CD3+ T cells and subsequently on CD4+ and CD8+ T cell subsets
(Supplemental Figure 1). Two-tailed non-parametric Mann-Whitney U test for independent groups
of Mono and MS z-scores using the mean and SD of the HC group. There were no differences in
total CD3+ T cell frequencies across groups (data not shown) and, similarly the groups did not
differ in terms of overall frequencies of CD4+ T cells, U=144, p=0.841 (A); overall frequencies of
CD8+ T cells, U=122.5, p=0.163 (D), frequencies of IFNγ-expressing total CD4+ T cells,
U=109.5, p=0.497 (B) or total CD8+ T cells, U=121.5, p=0.466 (E); nor frequencies of IL-17expressing total CD4+ T cells, U=105.5, p=0.406 (C) or total CD8+ T cells, U=133, p=0.742 (F).
Data are from children with MS (n=16), children with monoADS (Mono; n=21) and healthy control
children (HC; n=19).
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Appendix 2.2.3: Increased frequencies of memory Tregs, yet decreased frequencies of
Naive-Treg, RTE- Tregs, and Treg expressing CD39 in children with MS. PBMC from children
with MS, monoADS (Mono), or healthy controls (HC), were stained with monoclonal antibodies
against CD3, CD4, CD25, CD127, FOXP3, CD45RO, CD31 and CD39. (A) Flow cytometry dotplots depicting approach to gating on CD4+CD25+FOXP3+ Tregs. Cells were initially gated on
total

CD4+CD3+

T

cells

(See

Appendix

2.2.1).

Co-expression

of

CD31

on

naive

CD25+FOXP3+CD45RO- Treg identifies RTE-Treg. (B) Average percentages of circulating
Memory, Naïve and RTE subsets of CD4+CD25+FOXP3+ Tregs as well as (C) the frequency of
Treg expressing CD39, are shown for HC (n=7), Mono (n=7) and MS (n =7) children.
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Appendix 2.2.4: Gating strategy for T cell subset sorting and purity confirmation for use in
Treg suppression assays. Thawed PBMC were labeled with Live/Dead Stain-Aqua (LDS-Aqua)
and then stained for CD3, CD4, CD8, CD25, CD127, CCR2 and CCR5. (A) CD3+ T cells were
gated on live viable cells, and subsequently CD4+ and CD8+ T cell subsets were identified from
CD3+

cells.

Gating

on

CD4+

T

cells,

the

following

populations

were

sorted:

CD4+CD25hiCD127low Tregs, CD4+CD25-CD127+ Tresp cells and CD4+CCR2+CCR5+ Teff
cells. (B) Purity of the sorted cells was confirmed by FACS.
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Appendix 2.3: Supplementary Tables

2.3.1: Effector T cell subsets implicated in MS and other autoimmune diseases

Effector T Cell subset
CD4+

IFNγ-

expressing

(Th1)

cells

CD8+

and

IFNγ-expressing

Implication

•
•

(Tc1)cells

CD4+

IL-17

expressing

Th17

cells

•
•

•

CD4+CCR2+CCR5+ T
cells

•

•

•
•
•

References

Multiple reports implicating Th1 and Tc1
cells in EAE and multiple sclerosis, as
wellas other autoimmune diseases.
Reports of increased frequency as well
as increased responses of Th1 and Tc1
cells in MS. However, reports also
pointing to potential anti-inflammatory
roles of IFNγ expressing T cells.

(Olsson et al. 1990)
(Voskuhl et al. 1993)
(Lassmann

and

Ransohoff 2004)
(Rosa et al. 2016)

Th17 cells transmigrate across the BBB
andpromote CNS inflammation.

(Kebir et al. 2007)

Recruitment of IFNγ and IL-17 expressing
T cells in MS. Increased IL-17 responses
to putative CNS myelin target antigens by
T cells of children with MS compared to
healthy controls.

(Vargas-Lowy

(Kebir et al. 2009)
et

al.

2013)

No significant difference in percentages of
IL-17 or IFNγ by total CD4+ T cells
between pediatric patients with MS and
controls.
CCR2

plays

a

key

role

in

the

(Balashov et al. 1999)

transmigration of leukocytes across the

(Fife et al. 2000)

BBB in MS.

(Simpson et al. 2000)

CCL2-CCR2 interaction plays role in
trans- endothelial migration of effector
CD4+ T cells, suggesting importance of
CCR2
expression
for
BBB
transmigration.
CCR5 and IFNγ expressing leukocytes
are present in demyelinating lesions in
MS.
CCR2 and CCR5 are present on
large numbers of infiltrating
lymphocytes inpatients with MS.
CD4+CCR2+CCR5+ T cells in the blood
of MS patients produce both IFNγ and
IL-17;have higher capacity to invade the
CNS compared to other T cells and are
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(Connor et al. 2004)
(Mahad et al. 2006)
(Zhang et al. 2010)
(Sato et al. 2012)
(Shulman and Alon 2012)

enriched in the CSF of MS during
relapse.

•

CD4+CD161+ Th17 cells

•

•

CCR2 expression on host-derived
mononuclear cells is critical for
disease induction in EAE.
CCR2
contribute
to
accumulation of CD4+ T celn the
ileum in Crohn’s disease.
Subset of CD4+ T cells that are

(Cosmi et al. 2011)

CD161+ express high levels of IL-17

(Miao,

and IFNγ.

2014; Miao, Zhang, et

CD4+ T cells that are CD161+ and
express IL-17 present within synovial
fluid of patients with Rheumatoid arthritis
(RA) are

•

Resistant to Treg suppression.
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Geng,

et

al. 2014)
(Basdeo et al. 2015)
(Gonzalez et al. 2015)

al.

2.3.2: Multi-Parametric Flow Cytometry Panels
Panels

CCR2-CCR5
panel
Chemokine
panel

FITC

PE

PerCPCy5.5

PECF594

PECy7

BV421 BV500

APC

APCCy7

IL-17

CD4

TCR-Vα
7.2

CD4

IFNγ

CD4

CD127

CD4

TIGIT

CD4

LiveDead
CD127

IFNγ

CD3

CCR5

CD161 CCR2
LiveDead

CD8

Treg subsets
panel
CD127

CCR6 CD3

CCR5

CD161 CCR2
LiveDead

CD25 CD3

CD8

FOXP3 IL-17
LiveDead

RTE-Treg
panel

CD45RA CD25 CD3

CD45RO FOXP3 CD31
LiveDead

CD39+
Treg panel

CD127

CD25 CD3

FOXP3
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CD39

CD73

2.3.3: Flow Cytometry Reagents
Antibody

Fluorochrome

Catalogue #

Clone

Source

CD3

PerCp-Cy5.5

560835

UCHT1

BD Biosciences

CD4

APC-Cy7

557871

RPA-T4

BD Biosciences

CD8

PE-CF594

562282

RPA-T8

BD Biosciences

CD8

FITC

347313

SK1

BD Biosciences

CD25

PE

120-001-311

3G10

Miltenyi Biotec

CD25

BV421

562442

M-A251

BD Biosciences

CD127

FITC

8011-1278

RDR5

eBioscience

CD127

APC

17-1278-42

eBioRDR5

eBioscience

FOXP3

PE-Cy-7

25-4776-42

PCH101

eBioscience

FOXP3

PE-CF594

563955

236A/E7

BD Biosciences

CD161

PE-Cy7

25-1619-42

HP-3G10

eBioscience

CCR2

BV421

357209

K036C2

Biolegend

CCR5

PE-CF594

562456

2D7/CCR5

BD Biosciences

CCR6

PE

12-1969-42

R6H1

eBioscience

CXCR3

Alexa Fluor 488

558047

1C6/CXCR3

BD Biosciences

CD45RA

FITC

555488

HI100

BD Biosciences

CD45RO

PE-CF594

562299

UCHL1

BD Biosciences

CD31

BV421

303123

WM59

Biolegend

CD39

PE-Cy7

25-0399

eBioA1 (A1)

eBioscience

CD73

BV431

344008

AD2

Biolegend

TCR-Vα-7.2

BV421

351715

3C10

Biolegend

TCR-Vα-7.2

APC

351708

3C10

Biolegend

IL-17

Alexa Fluor 647

560437

SCPL1362

BD Biosciences

IL-17

BV421

562933

N49-653

BD Biosciences

IFNγ

APC

554702

B27

BD Biosciences

IFNγ

PE

554552

4S.B3

BD Biosciences

LIVE/DEAD™
Fixable Aqua Dead
Cell Stain Kit
Mouse IgG2a
(Isotypecontrol)

BV500

L34957

N/A

Invitrogen

APC

130-091-836

S43.10

Miltenyi Biotec

Rat IgG2a K (Isotype PE-Cy7
Control)

25-4321

eBR2a

eBioscience

Rat IgG1 K (Isotype PE
control)

551436

MOPC-21

BD Biosciences

Mouse IgG1 K
(Isotypecontrol)

562438

X40

BD Biosciences

00-5523

N/A

eBioscience

BV421

Foxp3/Transcription N/A
FactorStaining Buffer
Set
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Appendix 3.1: General Gating Strategy after 7-day culture
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Appendix 3.1. General gating strategy after 7-day culture: (A) For all analyses after culture, cells were first gated on lymphocytes, then
singlets (FSC-H vs. FSC-A) to exclude debris, while viable cells were identified using LDS-Aqua by gating on LDS-Aqua-/low cells. CD3 T cells,
and subsequently CD4 and CD8 T cell subsets were identified. Double-chemokine receptor CCR2 and CCR5 were gated within CD4 T cells.
(B) Representative plots of combination of different Activation Induced Markers (AIM) were gated within CD4 T cells after antigen stimulation.
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Appendix 4.1: CITE-seq (Cellular Indexing of Transcriptomes & Epitopes by Sequencing)
workflow
Part 1 - Sample preparation and staining: Cryopreserved PBMC from cohorts of children with
MS (n=6), MOG- (n=6), MOG+ (total n=6; including 3 monophasic MOG+ and 3 relapsing
MOG+), and HC (n=6) who were balanced for sex and age at blood draw. (1) Cells were thawed
in warm serum-free X-VIVO15 media, washed, centrifuged and after discarding the supernatant,
cells were treated with DNase to avoid formation of cell clumps. Cells were rested (2 hrs) in the
incubator. After cells were rested, they were washed and stained with LIVE/DEAD™ Fixable
Aqua dead cell stain protected from light, to exclude dead cells. Cells were washed and filtered
with a cell strainer to remove any large clumps. (2) Cells were sorted from each sample on
FACSAria (purity check was <95%). 2 x 105 sorted cells/sample were stained with Human
TrueStain FcX to block any non-specific antibody binding. (3) Cells from individual samples were
stained with diluted hashtag (HTO#1-8) and a mixture of diluted oligo-conjugated antibody.
Optimal antibody dilutions for the 55 oligo-conjugated antibodies were mixed before staining the
cells. Each selected antibody is conjugated to a unique oligonucleotides or antibody-derived tag
(ADT), comprised of a PCR handle, clone-specific barcode sequence and capture poly A
sequence. (4) Cell were washed, pooled from the 8 samples (in each batch) in equal ratios and
and counted one last time before being processed for scRNA-seq.
Part 2 - Library preparation, feature Barcoding, and RNA-sequencing: 10X Genomics
Chromium single cell (3’ gene expression) was used for Gel Bead-In-EMulsions (GEM)-single cell
generation, RNA library preparation and sequencing. (5) Staining of cells with oligo-conjugated
antibodies, allows for ADT to bind to the cell surface protein of interest. (6) Labeled single cells
were then transferred onto a compatible sequencing platform where each cell was encapsulated
into a nano-sized aqueous droplet in a microfluidic apparatus.

(7) To expose the mRNA,

individual stained cells were lysed the individual droplets. (8) Cellular mRNA and the antibodyderived oligos both hybridized with the microbeads that contain oligo-dT. These were later
indexed by a shared cellular barcode during reverse transcription. Reverse transcription reaction
occurred and produced cDNAs containing the reverse complement of the mRNAs and their
specific barcode sequence. (9) The amplified cDNAs and antibody derived tags (ADTs) were
separated by size and converted into Illumina-sequencing libraries independently. Simultaneously
but separately from the gene expression library, a feature barcoding library preparation was also
generated to account for all cell surface proteins (Antibody-Derived Tags (ADT)). cDNA was
amplified for 10 cycles and products were then sized separated with beads into <300 base pairs
containing the ADT and >300 base pairs containing cDNA derived from cellular mRNA. ADT was
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amplified for 10 additional cycles using specific primers which were used to be clustered on
Illumina flowcells. (10) Since the two library types were generated separately, their relative
proportions were adjusted in a pooled single lane and the required sequencing depth was
obtained for each library. Then ADT and cDNA libraries were merged and sequenced. Single-cell
data processing and filtering allows for RNA and ADT clustering to identify immune cell
populations. Adapted from Stoeckius et al 2017 Nature Communications. Adapted from “Cellular
Indexing of Transcriptomes & Epitopes by Sequencing”, by BioRender.com (2021). Retrieved
from https://app.biorender.com/biorender-templates
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